Nepal’s Flood: Chilling Example of Climate Devastation Facing Developing Countries 01/09/2026 Tanka Dhakal & Disha Shetty Flood flattened nearly everything in its way, leaving only a few homes still standing in Betrawati, Rasuwa. Many of these homes are filled with debris and in some cases, with dead bodies of those trapped inside. KATHMANDU – Shekhar Lamichhane is grieving even as he struggles to breathe. The 65-year-old asthma patient needs oxygen support. Some of his family members, including siblings, were swept away in Nepal’s flash flood on 26 August when glacial ice and rock slammed into the valley below near the Nepal–China border. “I am on oxygen support. I have severe asthma and the electricity has been gone since the flood. I am struggling to breathe without support,” Lamichhane said. The flash flood carrying rocks and debris gushed through the Nepal–Tibet border into northern Nepal. By Tuesday (1 September), over 1003 people were reported dead, and nearly 4,000 were missing. “The sudden glacial collapse and flash flood is a devastating reminder of how fragile these mountain environments can be, particularly in the Hindu Kush Himalayas. For years, scientists and local communities have been warning that the Hindu Kush Himalayas are at huge risk from climate change,” said Simon Stiell, executive secretary of UN Climate Change, in the aftermath of the floods. Nepal is the classic example of what climate scientists have been warning of: small nations facing disproportionate climate impacts despite contributing the least to climate change. In 2024, Nepal emitted around 0.05% of the world’s CO2 emissions, according to Our World in Data, based at Oxford University. Nestled in the pristine and fragile Himalayas, Nepal gets nearly all of its electricity from hydropower, and a fraction from solar and wind. Black carbon, the fine particles that remain after incomplete combustion of fuels, is a regional problem, though. Black carbon concentrations have increased by approximately 7.74% since 2000, according to a report by Climate Trends. This has contributed to faster warming of the Himalayan glaciers. A trail of destruction Shekhar Lamichhane charging his electric plug-in oxygen support device on the terrace of a house in Kalikasthan, Rasuwa. After days of without oxygen support Lamichhane was able to use his oxygen support to ease his Asthma. Preliminary estimates by scientists suggest that the enormous mass of bedrock and glacier ice broke off a slope north of Langtang Lirung and slammed into the valley about 4,000 feet (1,200 meters) below – a distance roughly three times the height of the Eiffel Tower. The debris fell into the Lhende River, which flows from Tibet into Nepal, sending floodwater and debris surging downstream. “This was an unprecedented and unexpected disaster. There was simply no detection and no time to issue a warning. The event was a sudden-onset hazard that could not be captured by conventional warning systems,” said Dr Farooq Azam, Senior Cryosphere Specialist and Intervention Manager at Nepal-based ICIMOD, a Nepal-based regional research organisation. A rapid assessment of the disaster by a group of International scientists, published by HiRisk, agrees that, given the “rapid speed of the initial avalanche, warning time from conventional in-channel systems would have been minimal and likely insufficient for successful evacuation at the Nepal-China border checkpoint at Rasuwagadhi”. However, they assert that further downstream, “with warning times of 10 minutes or more, comprehensive and well-capacitated systems could have saved a significant number of lives”. The HiRisk report notes that, while early warning systems (EWS) focused on several glacial lakes in China were recently set up, no operational EWS were set up “for glacier-related hazards”. They also point to “some pre-event indications that the ice surface sped up just prior to the event”, including that “meltwater had turned visibly brown by 24 August” and “some indication of a crack propagating into the surrounding bedrock slope in the days before the event”. Seismic event Satellite imagery shows the devastation in Syapru Besi, a mountain village in Rasuwa District, Nepal. Left: Post-event image taken on 27the of August and on the right is the pre-event image. The ice and rock collapse from the glacier was so powerful that it caused seismic activity equivalent to a 5.2‑magnitude earthquake, according to the US Geological Survey at 8.37 am local time. Sediment and boulders moved rapidly through the Bhote Koshi and Trishuli river systems, flattening everything in its path. According to the HiRisk report, satellite-based preliminary flood assessments show that “at least 68 bridges were hit, including 33 suspension bridges and 35 motorable bridges and 40 km of highway were washed away”. “Open-access datasets indicate that 12,944 buildings are located within the floodplain, with structural heights up to 9 meters.” Nepal struggles to coordinate relief efforts Mud covers Nuwakot district in central-northern Nepal following devastating flash floods. Nepal’s government is facing criticism for not accepting international assistance quickly enough – a delay some say hindered early rescue operations. Government spokesperson Sasmit Pokharel rejected the claim. “We are in contact and discussion with countries through the Ministry of Foreign Affairs, and we are constantly assessing the situation in the affected area,” Pokharel said during a press briefing on Monday. He added that rescue teams from India, China, South Korea, and other countries are already on the ground supporting search-and-rescue operations. “To avoid possible epidemics, a special medical team has been deployed with necessary medicines,” he said. “Children, women, and people with pre-existing health issues are prioritized.” He also addressed public criticism over the handling of dead bodies. Due to limited space and technology, some unaccounted or unidentified bodies have been buried in Chitwan, which has drawn concern from families and community members. “We are only managing the body as per the law and science; the body is not destroyed,” Pokhrel said. “In the future, if relatives come forward to claim it, all doors are open, and either the body or its remains will be handed over through DNA matching.” Before burial, DNA samples, fingerprints, and other necessary details are documented and securely stored, he added. “But the solutions to global heating are equally clear, especially a faster global shift from fossil fuels to renewables and more investment in climate resilience,” he added. Nepal disaster – a reminder for regional collaboration Nepal’s share to global carbon emissions in 2024 when compared to China, United States, Europe and its neighbours India and China. Nepal emitted 0.05% of the world’s CO2 emissions in 2024. The Hindu Kush Himalayan system spans multiple countries, many of them with ongoing border disputes, such as Pakistan-India and China-India. The flooding in Nepal highlights the need for regional collaboration that is currently missing. Over the past five decades, the glaciers here have recorded negative mass for 89% of the observed years, according to data from ICIMOD, a Nepal-based regional research organisation. Melting glaciers do not just have devastating consequences for mountain communities, but also for the downstream countries. “Early warning systems are being sold as the fix, but no siren can outrun a mountainside collapsing in seconds. The real failure sits upstream, in land-use decisions that pushed settlements and infrastructure onto riverbanks our ancestors deliberately avoided, and in a global economy still burning the fossil fuels that are cooking these glaciers from the inside out,” said Professor Anjal Prakash of FLAME University in India and an IPCC author. “Every villager who watched that valley disappear paid for emissions decisions made thousands of kilometres away,” he added. The UN’s Stiell also echoed a similar sentiment. “The solutions to global heating are equally clear, especially a faster global shift from fossil fuels to renewables and more investment in climate resilience.” Stories are emerging of communities downstream where even the 15-minute warning from those hit hard upstream saved hundreds of lives. Back in Nepal, Lamichhane shelters on the terrace of a house just above Betrawati, one of the flooded towns. He has managed to charge his electric oxygen concentrator device with the help of relief workers who brought generator‑powered charging devices as the power is out. Remembering how it felt when the floodwaters came, he said, “It was making a sound like a helicopter makes. It was like all clouds and dust running high in the sky. The river climbed up the mountains on both sides and took everything in its way.” Image Credits: Manish Aryal, Copernicus Emergency Management Service (CEMS) situation report, UNICEF/Laxmi Prasad Ngakhusi, Our World in Data. Aid Cuts Exacerbate Food Insecurity in the West Bank, Health Crisis in the Gaza Strip 01/09/2026 Felix Sassmannshausen Violence, economic distress and funding cuts leave nearly a million people in the West Bank facing severe food insecurity, according to the World Food Programme. Around 200,000 people in the Israeli-occupied West Bank will lose access to vital food aid from the United Nations World Food Programme (WFP) due to funding cuts, exacerbating food insecurity. In the Gaza Strip, the nutrition and health crisis is set to worsen further due to a lack of medical supplies and sanitation, the World Health Organization (WHO) warns. Over the past two years, the number of people affected by food insecurity in the West Bank has doubled to almost one million – over a quarter of the population, according to latest WFP data. Due to drastic funding shortfalls, the WFP is halving its aid to the 400,000 recipients starting in September, the organisation announced. Already, 12% of the surveyed population suffer from inadequate food consumption, whilst a third of West Bank households can no longer afford a nutritious diet. “Food may be available in the markets, but people simply cannot afford it,” said WFP Country Director Shaun Hughes, describing the crisis at a UN press briefing in Geneva on Tuesday. In future, only the most needy families will receive cash support of around 50 shekels (under $20) per person per month. The cuts impact the provision of vouchers, food, livelihood support and nutritional aid for children and pregnant women. Economic crisis and rising settler violence WFP’s Shaun Hughes warns funding cuts deepen severe food insecurity. The West Bank’s economy is in a deep economic crisis on two fronts simultaneously. Unemployment now stands at 30% after Israel closed its gates to most Palestinian workers following the 7 October 2023 Hamas-led massacre in Israel. At the same time, the governing Palestinian Authority (PA) has been economically crippled by the refusal of Israel’s hardline government to transfer some $5 billion, to date, in import and customs taxes on goods entering the West Bank as it is legally obliged to do. Normally, such transfers make up about 70% of the PA’s budget, and the withheld funds are mostly earmarked for salaries, particularly for employees in healthcare and education. The PA, meanwhile, has also been plagued by widespread corruption, according to Freedom House, and immense public debt, estimated by the World Bank at $4.8 billion by the end of 2025. According to WFP data, 76% of all West Bank households have thus experienced a significant decline in their income. Against that context, the WFP aid payments represent crucial safety nets for many recipients facing severe financial crisis in the conflict-ridden region. However, Hughes also blames rising settler violence, Israeli military operations, roadblocks, and arbitrary house demolitions for exacerbating the situation. “In my recent visits to the West Bank, I have witnessed families once thriving and earning a living off their land now forced from their homes, their livelihoods destroyed. They now find themselves in a chokehold,” he said. Israeli Prime Minister Benjamin Netanyahu recently criticised violent acts in the West Bank as criminal and damaging to Israel’s standing in the world. But critics, including voices in the military, say that his government has failed entirely to show real muscle in reining in the increasingly violent and frequent settler rampages, leading to progressively greater limitations on Palestinian movement and access to their lands. Health risks and acute food insecurity in the Gaza Strip Stagnant water in Gaza’s makeshift camps fosters pest infestations, sharply increasing the risk of diarrhoeal diseases as food insecurity worsens. In the Gaza Strip, too, the WFP cut cash assistance for 375,000 people by 40% back in July. To continue providing vital supplies in both areas, the organisation urgently needs an additional $386 million for the next six months, it said. This massive funding shortfall threatens an already fragile situation on the ground. Although food deliveries have improved supplies since the October 2025 ceasefire, two-thirds of the population in the Gaza Strip continue to suffer from crisis and emergency levels of acute food insecurity. The UN-linked Integrated Food Security Classification (IPC) forecasts that high levels of acute food insecurity will affect up to 90% of the population by the end of the year if humanitarian aid is not sustained. Indeed, chronic undernutrition has emerged as the primary challenge, according to a June survey of Gaza by UNICEF. While emergency aid stabilized acute malnutrition (wasting) at 1.3%, chronic malnutrition (stunting) now affects 12.2% of children under five. Dietary quality is also dismal: only 30.3% of children aged 6–23 months achieve minimum dietary diversity, and just 22.4% receive a minimum acceptable diet, leaving them highly vulnerable to developmental and cognitive impairments. The nutrition crisis is compounded by catastrophic living conditions; some 94% of Gaza’s 2.1 million residents lack adequate shelter, and approximately 100,000 children and pregnant or lactating women remain in need of continuous nutritional aid. Disease outbreaks loom amidst the destroyed infrastructure WHO epidemiologist Reinhilde Van De Weerdt warns that contaminated water and severe medical shortages pose imminent disease threats to displaced populations in Gaza. After the searing heat of summer, winter rains will mean flooding in overcrowded tent cities, and that, “will spread the sewage, the waste and contaminated water into the places where people sleep, cook and care for their loved ones,” warned WHO epidemiologist Reinhilde Van De Weerdt at the UN briefing. Damp tents and mould also dramatically increase the risk of respiratory diseases, particularly among young children, she pointed out. According to WHO data, microbiological contamination of tested water samples nearly tripled this year, rising from under 6% in January to almost 20% in August. As a result, cases of acute watery diarrhoea almost doubled from around 30,000 in March to over 58,000 recorded cases in August. However, the WHO warns that the severely limited local laboratory capacity can currently only detect basic microbiological contaminants, meaning that further contamination remains undetected. Furthermore, stagnant water encourages the uncontrolled breeding of disease-carrying mosquitoes and pests. Additionally, restrictive import licences have been blocking vital deliveries of medical supplies such as prosthetics and other medical aids since May 2024, according to the WHO. As a result, only 12% of those who lost limbs since the war began have been fitted with a prosthetic device, while more than 6,600 amputees in total require long-term care, said Van De Weerdt. The WHO is calling for the accelerated import of medical supplies, including diagnostic laboratory materials for the rapid identification of viruses and bacteria. Without this equipment, the early detection and containment of potential disease outbreaks on the ground would be virtually impossible. Israeli government pushes back against allegations Responding to a query by Health Policy Watch, the Coordinator of Government Activities in the Territories (COGAT) stated that Israel exercises “heightened caution” regarding dual-use items due to the risk of exploitation by Hamas for military purposes, but stressed that these items are “not subject to a blanket prohibition.” The agency added that it coordinates a continuous response with UN agencies to facilitate alternative items, such as spare parts and engine oil, while fuel is brought into the Gaza Strip daily by UN agencies. COGAT also strongly disputed claims of restrictive barriers on medical supplies, stating that “all medicines submitted for entry into the Gaza Strip are approved and cleared without restriction.” The agency maintained that advanced medical equipment – including X-ray machines, diagnostic devices, laboratory tools, and backup generators – was recently transferred to support international health facilities, including field hospitals operated by the Red Cross, the United Arab Emirates (UAE), the International Medical Corps (IMC), and UK-Med. Responding to concerns over water infrastructure, COGAT stated that Israel actively facilitates the entry of equipment and piping to repair and maintain water networks. According to the agency, a desalination facility in southern Gaza was recently repaired and connected to the “Kela” electricity line to increase water supply. It added that 10 major water, sanitation, and hygiene (WASH) projects were recently approved, allowing international organisations to import sewage pipes, fittings, engine oil, water storage equipment, and water quality testing kits. The Israeli Ministry of Foreign Affairs (MFA) did not respond to a query by Health Policy Watch. See related story: Most Gaza Palestinians Living in Dangerous, Unsanitary and Unhealthy Shelters Image Credits: WFP/Claire Nevill, Felix Sassmannshausen/HPW, WHO. United States to Cut Health Funding to 18 Countries 59% by 2030 31/08/2026 Kerry Cullinan Kenya’s President William Ruto applauds Kenyan Cabinet Secretary Musalia Mudavadi and US Secretary of State Marco Rubio after they signed an MOU for health funding. The United States plans to cut its health funding to 18 countries by 59% of pre-2025 levels by 2030, according to a Public Citizen and Partners In Health analysis of the bilateral agreements the US has signed with these countries. The bilateral Memorandums of Understanding (MOUs) were signed as part of the ‘America First Global Health Strategy’ adopted by the Trump administration in 2025, and are intended to rapidly wean countries off US aid by 2030. The reduction amounts to a cut of some $2 billion to US aid dispensed before 2025, according to Public Citizen, which analysed the MOUs – some of which it initially obtained via a Freedom of Information Act (FOIA) lawsuit against the Trump administration. Countries facing the steepest cuts are Rwanda (97% reduction), Liberia (84%), Burundi (78%), Madagascar (77%), and Sierra Leone (71%). All MOUs require countries to make substantial co-financing commitments. These are for activities identified as priorities by the US, and do not necessarily align with the countries’ priorities. For example, the US wants all countries to improve their ability to identify disease outbreaks, so it requires substantial investment in epidemiologists and data capturers. But many recipient countries may prefer to prioritise employing health workers. In 11 out of the 18 countries, the co-financing commitments fail to cover the US cuts over five years compared to pre-2025 government funding. “Countries may also struggle to meet these funding expectations,” says the analysis. “For example, Malawi would have to mobilize new funding equal to 56% of the country’s total health expenditure to meet its annualized co-financing commitment.” Co-financing ‘punishment’ The US government also reserves the right to reduce or cease funding if countries don’t meet their co-financing commitments. In addition, the MOUs stipulate that the co-investments “may not include funding from other donors or multilateral organizations, but must be funds ‘raised directly’ by the country”, says Public Citizen and Partners In Health. “There is no transparent logic guiding the application of penalties across countries,” their analysis notes. If Ethiopia, Kenya, Mozambique, Cameroon, and Malawi fail to meet co-financing commitments, the US will reduce its funding by $1 for every $1 shortfall. Uganda and Côte d’Ivoire face a 2:1 reduction. However, no penalties are specified in the MOUs with Rwanda, Liberia, Lesotho, Eswatini, Sierra Leone, Madagascar, Burundi, Botswana, and South Sudan. Many of the MOUs also include “performance incentives” for meeting process and outbreak response metrics, but quantifying them is vague. Seven African countries will have fewer health workers by 2030, thanks to reduced US and partner government commitments. These are Burundi, Cameroon, Eswatini, Kenya, Lesotho, Madagascar and Malawi. “This is a major concern since the African region currently has only 46% of the health workers it needs, and by 2030 it is projected to face a health workforce shortage of 5.85 million workers,” the analysis notes. Burundi will lose all US-funded community health workers (CHW). Malawi will lose 3,436 CHWs (72% of its total), and Madagascar, 8,200 (39%). Cameroon faces a 20% reduction in CHW and nurses despite already facing “a severe shortage” of both. The one piece of good news is that the MOUs reduce the duration of controversial data-sharing and pathogen specimen-sharing agreements, which were initially for up to 25 years – despite the MOUs only lasting up to five years. But “these agreements stand apart from the MOU itself, and most are not available in wider circulation, making a full assessment of final terms impossible in most cases”. Some countries have baulked at the data-sharing requirements, with Zimbabwe deciding not to pursue an MOU with the US. Several countries point out that these data-sharing agreements, usually appendices to the MOUs, directly undermine the pathogen access and benefit-sharing (PABS) system currently being negotiated at the World Health Organization (WHO). “These documents suggest that the Trump administration is on course to underspend on global health by billions of dollars compared to what Congress has ordered, risking lives and allowing diseases to spread,” said Peter Maybarduk, Access to Medicines director for Public Citizen. “The administration must answer how and when it intends to invest the missing billions for health.” Clashing Convictions of Taliban and the West is Costing Afghan Lives 31/08/2026 Mukesh Kapila Afghan women have been almost erased from public life. Two sets of dogmas contend in Afghanistan: those of the Taliban and the West. Neither side pays the real price for their beliefs. Ordinary Afghans do with their lives. Some aid agencies labour quietly to bring help and hope through a dozen practical ways that bypass competing doctrines. They deserve support. In March last year, 23-year-old Khatera (pseudonym) went into prolonged labour. Her village clinic in western Afghanistan was long shuttered, and the nearest help was Herat city across a swollen river. Her husband carried her across the raging waters, both submerged to the shoulders. It took them 12 hours to reach the hospital. Khatera’s vital signs – and those of her baby – stopped registering hours after reaching the hospital. Why were they not saved? Perhaps no medical equipment or supplies? Perhaps few trained staff? Or perhaps sheer exhaustion? This everyday tragedy is commonplace for Afghans. Their misfortune is to be squeezed between the beliefs of their Taliban rulers and those of the international community that fled the country. This clash of convictions is fought over the easiest of targets: the defenceless bodies of millions like Khatera. The outcome is a generation of losers, not just Afghans but those who would save them. As with all lose-lose “games”, the focus quickly shifts to ascribing blame, as in the acres of commentary around the fifth anniversary of the Taliban’s re-accession to power. Vital symptoms and signs Extensive research has established that the fundamental drivers of health outcomes are social determinants. Unsurprisingly, the Taliban’s draconian restrictions that pervert the noble Islamic faith have dealt a crippling blow. Women have been almost erased from public spaces (except when they are flogged), with restrictions on their movement, education, and employment. Women’s access to health care has shrunk, and very young girls are being forced into marriages to settle debts or relieve poverty. Let us begin with basic health battlefield statistics. Afghans die young, with a life expectancy of 66.3 years, and under-five child mortality exceeding 50 deaths per 1,000 births – some 40% above the global average. Mothers suffer one of the world’s highest mortality ratios at 638 deaths per 100,000 livebirths. All these numbers were improving but have reversed under the Taliban. Fourteen million Afghans – a third of the population – face crisis-level hunger and there is record-breaking malnutrition with around 4.9 million children and pregnant and breastfeeding women affected. This equates to a tenth of children acutely malnourished and 45% chronically stunted. Other conditions – communicable, non-communicable, physical and mental trauma – flourish. Suicide rates, especially among females, are mounting. Six million coerced refugee returns from Pakistan and Iran, and climate disasters add to the strain. Malnutrition amongst children and the wider public has reached record levels in Afghanistan. When levers crumble All this is familiar. But it is also well known that regimes that claim divine inspiration are not amenable to earthly leverage by traditional aid, trade, diplomatic and military tools, as I discovered in my role as a past special adviser to the United Nations Assistance Mission in Afghanistan (UNAMA). Meanwhile, the Taliban are amenable to receiving assistance but on their own terms. That poses a dilemma for those who wish to relieve the suffering of Afghans without supporting their autocratic and misogynistic rulers. So the real question in a country that has always been aid-dependent becomes: how to help, also knowing that Taliban regulations complicate aid delivery and utilisation, especially as it is not possible to employ women to reach vulnerable families. This creates a difficult picture for foreign policymakers, who have many complex problems elsewhere to deal with. With the second coming of the Taliban in 2021, they found it much easier to walk away, whatever the morality of leaving Afghanistan to its own devices in light of the historic responsibilities of external powers in creating the turmoil. The walkout, in numbers The principal consequence of the walkout has been felt in the aid sector. UN-coordinated funding dropped 69% from $3.27 billion in 2022 to $1.01 billion last year. Afghanistan’s 2026 humanitarian appeal seeks $1.71 billion. With three-quarters of the year gone, it has received just 30% or $513 million (30 August). The health cluster has around $73 million, or 38% of what it wants; nutrition has $51 million (17%), and water, sanitation and hygiene received $19.5 million (12%). As a consequence, some 445 health facilities closed or suspended operations during 2025 and another 295 in the first half of this year. This includes 203 mobile health and nutrition teams. This means that at least four million people had lifesaving services switched off, including Khatera’s village. Prevention and public health services also dwindle. The epicentre of wild poliovirus has shifted to Afghanistan with 19 cases this year compared to Pakistan’s three, as house-to-house vaccination stopped in October 2024 and women vaccinators became rare. Meanwhile, and with no trace of irony, Afghanistan’s de facto Ministry of Public Health has just launched a surreal document with the vision of health as “a fundamental right” and a “goal of care for all Afghans”. This is its National Health Strategy 2026-2030 prepared with WHO support. One of its “seven pillars” concerns human resource development. It is not clear how this will be squared with the Taliban bar on women studying medicine, midwifery, nursing, and allied sciences, closing the pipeline for producing the clinicians Afghan women need. Does cutting aid kill? The political economy of aid requires deeper scrutiny. Do aid cuts lead to deaths? The US Secretary of State has asserted that it does not, as the US drastically cut foreign assistance. It is difficult to attribute specific mortality to general loss of aid, especially in Africa where American aid cuts have, in part, been made up by host budgets and other donors. But the causal association is stronger in Afghanistan, where neither the Taliban authorities nor other donors have stepped in to replace sharply dwindled US assistance, which had peaked above 40% of the country’s humanitarian spend. The US gave $728.6 million in 2024, $243.2 million in 2025, and nothing so far in 2026. An interesting study provides frontline evidence of impacts, such as neonatal deaths in Kunar and Farah rising 156% and 167% respectively between 2024 and 2025. Two sides of the humanitarian red line But there is a paradoxical aid economy at work. Even with pre-Taliban funding, most aid bypassed the government budget – except for some health basics. Since 2021, that has also gone, with UN agencies contracting providers that pay nurses and midwives directly into their personal bank accounts. So cutting such assistance does not defund the Taliban administration but individual health workers. Thus, the ‘no Taliban support’ dogma costs nothing to their officials standing on one side of the humanitarian red line and everything to the beneficiaries on the other side. No Taliban enforcer misses a meal when yet another aid-funded nutrition site shuts. Meanwhile, some $4.2 billion of Afghan central bank money sits in a Fund for the Afghan People at a Geneva non-profit foundation that has not disbursed a single dollar since its creation in 2022. There is a further $3.5 billion frozen in the US and snarled up in post 9/11 litigation. And so, Afghanistan’s own money sits idle in Western banks while an ideological contest fires off competing virtue signals over the emaciated and expired bodies of its most vulnerable citizens who were never consulted on any of it. The wider aid chill In parallel, aid implementers relying on Western governments remain wary of counter-terrorism law. On paper, there are humanitarian carve-outs including American general licences. But, amidst the friable present mood, who is so rash as to trust a piece of paper? Apart from cumbersome procedures and added administrative costs around getting waivers, imagine what happens if an agency makes a small payment for rendered services to a doctor who happens to have a Taliban relative, or a local Taliban official demands a small tax on the cash transfer. The agency could inadvertently face the nightmare of legal penalties and criminal prosecution. Meanwhile, the general donor trend of conditioning humanitarian aid accelerates. Thus, $2 billion US global humanitarian funding via OCHA specifically excludes Afghanistan. Perhaps partly because the Taliban will not agree to a US return to control the strategic Bagram airbase? Although the European Commission – now Afghanistan’s biggest donor – has maintained funding levels (around €162 million this year), it also invited the Taliban to Brussels to discuss repatriating failed Afghan asylum seekers. With some 500,000 Afghans applying for asylum since the Taliban came, and the increased political toxicity associated with the migration issue, there is a trend towards attaching conditions to European aid. As Western-espoused humanitarian values sink under their own hypocrisy and the world order splits into ‘the West’ and ‘the Rest’, Afghanistan is finding new friends. China is courting the Taliban with infrastructure investments in return for accessing Afghanistan’s massive mineral resources. Russia is giving some aid alongside military co-operation to bring Afghanistan into its sphere of influence. Central Asian and Gulf nations, as well as India and Iran, get closer to the Taliban through aid, trade, and diplomacy. This further entrenches the Taliban regime and brings little succour for people. Creative ways to bypass Taliban Afghan women and children are paying the highest price for plunging aid. That makes it even more vital to maximise the good effects of available limited humanitarian funding. This translates into aid givers finding creative ways to bypass the Taliban without getting thrown out themselves. That high-wire act to stay in the game to do good is the real story from the past five years. It is a tale of the extraordinary resilience of the Afghan people and their own traditional community and social institutions. And a tale of redemption for the very same aid agencies – UN and NGO – that are so heavily criticised for their shortcomings in other corners of the world. Here are a dozen key strategies learnt from their trial, error and courageous risk-taking that are saving lives here and there in Afghanistan. These deserve scaling up while implementers stay under the Taliban radar as much as possible. The first is about realising that aid delivery in Afghanistan is a retail affair, not a wholesale business. It requires negotiating for access locally and quietly, knowing that fierce-sounding national decrees are enforced unevenly. Province-by-province technical exemptions, brokered by Afghan staff and elders rather than announced from Geneva or Kabul, have, for example, kept some female vaccinators and midwives working. Second, more of the dwindling numbers of Afghan professionals could be pressed into service to sustain healthcare frontlines. It means expanding direct-to-worker electronic payments, which would also inject cash into local economies without going through Taliban coffers. Electronic transactions are also easily tracked and audited to encourage small agencies fearing Western anti-terror legislation to expand their services. Third, pay the mahram, the authorised male required under Taliban restrictions to accompany a female patient or the female health worker going to work. If this offends our Western sensibilities, think of the mahram as staff akin to the clinic watchman or ambulance driver. We are already compromising on mahram in practice while refusing to fund them in principle, which buys us the moral posture and the dead mother alike. Some communities show incredible creativity with the mahram requirement. For example, groups of women going together to a health centre have negotiated to be escorted by a village elder as their ‘collective mahram’ – thereby allowing their wage-earning husbands, brothers, and sons not to take time off work. Fourth, where patients cannot travel to clinics, bring them to her. Mobile health and nutrition units are well-known worldwide. Restoring and expanding Afghanistan’s mobile teams whose funding was indiscriminately cut would be a cost-effective boost for healthcare provision. A mother and her child in a WHO-supported maternal care facility in Bajnab, Afghanistan. Fifth, co-locate necessary institutional facilities such as operating rooms, laboratory and diagnostic capacities with existing national, provincial, and district hospitals, and re-equip and re-supply them. This makes it politically difficult for the Taliban to close them. Installing or repairing an ultrasound machine and refurbishing hospital electricity and water saves lives and does not mean condoning the Taliban administration. Sixth, direct-to-clinic logistics that move vital medicines, therapeutic foods and other supplies from cargo planes to pharmacies under trusted supervision help to minimise diversion and reduce manipulated distribution. Seventh, investing in autonomous, solar-powered clinic microgrids, including battery storage, has many benefits, not just for preventing the ruin of temperature-sensitive vaccines but also to allow anaesthesia and surgery for common trauma, obstetric, and other emergencies. Eighth, revive grassroots public health surveillance for marker diseases, hunger and malnutrition, and vital statistics collection around births and deaths. That means paying local community enumerators as done in past smallpox and polio campaigns. It is when operational circumstances are most complex, that programmes cannot afford to go blind from lacking local trend data. Ninth, take more measured risks. As international humanitarianism retreats while the “duty of care” movement gathers momentum, risk-aversion and institutional self-protection also grow. Understandable, of course, but is this not getting over the top? This is one of the most expressed frustrations by motivated and seasoned aid workers. Risk assessment systems – including utilising AI – have advanced but many agencies are stuck in centralised modes that mistrust well-informed local judgements. That triggers another thought. With the growing shortage of female Afghan health professionals, could more foreign females volunteer to fill the gap? That raises the associated challenge of their accompanying mahram. There are pragmatic solutions here, including negotiating ad hoc exemptions or facilitating couples to serve together. Tenth, keep the health and training pipeline rumbling along. Afghanistan’s education sector provides remarkable inspiration through clandestine home and digital schooling initiatives for girls. Can these approaches be applied in the health sector, both for refreshing basic health worker knowledge and for general public education around essential skills such as first aid, nutrition, and preventing and treating common conditions, including psychosocial support and suicide risk handling? Further, by investing in enhanced digital connectivity in selected (especially secondary) hospitals via low-cost technologies like Starlink that are available worldwide, expert Afghan medical diaspora with relevant linguistic skills could provide online consultations. Eleventh, sustaining a health delivery system that works for people is a crucial concern as there is no possibility of political change in the foreseeable future. Meanwhile, high-profile international aid brands and large corporate logos draw intense, negative Taliban scrutiny. They could, instead, sponsor low-profile hyper-local community networks via pre-existing local volunteer bodies and underground civic networks to distribute medical micro-assistance, including medicines, hygiene kits, consultation referrals, and even skills training. Twelfth, and most crucially, health aid givers should agree on common operating rules pragmatically applied in local circumstances. That means less policy rhetoric on confrontational red lines and more about working solutions that focus on patients. Facility-by-facility, the Taliban morality inspectors are conceding that medical spaces be demilitarised. Also female and male colleagues may work alongside each other during lifesaving procedures. Such bargains can be built upon. Consistency and patience are missing The Taliban rank-and-file know that their loved ones also need healthcare, often under desperate circumstances. Their rigid mindsets are curiously mirrored in their respect for others who also stubbornly hold onto their own principles. Hence, a package of negotiated measures that bring predictable cooperation over health is quite feasible, as shown by pioneering agencies such as Médecins Sans Frontières. In short, much more can be done to safeguard the health of Afghans despite numerous obstacles. There is nothing novel in the proposed approaches that have already shown good results in Afghanistan and other complex resource-poor contexts. So what is missing? Beyond insufficient resources, it is a sense of coherent mission that believes in the feasibility of improving the health chances of Afghans. This will not come from the current defeatist attitudes among humanitarian, global health, and multilateral aid communities with low expectations and marked risk aversion. Neither will it come from composing national health strategies that are little more than fantasies. We need pragmatic but consistent labouring from the bottom-up organised around whatever Afghans find feasible. Above all is the requirement for patience that the international community is not known for. Mukesh Kapila is professor emeritus of global health and humanitarian affairs at the University of Manchester, and a board member of Health Policy Watch. Vital Signs in Global Health is a regular column, and the opinions expressed are solely those of the author. Image Credits: Charlotte Cans/ UNOCHA, Karimi/ UNICEF Afghanistan, WHO EMRO, WHO. South Africa Grapples With The Promise and Price of Injectable Lenacapavir to Prevent HIV 30/08/2026 Kerry Cullinan Sex worker advocate Precious Mafanga describes lenacapavir as very easy to take for her sector. The antiretroviral medicine lenacapavir, delivered via injection every six months, is almost completely effective in preventing HIV. But it is expensive at present, and millions will need to be initiated on it every year to make a dent on HIV transmission in South Africa. CAPE TOWN – South Africa has the biggest population of people living with HIV in the world – over eight million people, around 18% of those aged 15 to 49. So its Health Ministry and researchers are laser-focused on HIV prevention tools, particularly how to optimise pre-exposure prophylaxis (PrEP), which involves using antiretroviral medication to prevent HIV. The newest PrEP offering is lenacapavir, Gilead’s “miracle” twice-yearly injection that has prevented almost 100% of HIV transmission in clinical trials, some of which took place in South Africa. The country started to roll out lenacapavir in June, and it is now available at 360 health facilities to anyone who feels at risk of HIV. South Africa’s President Cyril Ramaphosa described the introduction of lenacapavir as “a major turning point in South Africa’s national story. It is the triumph of science over despair and the power of innovation to save lives”. But fewer than 47,000 people have been initiated so far – mainly because the health department cannot afford a huge rollout. Yet health economists advising the government have worked out that the country needs to get at least 1.7 million people on lenacapavir every year for the next five years if it wants to break the transmission of HIV. Drug price and procurement Hasina Subedar, senior technical advisor to the South Africa Department of Health. The Global Fund, which has an agreement with Gilead, is procuring the drug for South Africa, and has asked the health department to ring-fence $29.2 million of its three-year Global Fund grant for lenacapavir. “The Global Fund asked us to budget for $60 per person per annum, and it is topping this up, but the price they are paying [to Gilead] is confidential,” says Hasina Subedar, senior technical advisor at the South African Department of Health. This budget translates into doses for around 420,000 people. While the United States government is assisting other countries to buy lenacapavir, it decided not to support South Africa over political disagreements. However, the Children’s Investment Fund Foundation (CIFF) has stepped in to assist the country. “We will really only be able to have roll-out at scale when we have the generics,” says Subedar, noting that lenacapavir has been included on the country’s essential medicines list, subject to the availability of generics at $40 per annual dose. In October 2024, Gilead announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir for 120 “high-incidence, resource-limited countries”. It has prioritised 18 of these countries, including South Africa. The six are Dr Reddy’s Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero and Mylan – none South African. So far, only Hetero has submitted its dossier for regulatory approval to the South African Health Products Regulatory Authority (SAHPRA). Generics are expected by mid-2027, but it is unclear yet when they will reach South Africa. Lumps and bumps: administering lenacapavir South African health facilities have offered oral PrEP since 2016, although the small supplies initially available were first directed to groups most at risk: sex workers, then men who have sex with men and then teenage girls and young women. Since its introduction, some 2.3 million people have started oral PrEP, but have stopped taking the pills. Supply has been affected by the 2025 US budget cuts. But some people also get tired of daily pill-taking. Others, particularly vulnerable young women, are reluctant for their partners to know that they are taking precautions against potential HIV infection. This makes the six-monthly injectable option so attractive. But it’s not a simple process, as Subedar explains. Lenacapavir initiation happens over two days. On day one, people get two 1.5ml injections in separate areas, administered subcutaneously (in the fatty layer of skin). This is usually in the person’s abdomen or buttocks. At the same time, they get two 300mg pills. People are sent home with two 300 mg pills, which they need to take the following day. By day three, they are protected against HIV for the next 26 weeks until their next injections. They have a two-week grace period either side of their 26-week date to get their next injections. No pills are needed on subsequent visits unless they miss the two-week window. Patients’ experiences: ‘Next time, the buttocks’ Trans activist Dimpho Tsotetsi says oral PrEP made me nauseous. Dimpho Tsotetsi, who has used oral PrEP since 2017, switched to lenacapavir in a Soweto clinic on 4 July. “I used to work in a [USAID] donor-funded clinic, so I knew it was coming,” said Tsotetsi, an extroverted 32-year-old trans woman who describes herself as a health advocate for her community. “I had nausea every day with oral PrEP,” she added, and despite about two weeks of discomfort after her injections, Tsotetsi describes the experience as “pleasant”. “I got two shots on my stomach, one on the left, one on the right. Until today I still have the bumps. I can feel them,” said Tsotetsi, who adds that this has made wearing clothes with tight waistbands harder as they rub against the injection bumps. “Hence I’m wearing something flowy”, she laughs. Precious Mafanga, a sex worker and sex worker advocate, describes lenacapavir as “very helpful and easy to take” – unlike oral PrEP “which makes you hungry”. She and many others working in organisations serving “key populations” – those most at risk of HIV – have had a rough time since the US stopped funding these groups after Donald Trump came to power in January 2025. Mafanga describes chaos in the sex worker sector, with job losses for peer educators, sex workers defaulting on antiretroviral medication and a lack of support for people who inject drugs as specialised clinics and mobile outreach came to a screeching halt. In the past few months, a new organisation, Tholwana e Molemo, has stepped up to assist sex workers. While resources are much more limited, the organisation’s nurses have been able to work with government clinics to enable sex workers to get fast access to lenacapavir. Lindiwe Mqatazana, who is pregnant, opted for lenacapavir to protect her baby. Meanwhile, Siviwe Gaika, a 24-year-old law student and church-goer who uses PrEP to protect herself, said she tried to get lenacapavir three times before her local clinic, a designated site, was ready to administer it. She also describes bumps on her abdomen at the injection sites: “I think next time I will get it on the buttocks.” It was the buttocks for Lindiwe Mqatazana, who had a positive pregnancy test and lenacapavir all in the same day. “It was a bit scary, but the nurses explained that this is the best way to protect my baby and that it won’t hurt the baby,” said Mqatazana. Million-person rollout Dr Lise Jamieson from the Health Economics and Epidemiology Research Office (HE2RO) at Wits University is one of the health economists advising the health department. Using Thembisa, a mathematical model of the South African HIV epidemic, researchers have made various forecasts, said Jamieson. Their key message is that lenacapavir will be far more effective than oral PrEP – if it is rolled out at scale. The impact of lenacapavir in comparison to oral PrEP (TDF/ FTC) After modelling various scenarios, they calculate that lenacapvir can reduce HIV by 19-31% over 20 years in comparison to 4% by oral PrEP. It will also end AIDS seven to 10 years earlier than oral PrEP. But this impact requires serious volumes: between 1.7 million and 2.3 million people need to start lenacapavir every year for at least the next five years. The rollout needs to be more targeted at those who need it most, with the most optimal breakdown to be 45% for adolescent girls and young women (AGYW); 30% for men who have sex with men (MSM); 15% for female sex workers; and 10% for pregnant and breastfeeding women. The health department’s targets are weighted more heavily towards teenage girls, young women, and pregnant and breastfeeding women. However, currently it is hard to tell which groups most of the 47,000+ people who have opted for lenacapavir come from, as over 70% describe themselves as the “general population”. Targeting certain key populations – female sex workers (FSW), men who have sex with men (MSM), and adolescent girls and young women (AGYW) – will have more impact than an over-emphasis on pregnant and breastfeeding women (PBFW), according to experts. Meanwhile, the financial investment is substantial, with up to $106 million needed for five years – but, says Jamieson, this is still four times more cost-effective than oral PrEP. More choices “The excitement about lenacapavir is huge, but what is the follow-up going to be like?” asks Dr Pippa McDonald, from the Desmond Tutu Health Foundation. The foundation was one of the partners that ran the clinical trial of lenacapavir, and is currently monitoring people’s responses and uptake to the medication. So far, over 80% of people surveyed want the six-monthly injections rather than oral PrEP, said MacDonald. “Choice is really important,” says MacDonald, who believes that offering different PrEP options and points of delivery are important ingredients for success. A monthly PrEP pill, alimatravir, is currently undergoing clinical trials – and may prove even more popular than the six-monthly injections. At the International AIDS Society (IAS) conference in Brazil in July, the company developing the pill, Merck/ MSD, announced that it has already granted voluntary licenses to seven generic companies – three in sub-Saharan Africa and four in India – to produce the medicine for 129 low- and middle-income countries. This is even before the medicine has been proven effective. There are many possibilities in the mix, including the government distributing PrEP in partnership with private pharmacies and people self-injecting follow-up lenacapavir doses. But there are still many unknowns too, particularly how fast generic lenacapavir can be produced, whether there will be enough money for the scale-up that is needed, and how many people will come back after six months. Interviews for this article are from a media workshop on South Africa’s lenacapavir rollout organised by Bhekisisa. India’s Flagship Air Pollution Programme Is Failing 28/08/2026 Chetan Bhattacharji Dr Piyush Bharadwaj, CSTEP, presenting research on the air quality and climate co-benefits possible in India at the India Clean Air Summit. BENGALURU – India’s flagship air pollution action plan, the National Clean Air Programme (NCAP), has mostly failed to deliver, according to research presented at the eighth India Clean Air Summit. Officials, scientists, and other experts highlighted the 2019 program’s severe shortcomings and red-flagged critical gaps. An “NCAP 2.0′ has been widely expected, but the central government has yet to announce a launch timeline. Data shared by the summit organiser, the Center for Study of Science, Technology and Policy (CSTEP), showed that fewer than 7% of the 131 targeted cities met NCAP’s goal to reduce pollution by 40% by 2025-26, and 35% of cities showed an increase in coarse particulate matter (PM10). This failure comes despite the government releasing over INR 16,423 crore (approximately $1.5 billion) to support the program. Speakers at the conference emphasized that future iterations of the programme must bridge air pollution control measures with climate action policies. Crucially, at least two government experts warned of emerging, interconnected feedback loops between climate change and air quality. Structural flaws in programme According to CSTEP, NCAP’s limited impact stems from several core design flaws. These include that it targets cities; focuses on PM 10 and dust mitigation measures not the finer, deadlier PM2.5 particulate matter pollutant; has no systemic assessment of interventions; and it covers short-term measures rather than long-term planning considering growth. There is also limited technical understanding of urban local bodies (ULBs). About 95% of India’s PM2.5 pollution, a universally tracked pollutant, is emitted from cities and rural areas that are excluded from NCAP’s focus, which tracks 131 cities. Seventy percent of PM2.5 is from “non-urban areas” according to PAVITRA, an air quality management tool developed by IIT Bombay, CSTEP and two American universities. Data shows how much of India’s air pollution sources lie outside cities and outside the National Clean Air Programme’s focus centres. Source: Air Pollution Management And Intervention Tool For India (PAVITRA), by IIT Bombay, CSTEP, University of Washington, Berkeley University of California. Another limitation is the lack of funding for places where pollution is rising, such as the coastal state of Kerala. “What I really want to request is that when NCAP 2.0 is happening, there should be some funds available to the cities which are not non-attainment, but are trying to prevent becoming a non-attainment city,” says Ratish Menon, a senior official of Kerala’s Pollution Control Board. Non-attainment means cities that have consistently failed to attain air quality that meets the national ambient air quality standard of 40 micrograms/cubic metre of PM2.5. Indo-Gangetic plain: India’s pollution hotspot That plain stretches about 2,000 kilometres across northern India, south of the Himalayan foothills and east to Bangladesh. However, the most severe challenge remains concentrated in northern plains of India, described as an “emission hotspot” by SD Attri, a senior official and scientist of the Commission for Air Quality Management (CAQM). The CAQM is in-charge of reducing pollution in and around Delhi, which is situated in the plains. “The Indo-Gangetic Plain (IGP) covers only 15% of India’s land but accommodates around 37% of its population and emits 35% of India’s total emissions, making it an emission hotspot,” Attri explained, which is why Delhi and other places here often make it to the list of the top, most polluted places in the world. Residents across the northern plains are exposed to persistently high pollution levels year-round. On an annual basis, average concentrations of PM2.5 or smaller particulate matter reach 84 µg/m³ (micrograms/cubic metre), which is more than twice the permissible standard of 40 micrograms under India’s National Ambient Air Quality Standard and almost 17 times the WHO’s safety guideline of 5 µg/m³ . Target mitigation: Black carbon in UP and Bihar A sharper focus on just two states, Uttar Pradesh and Bihar, and one pollutant, black carbon or soot, has been recommended by a CSTEP report launched at the summit. The largest source of black carbon is from homes burning biomass and other dirty fuels for cooking and heating. And more than 60% of this pollution is from the IGP states. Uttar Pradesh and Bihar is where domestic emissions have the greatest regional spillover. These two states dominate India’s northern plains, with a combined area about the same as Finland but with a combined population larger than the US. Reducing black carbon emissions can save lives, and the largest benefits are to be achieved through a multisectoral airshed approach. Reducing black carbon emissions from all major sources in the IGP results in a 37% reduction in black carbon concentration and prevents 2,290 PM2.5-attributable premature deaths. This number is conservative, as the authors explain there is limited research on the health effects of black carbon, unlike that of PM2.5, which is linked to about a million deaths in the country. “The mortality burden estimated in this study is conservative because the exposure–response function used is derived for ambient PM 2.5 mass concentration rather than for individual PM 2.5 components (Black carbon, organic carbon, sulphates, nitrates, etc). “Consequently, the potential toxicity of black carbon is not explicitly captured in the mortality estimation,” Piyush Bharadwaj, head of the air quality observations and modelling group at CSTEP, told Health Policy Watch. Climate change – air pollution link The CSTEP report also highlights significant co-benefits between clean air initiatives and carbon mitigation. In a best-case scenario, aggressive black carbon reduction in northern India would yield climate co-benefits equivalent to 639.3 MT CO2, roughly similar to Germany or South Korea’s annual emissions. Dr Ratish Menon, senior official, Kerala State Pollution Control Board, India There were other warnings about the link between global warming and air pollution. Menon attributed part of the rise in Kerala’s air pollution levels to pollution from neighbouring states, but also to global warming. Last winter’s peak in “all (air quality monitoring) stations” was more because there was lesser wind transport between the land and ocean, he says, “because the ocean temperatures are increasing and that exchange is getting affected. That causes a regional buildup.” A separate climate link was flagged by a senior scientist at IIT Kanpur, SN Tripathi, whose team has overseen the deployment of almost 1,400 low-cost sensors in Uttar Pradesh and Bihar. Based on this data, Tripathi said they have been able to create an index where “we have combined temperature and relative humidity to provide some kind of a universal climate index, and we are basically trying to give that how it looks during summer times when the temperatures are very high and the overall comfort level for human beings becomes very unmanageable.” They are seeing that a good part of these two states have a “very high amount of this compound index.” When asked by Health Policy Watch, how this ‘universal climate index’ is to be used, Tripathi said it was work in progress and premature to comment. Call to change air quality action plans India’s peak pollution season begins in October and ahead of that, Attri, the most senior official from the government of India at the summit, listed several measures taken to reduce air pollution. The latest include increasing the number of top grade air quality monitoring stations from about 90 currently to 157 in the next month as well a “new GRAP” system which he says will be open for the public’s comments and suggestions; GRAP is the Delhi region’s Graded Response Action Plan, a series of tighter curbs – on transport, construction, diesel generators, cooking fuels and even schools – as pollution levels rise However, the larger messaging from ICAS 2026 is that urgent changes in air quality management are required. Pointing to a series of policy actions since the Air (Prevention and Control of Pollution) Act was cleared by Parliament 45 years ago, and the INR 16,423 crore in funding released by the government, Abinaya Sekar of Health Effects Institute underscored the need to assess the effectiveness of air pollution interventions, offering a framework on how to do this. CSTEP researchers urged the government to integrate air quality targets into both NCAP 2.0 and India’s international commitments under the UN Nationally Determined Contributions (NDCs), that is, self-identified pledges for climate action by every country. Aligning these policies would allow air quality improvement to be recognised as a critical element of near-term climate mitigation, particularly by targeting short-lived climate pollutants like black carbon. In eight years of the India Clean Air Summit and similar gatherings, the one constant has been the demand for better implementation. The other constant has been Delhi’s annual average PM2.5 pollution level stubbornly hovering around 100 micrograms, in the last eight years. Image Credits: Source: Press Information Bureau, Indian Government. Historic Meta Settlement Mandates Safer Social Media for Youth 27/08/2026 Editorial team Meta agreed to silence notifications for teens from midnight to 6:00 AM, but this excludes direct messaging and can be disabled by parents. Following a landmark agreement in the United States on Wednesday, social media giant Meta agreed to pay up to $18 billion to US states. This historic settlement obliges the company to make Instagram and Facebook safer for children. Scientific research – including a landmark report by an expert panel commissioned by the European Commission – shows that excessive social media use damages early childhood brain development and fuels mental health crises among young people. Meta emphasises that the settlement is not proof of harmful health effects caused by its platforms. However, the unprecedented sum is likely to increase global pressure on platform operators to take action. The company said it had agreed to distribute the payments in annual instalments over a 10-year period to fund youth online safety initiatives across the participating states. Meta limits social media access for youth The agreement stipulates that Meta must limit daily usage time to two hours, disable extreme beauty filters, pause nighttime notifications and hide ‘like’ counts on posts by teenagers. In addition, the company will implement an age verification system under which no more than 3% of 13- to 15-year-olds and 10% cent of older teenagers may be incorrectly classified as adults. “The framework we’ve negotiated will empower parents to easily manage how their children access our platforms,” said CJ Mahoney, chief legal officer at Meta in a statement on Wednesday. Meta is required to phase in these modifications, with a strict compliance deadline set for six months after the court has now approved the settlement. To prevent an exodus of young users, Meta is urging its competitors, YouTube and TikTok, to adopt these standards. Doubts about effectiveness of settlement However, experts question whether the agreed time limits will effectively curb deep-rooted addiction risks. Parents can easily disable these daily usage caps, and the overnight notification pause does not cover direct messaging. Biometric facial scans for age verification remain controversial because processing sensitive video data violates data protection principles. Furthermore, teenagers easily bypass basic digital blocks using virtual private networks (VPNs), while privacy-friendly age verification methods remain unavailable on a large scale. A signal to regulators worldwide Nevertheless, the US settlement establishes a benchmark for youth social media bans passed in Australia and proposed in New Zealand. The European Commission plans to introduce a draft regulation this autumn to enforce a harmonised European age limit and strict safety-by-design standards. This proposed framework aims to end the current patchwork of legislation across Europe, as national restrictions often clash with the strict rules of the EU’s Digital Services Act (DSA). Related Story: Warning labels, Time restrictions? Experts Mull How to Curb Social Media Harms Editorial note: The piece has been updated on 28 August to reflect that the court has now approved the settlement. Image Credits: cottonbro studio via Pexels. The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
Aid Cuts Exacerbate Food Insecurity in the West Bank, Health Crisis in the Gaza Strip 01/09/2026 Felix Sassmannshausen Violence, economic distress and funding cuts leave nearly a million people in the West Bank facing severe food insecurity, according to the World Food Programme. Around 200,000 people in the Israeli-occupied West Bank will lose access to vital food aid from the United Nations World Food Programme (WFP) due to funding cuts, exacerbating food insecurity. In the Gaza Strip, the nutrition and health crisis is set to worsen further due to a lack of medical supplies and sanitation, the World Health Organization (WHO) warns. Over the past two years, the number of people affected by food insecurity in the West Bank has doubled to almost one million – over a quarter of the population, according to latest WFP data. Due to drastic funding shortfalls, the WFP is halving its aid to the 400,000 recipients starting in September, the organisation announced. Already, 12% of the surveyed population suffer from inadequate food consumption, whilst a third of West Bank households can no longer afford a nutritious diet. “Food may be available in the markets, but people simply cannot afford it,” said WFP Country Director Shaun Hughes, describing the crisis at a UN press briefing in Geneva on Tuesday. In future, only the most needy families will receive cash support of around 50 shekels (under $20) per person per month. The cuts impact the provision of vouchers, food, livelihood support and nutritional aid for children and pregnant women. Economic crisis and rising settler violence WFP’s Shaun Hughes warns funding cuts deepen severe food insecurity. The West Bank’s economy is in a deep economic crisis on two fronts simultaneously. Unemployment now stands at 30% after Israel closed its gates to most Palestinian workers following the 7 October 2023 Hamas-led massacre in Israel. At the same time, the governing Palestinian Authority (PA) has been economically crippled by the refusal of Israel’s hardline government to transfer some $5 billion, to date, in import and customs taxes on goods entering the West Bank as it is legally obliged to do. Normally, such transfers make up about 70% of the PA’s budget, and the withheld funds are mostly earmarked for salaries, particularly for employees in healthcare and education. The PA, meanwhile, has also been plagued by widespread corruption, according to Freedom House, and immense public debt, estimated by the World Bank at $4.8 billion by the end of 2025. According to WFP data, 76% of all West Bank households have thus experienced a significant decline in their income. Against that context, the WFP aid payments represent crucial safety nets for many recipients facing severe financial crisis in the conflict-ridden region. However, Hughes also blames rising settler violence, Israeli military operations, roadblocks, and arbitrary house demolitions for exacerbating the situation. “In my recent visits to the West Bank, I have witnessed families once thriving and earning a living off their land now forced from their homes, their livelihoods destroyed. They now find themselves in a chokehold,” he said. Israeli Prime Minister Benjamin Netanyahu recently criticised violent acts in the West Bank as criminal and damaging to Israel’s standing in the world. But critics, including voices in the military, say that his government has failed entirely to show real muscle in reining in the increasingly violent and frequent settler rampages, leading to progressively greater limitations on Palestinian movement and access to their lands. Health risks and acute food insecurity in the Gaza Strip Stagnant water in Gaza’s makeshift camps fosters pest infestations, sharply increasing the risk of diarrhoeal diseases as food insecurity worsens. In the Gaza Strip, too, the WFP cut cash assistance for 375,000 people by 40% back in July. To continue providing vital supplies in both areas, the organisation urgently needs an additional $386 million for the next six months, it said. This massive funding shortfall threatens an already fragile situation on the ground. Although food deliveries have improved supplies since the October 2025 ceasefire, two-thirds of the population in the Gaza Strip continue to suffer from crisis and emergency levels of acute food insecurity. The UN-linked Integrated Food Security Classification (IPC) forecasts that high levels of acute food insecurity will affect up to 90% of the population by the end of the year if humanitarian aid is not sustained. Indeed, chronic undernutrition has emerged as the primary challenge, according to a June survey of Gaza by UNICEF. While emergency aid stabilized acute malnutrition (wasting) at 1.3%, chronic malnutrition (stunting) now affects 12.2% of children under five. Dietary quality is also dismal: only 30.3% of children aged 6–23 months achieve minimum dietary diversity, and just 22.4% receive a minimum acceptable diet, leaving them highly vulnerable to developmental and cognitive impairments. The nutrition crisis is compounded by catastrophic living conditions; some 94% of Gaza’s 2.1 million residents lack adequate shelter, and approximately 100,000 children and pregnant or lactating women remain in need of continuous nutritional aid. Disease outbreaks loom amidst the destroyed infrastructure WHO epidemiologist Reinhilde Van De Weerdt warns that contaminated water and severe medical shortages pose imminent disease threats to displaced populations in Gaza. After the searing heat of summer, winter rains will mean flooding in overcrowded tent cities, and that, “will spread the sewage, the waste and contaminated water into the places where people sleep, cook and care for their loved ones,” warned WHO epidemiologist Reinhilde Van De Weerdt at the UN briefing. Damp tents and mould also dramatically increase the risk of respiratory diseases, particularly among young children, she pointed out. According to WHO data, microbiological contamination of tested water samples nearly tripled this year, rising from under 6% in January to almost 20% in August. As a result, cases of acute watery diarrhoea almost doubled from around 30,000 in March to over 58,000 recorded cases in August. However, the WHO warns that the severely limited local laboratory capacity can currently only detect basic microbiological contaminants, meaning that further contamination remains undetected. Furthermore, stagnant water encourages the uncontrolled breeding of disease-carrying mosquitoes and pests. Additionally, restrictive import licences have been blocking vital deliveries of medical supplies such as prosthetics and other medical aids since May 2024, according to the WHO. As a result, only 12% of those who lost limbs since the war began have been fitted with a prosthetic device, while more than 6,600 amputees in total require long-term care, said Van De Weerdt. The WHO is calling for the accelerated import of medical supplies, including diagnostic laboratory materials for the rapid identification of viruses and bacteria. Without this equipment, the early detection and containment of potential disease outbreaks on the ground would be virtually impossible. Israeli government pushes back against allegations Responding to a query by Health Policy Watch, the Coordinator of Government Activities in the Territories (COGAT) stated that Israel exercises “heightened caution” regarding dual-use items due to the risk of exploitation by Hamas for military purposes, but stressed that these items are “not subject to a blanket prohibition.” The agency added that it coordinates a continuous response with UN agencies to facilitate alternative items, such as spare parts and engine oil, while fuel is brought into the Gaza Strip daily by UN agencies. COGAT also strongly disputed claims of restrictive barriers on medical supplies, stating that “all medicines submitted for entry into the Gaza Strip are approved and cleared without restriction.” The agency maintained that advanced medical equipment – including X-ray machines, diagnostic devices, laboratory tools, and backup generators – was recently transferred to support international health facilities, including field hospitals operated by the Red Cross, the United Arab Emirates (UAE), the International Medical Corps (IMC), and UK-Med. Responding to concerns over water infrastructure, COGAT stated that Israel actively facilitates the entry of equipment and piping to repair and maintain water networks. According to the agency, a desalination facility in southern Gaza was recently repaired and connected to the “Kela” electricity line to increase water supply. It added that 10 major water, sanitation, and hygiene (WASH) projects were recently approved, allowing international organisations to import sewage pipes, fittings, engine oil, water storage equipment, and water quality testing kits. The Israeli Ministry of Foreign Affairs (MFA) did not respond to a query by Health Policy Watch. See related story: Most Gaza Palestinians Living in Dangerous, Unsanitary and Unhealthy Shelters Image Credits: WFP/Claire Nevill, Felix Sassmannshausen/HPW, WHO. United States to Cut Health Funding to 18 Countries 59% by 2030 31/08/2026 Kerry Cullinan Kenya’s President William Ruto applauds Kenyan Cabinet Secretary Musalia Mudavadi and US Secretary of State Marco Rubio after they signed an MOU for health funding. The United States plans to cut its health funding to 18 countries by 59% of pre-2025 levels by 2030, according to a Public Citizen and Partners In Health analysis of the bilateral agreements the US has signed with these countries. The bilateral Memorandums of Understanding (MOUs) were signed as part of the ‘America First Global Health Strategy’ adopted by the Trump administration in 2025, and are intended to rapidly wean countries off US aid by 2030. The reduction amounts to a cut of some $2 billion to US aid dispensed before 2025, according to Public Citizen, which analysed the MOUs – some of which it initially obtained via a Freedom of Information Act (FOIA) lawsuit against the Trump administration. Countries facing the steepest cuts are Rwanda (97% reduction), Liberia (84%), Burundi (78%), Madagascar (77%), and Sierra Leone (71%). All MOUs require countries to make substantial co-financing commitments. These are for activities identified as priorities by the US, and do not necessarily align with the countries’ priorities. For example, the US wants all countries to improve their ability to identify disease outbreaks, so it requires substantial investment in epidemiologists and data capturers. But many recipient countries may prefer to prioritise employing health workers. In 11 out of the 18 countries, the co-financing commitments fail to cover the US cuts over five years compared to pre-2025 government funding. “Countries may also struggle to meet these funding expectations,” says the analysis. “For example, Malawi would have to mobilize new funding equal to 56% of the country’s total health expenditure to meet its annualized co-financing commitment.” Co-financing ‘punishment’ The US government also reserves the right to reduce or cease funding if countries don’t meet their co-financing commitments. In addition, the MOUs stipulate that the co-investments “may not include funding from other donors or multilateral organizations, but must be funds ‘raised directly’ by the country”, says Public Citizen and Partners In Health. “There is no transparent logic guiding the application of penalties across countries,” their analysis notes. If Ethiopia, Kenya, Mozambique, Cameroon, and Malawi fail to meet co-financing commitments, the US will reduce its funding by $1 for every $1 shortfall. Uganda and Côte d’Ivoire face a 2:1 reduction. However, no penalties are specified in the MOUs with Rwanda, Liberia, Lesotho, Eswatini, Sierra Leone, Madagascar, Burundi, Botswana, and South Sudan. Many of the MOUs also include “performance incentives” for meeting process and outbreak response metrics, but quantifying them is vague. Seven African countries will have fewer health workers by 2030, thanks to reduced US and partner government commitments. These are Burundi, Cameroon, Eswatini, Kenya, Lesotho, Madagascar and Malawi. “This is a major concern since the African region currently has only 46% of the health workers it needs, and by 2030 it is projected to face a health workforce shortage of 5.85 million workers,” the analysis notes. Burundi will lose all US-funded community health workers (CHW). Malawi will lose 3,436 CHWs (72% of its total), and Madagascar, 8,200 (39%). Cameroon faces a 20% reduction in CHW and nurses despite already facing “a severe shortage” of both. The one piece of good news is that the MOUs reduce the duration of controversial data-sharing and pathogen specimen-sharing agreements, which were initially for up to 25 years – despite the MOUs only lasting up to five years. But “these agreements stand apart from the MOU itself, and most are not available in wider circulation, making a full assessment of final terms impossible in most cases”. Some countries have baulked at the data-sharing requirements, with Zimbabwe deciding not to pursue an MOU with the US. Several countries point out that these data-sharing agreements, usually appendices to the MOUs, directly undermine the pathogen access and benefit-sharing (PABS) system currently being negotiated at the World Health Organization (WHO). “These documents suggest that the Trump administration is on course to underspend on global health by billions of dollars compared to what Congress has ordered, risking lives and allowing diseases to spread,” said Peter Maybarduk, Access to Medicines director for Public Citizen. “The administration must answer how and when it intends to invest the missing billions for health.” Clashing Convictions of Taliban and the West is Costing Afghan Lives 31/08/2026 Mukesh Kapila Afghan women have been almost erased from public life. Two sets of dogmas contend in Afghanistan: those of the Taliban and the West. Neither side pays the real price for their beliefs. Ordinary Afghans do with their lives. Some aid agencies labour quietly to bring help and hope through a dozen practical ways that bypass competing doctrines. They deserve support. In March last year, 23-year-old Khatera (pseudonym) went into prolonged labour. Her village clinic in western Afghanistan was long shuttered, and the nearest help was Herat city across a swollen river. Her husband carried her across the raging waters, both submerged to the shoulders. It took them 12 hours to reach the hospital. Khatera’s vital signs – and those of her baby – stopped registering hours after reaching the hospital. Why were they not saved? Perhaps no medical equipment or supplies? Perhaps few trained staff? Or perhaps sheer exhaustion? This everyday tragedy is commonplace for Afghans. Their misfortune is to be squeezed between the beliefs of their Taliban rulers and those of the international community that fled the country. This clash of convictions is fought over the easiest of targets: the defenceless bodies of millions like Khatera. The outcome is a generation of losers, not just Afghans but those who would save them. As with all lose-lose “games”, the focus quickly shifts to ascribing blame, as in the acres of commentary around the fifth anniversary of the Taliban’s re-accession to power. Vital symptoms and signs Extensive research has established that the fundamental drivers of health outcomes are social determinants. Unsurprisingly, the Taliban’s draconian restrictions that pervert the noble Islamic faith have dealt a crippling blow. Women have been almost erased from public spaces (except when they are flogged), with restrictions on their movement, education, and employment. Women’s access to health care has shrunk, and very young girls are being forced into marriages to settle debts or relieve poverty. Let us begin with basic health battlefield statistics. Afghans die young, with a life expectancy of 66.3 years, and under-five child mortality exceeding 50 deaths per 1,000 births – some 40% above the global average. Mothers suffer one of the world’s highest mortality ratios at 638 deaths per 100,000 livebirths. All these numbers were improving but have reversed under the Taliban. Fourteen million Afghans – a third of the population – face crisis-level hunger and there is record-breaking malnutrition with around 4.9 million children and pregnant and breastfeeding women affected. This equates to a tenth of children acutely malnourished and 45% chronically stunted. Other conditions – communicable, non-communicable, physical and mental trauma – flourish. Suicide rates, especially among females, are mounting. Six million coerced refugee returns from Pakistan and Iran, and climate disasters add to the strain. Malnutrition amongst children and the wider public has reached record levels in Afghanistan. When levers crumble All this is familiar. But it is also well known that regimes that claim divine inspiration are not amenable to earthly leverage by traditional aid, trade, diplomatic and military tools, as I discovered in my role as a past special adviser to the United Nations Assistance Mission in Afghanistan (UNAMA). Meanwhile, the Taliban are amenable to receiving assistance but on their own terms. That poses a dilemma for those who wish to relieve the suffering of Afghans without supporting their autocratic and misogynistic rulers. So the real question in a country that has always been aid-dependent becomes: how to help, also knowing that Taliban regulations complicate aid delivery and utilisation, especially as it is not possible to employ women to reach vulnerable families. This creates a difficult picture for foreign policymakers, who have many complex problems elsewhere to deal with. With the second coming of the Taliban in 2021, they found it much easier to walk away, whatever the morality of leaving Afghanistan to its own devices in light of the historic responsibilities of external powers in creating the turmoil. The walkout, in numbers The principal consequence of the walkout has been felt in the aid sector. UN-coordinated funding dropped 69% from $3.27 billion in 2022 to $1.01 billion last year. Afghanistan’s 2026 humanitarian appeal seeks $1.71 billion. With three-quarters of the year gone, it has received just 30% or $513 million (30 August). The health cluster has around $73 million, or 38% of what it wants; nutrition has $51 million (17%), and water, sanitation and hygiene received $19.5 million (12%). As a consequence, some 445 health facilities closed or suspended operations during 2025 and another 295 in the first half of this year. This includes 203 mobile health and nutrition teams. This means that at least four million people had lifesaving services switched off, including Khatera’s village. Prevention and public health services also dwindle. The epicentre of wild poliovirus has shifted to Afghanistan with 19 cases this year compared to Pakistan’s three, as house-to-house vaccination stopped in October 2024 and women vaccinators became rare. Meanwhile, and with no trace of irony, Afghanistan’s de facto Ministry of Public Health has just launched a surreal document with the vision of health as “a fundamental right” and a “goal of care for all Afghans”. This is its National Health Strategy 2026-2030 prepared with WHO support. One of its “seven pillars” concerns human resource development. It is not clear how this will be squared with the Taliban bar on women studying medicine, midwifery, nursing, and allied sciences, closing the pipeline for producing the clinicians Afghan women need. Does cutting aid kill? The political economy of aid requires deeper scrutiny. Do aid cuts lead to deaths? The US Secretary of State has asserted that it does not, as the US drastically cut foreign assistance. It is difficult to attribute specific mortality to general loss of aid, especially in Africa where American aid cuts have, in part, been made up by host budgets and other donors. But the causal association is stronger in Afghanistan, where neither the Taliban authorities nor other donors have stepped in to replace sharply dwindled US assistance, which had peaked above 40% of the country’s humanitarian spend. The US gave $728.6 million in 2024, $243.2 million in 2025, and nothing so far in 2026. An interesting study provides frontline evidence of impacts, such as neonatal deaths in Kunar and Farah rising 156% and 167% respectively between 2024 and 2025. Two sides of the humanitarian red line But there is a paradoxical aid economy at work. Even with pre-Taliban funding, most aid bypassed the government budget – except for some health basics. Since 2021, that has also gone, with UN agencies contracting providers that pay nurses and midwives directly into their personal bank accounts. So cutting such assistance does not defund the Taliban administration but individual health workers. Thus, the ‘no Taliban support’ dogma costs nothing to their officials standing on one side of the humanitarian red line and everything to the beneficiaries on the other side. No Taliban enforcer misses a meal when yet another aid-funded nutrition site shuts. Meanwhile, some $4.2 billion of Afghan central bank money sits in a Fund for the Afghan People at a Geneva non-profit foundation that has not disbursed a single dollar since its creation in 2022. There is a further $3.5 billion frozen in the US and snarled up in post 9/11 litigation. And so, Afghanistan’s own money sits idle in Western banks while an ideological contest fires off competing virtue signals over the emaciated and expired bodies of its most vulnerable citizens who were never consulted on any of it. The wider aid chill In parallel, aid implementers relying on Western governments remain wary of counter-terrorism law. On paper, there are humanitarian carve-outs including American general licences. But, amidst the friable present mood, who is so rash as to trust a piece of paper? Apart from cumbersome procedures and added administrative costs around getting waivers, imagine what happens if an agency makes a small payment for rendered services to a doctor who happens to have a Taliban relative, or a local Taliban official demands a small tax on the cash transfer. The agency could inadvertently face the nightmare of legal penalties and criminal prosecution. Meanwhile, the general donor trend of conditioning humanitarian aid accelerates. Thus, $2 billion US global humanitarian funding via OCHA specifically excludes Afghanistan. Perhaps partly because the Taliban will not agree to a US return to control the strategic Bagram airbase? Although the European Commission – now Afghanistan’s biggest donor – has maintained funding levels (around €162 million this year), it also invited the Taliban to Brussels to discuss repatriating failed Afghan asylum seekers. With some 500,000 Afghans applying for asylum since the Taliban came, and the increased political toxicity associated with the migration issue, there is a trend towards attaching conditions to European aid. As Western-espoused humanitarian values sink under their own hypocrisy and the world order splits into ‘the West’ and ‘the Rest’, Afghanistan is finding new friends. China is courting the Taliban with infrastructure investments in return for accessing Afghanistan’s massive mineral resources. Russia is giving some aid alongside military co-operation to bring Afghanistan into its sphere of influence. Central Asian and Gulf nations, as well as India and Iran, get closer to the Taliban through aid, trade, and diplomacy. This further entrenches the Taliban regime and brings little succour for people. Creative ways to bypass Taliban Afghan women and children are paying the highest price for plunging aid. That makes it even more vital to maximise the good effects of available limited humanitarian funding. This translates into aid givers finding creative ways to bypass the Taliban without getting thrown out themselves. That high-wire act to stay in the game to do good is the real story from the past five years. It is a tale of the extraordinary resilience of the Afghan people and their own traditional community and social institutions. And a tale of redemption for the very same aid agencies – UN and NGO – that are so heavily criticised for their shortcomings in other corners of the world. Here are a dozen key strategies learnt from their trial, error and courageous risk-taking that are saving lives here and there in Afghanistan. These deserve scaling up while implementers stay under the Taliban radar as much as possible. The first is about realising that aid delivery in Afghanistan is a retail affair, not a wholesale business. It requires negotiating for access locally and quietly, knowing that fierce-sounding national decrees are enforced unevenly. Province-by-province technical exemptions, brokered by Afghan staff and elders rather than announced from Geneva or Kabul, have, for example, kept some female vaccinators and midwives working. Second, more of the dwindling numbers of Afghan professionals could be pressed into service to sustain healthcare frontlines. It means expanding direct-to-worker electronic payments, which would also inject cash into local economies without going through Taliban coffers. Electronic transactions are also easily tracked and audited to encourage small agencies fearing Western anti-terror legislation to expand their services. Third, pay the mahram, the authorised male required under Taliban restrictions to accompany a female patient or the female health worker going to work. If this offends our Western sensibilities, think of the mahram as staff akin to the clinic watchman or ambulance driver. We are already compromising on mahram in practice while refusing to fund them in principle, which buys us the moral posture and the dead mother alike. Some communities show incredible creativity with the mahram requirement. For example, groups of women going together to a health centre have negotiated to be escorted by a village elder as their ‘collective mahram’ – thereby allowing their wage-earning husbands, brothers, and sons not to take time off work. Fourth, where patients cannot travel to clinics, bring them to her. Mobile health and nutrition units are well-known worldwide. Restoring and expanding Afghanistan’s mobile teams whose funding was indiscriminately cut would be a cost-effective boost for healthcare provision. A mother and her child in a WHO-supported maternal care facility in Bajnab, Afghanistan. Fifth, co-locate necessary institutional facilities such as operating rooms, laboratory and diagnostic capacities with existing national, provincial, and district hospitals, and re-equip and re-supply them. This makes it politically difficult for the Taliban to close them. Installing or repairing an ultrasound machine and refurbishing hospital electricity and water saves lives and does not mean condoning the Taliban administration. Sixth, direct-to-clinic logistics that move vital medicines, therapeutic foods and other supplies from cargo planes to pharmacies under trusted supervision help to minimise diversion and reduce manipulated distribution. Seventh, investing in autonomous, solar-powered clinic microgrids, including battery storage, has many benefits, not just for preventing the ruin of temperature-sensitive vaccines but also to allow anaesthesia and surgery for common trauma, obstetric, and other emergencies. Eighth, revive grassroots public health surveillance for marker diseases, hunger and malnutrition, and vital statistics collection around births and deaths. That means paying local community enumerators as done in past smallpox and polio campaigns. It is when operational circumstances are most complex, that programmes cannot afford to go blind from lacking local trend data. Ninth, take more measured risks. As international humanitarianism retreats while the “duty of care” movement gathers momentum, risk-aversion and institutional self-protection also grow. Understandable, of course, but is this not getting over the top? This is one of the most expressed frustrations by motivated and seasoned aid workers. Risk assessment systems – including utilising AI – have advanced but many agencies are stuck in centralised modes that mistrust well-informed local judgements. That triggers another thought. With the growing shortage of female Afghan health professionals, could more foreign females volunteer to fill the gap? That raises the associated challenge of their accompanying mahram. There are pragmatic solutions here, including negotiating ad hoc exemptions or facilitating couples to serve together. Tenth, keep the health and training pipeline rumbling along. Afghanistan’s education sector provides remarkable inspiration through clandestine home and digital schooling initiatives for girls. Can these approaches be applied in the health sector, both for refreshing basic health worker knowledge and for general public education around essential skills such as first aid, nutrition, and preventing and treating common conditions, including psychosocial support and suicide risk handling? Further, by investing in enhanced digital connectivity in selected (especially secondary) hospitals via low-cost technologies like Starlink that are available worldwide, expert Afghan medical diaspora with relevant linguistic skills could provide online consultations. Eleventh, sustaining a health delivery system that works for people is a crucial concern as there is no possibility of political change in the foreseeable future. Meanwhile, high-profile international aid brands and large corporate logos draw intense, negative Taliban scrutiny. They could, instead, sponsor low-profile hyper-local community networks via pre-existing local volunteer bodies and underground civic networks to distribute medical micro-assistance, including medicines, hygiene kits, consultation referrals, and even skills training. Twelfth, and most crucially, health aid givers should agree on common operating rules pragmatically applied in local circumstances. That means less policy rhetoric on confrontational red lines and more about working solutions that focus on patients. Facility-by-facility, the Taliban morality inspectors are conceding that medical spaces be demilitarised. Also female and male colleagues may work alongside each other during lifesaving procedures. Such bargains can be built upon. Consistency and patience are missing The Taliban rank-and-file know that their loved ones also need healthcare, often under desperate circumstances. Their rigid mindsets are curiously mirrored in their respect for others who also stubbornly hold onto their own principles. Hence, a package of negotiated measures that bring predictable cooperation over health is quite feasible, as shown by pioneering agencies such as Médecins Sans Frontières. In short, much more can be done to safeguard the health of Afghans despite numerous obstacles. There is nothing novel in the proposed approaches that have already shown good results in Afghanistan and other complex resource-poor contexts. So what is missing? Beyond insufficient resources, it is a sense of coherent mission that believes in the feasibility of improving the health chances of Afghans. This will not come from the current defeatist attitudes among humanitarian, global health, and multilateral aid communities with low expectations and marked risk aversion. Neither will it come from composing national health strategies that are little more than fantasies. We need pragmatic but consistent labouring from the bottom-up organised around whatever Afghans find feasible. Above all is the requirement for patience that the international community is not known for. Mukesh Kapila is professor emeritus of global health and humanitarian affairs at the University of Manchester, and a board member of Health Policy Watch. Vital Signs in Global Health is a regular column, and the opinions expressed are solely those of the author. Image Credits: Charlotte Cans/ UNOCHA, Karimi/ UNICEF Afghanistan, WHO EMRO, WHO. South Africa Grapples With The Promise and Price of Injectable Lenacapavir to Prevent HIV 30/08/2026 Kerry Cullinan Sex worker advocate Precious Mafanga describes lenacapavir as very easy to take for her sector. The antiretroviral medicine lenacapavir, delivered via injection every six months, is almost completely effective in preventing HIV. But it is expensive at present, and millions will need to be initiated on it every year to make a dent on HIV transmission in South Africa. CAPE TOWN – South Africa has the biggest population of people living with HIV in the world – over eight million people, around 18% of those aged 15 to 49. So its Health Ministry and researchers are laser-focused on HIV prevention tools, particularly how to optimise pre-exposure prophylaxis (PrEP), which involves using antiretroviral medication to prevent HIV. The newest PrEP offering is lenacapavir, Gilead’s “miracle” twice-yearly injection that has prevented almost 100% of HIV transmission in clinical trials, some of which took place in South Africa. The country started to roll out lenacapavir in June, and it is now available at 360 health facilities to anyone who feels at risk of HIV. South Africa’s President Cyril Ramaphosa described the introduction of lenacapavir as “a major turning point in South Africa’s national story. It is the triumph of science over despair and the power of innovation to save lives”. But fewer than 47,000 people have been initiated so far – mainly because the health department cannot afford a huge rollout. Yet health economists advising the government have worked out that the country needs to get at least 1.7 million people on lenacapavir every year for the next five years if it wants to break the transmission of HIV. Drug price and procurement Hasina Subedar, senior technical advisor to the South Africa Department of Health. The Global Fund, which has an agreement with Gilead, is procuring the drug for South Africa, and has asked the health department to ring-fence $29.2 million of its three-year Global Fund grant for lenacapavir. “The Global Fund asked us to budget for $60 per person per annum, and it is topping this up, but the price they are paying [to Gilead] is confidential,” says Hasina Subedar, senior technical advisor at the South African Department of Health. This budget translates into doses for around 420,000 people. While the United States government is assisting other countries to buy lenacapavir, it decided not to support South Africa over political disagreements. However, the Children’s Investment Fund Foundation (CIFF) has stepped in to assist the country. “We will really only be able to have roll-out at scale when we have the generics,” says Subedar, noting that lenacapavir has been included on the country’s essential medicines list, subject to the availability of generics at $40 per annual dose. In October 2024, Gilead announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir for 120 “high-incidence, resource-limited countries”. It has prioritised 18 of these countries, including South Africa. The six are Dr Reddy’s Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero and Mylan – none South African. So far, only Hetero has submitted its dossier for regulatory approval to the South African Health Products Regulatory Authority (SAHPRA). Generics are expected by mid-2027, but it is unclear yet when they will reach South Africa. Lumps and bumps: administering lenacapavir South African health facilities have offered oral PrEP since 2016, although the small supplies initially available were first directed to groups most at risk: sex workers, then men who have sex with men and then teenage girls and young women. Since its introduction, some 2.3 million people have started oral PrEP, but have stopped taking the pills. Supply has been affected by the 2025 US budget cuts. But some people also get tired of daily pill-taking. Others, particularly vulnerable young women, are reluctant for their partners to know that they are taking precautions against potential HIV infection. This makes the six-monthly injectable option so attractive. But it’s not a simple process, as Subedar explains. Lenacapavir initiation happens over two days. On day one, people get two 1.5ml injections in separate areas, administered subcutaneously (in the fatty layer of skin). This is usually in the person’s abdomen or buttocks. At the same time, they get two 300mg pills. People are sent home with two 300 mg pills, which they need to take the following day. By day three, they are protected against HIV for the next 26 weeks until their next injections. They have a two-week grace period either side of their 26-week date to get their next injections. No pills are needed on subsequent visits unless they miss the two-week window. Patients’ experiences: ‘Next time, the buttocks’ Trans activist Dimpho Tsotetsi says oral PrEP made me nauseous. Dimpho Tsotetsi, who has used oral PrEP since 2017, switched to lenacapavir in a Soweto clinic on 4 July. “I used to work in a [USAID] donor-funded clinic, so I knew it was coming,” said Tsotetsi, an extroverted 32-year-old trans woman who describes herself as a health advocate for her community. “I had nausea every day with oral PrEP,” she added, and despite about two weeks of discomfort after her injections, Tsotetsi describes the experience as “pleasant”. “I got two shots on my stomach, one on the left, one on the right. Until today I still have the bumps. I can feel them,” said Tsotetsi, who adds that this has made wearing clothes with tight waistbands harder as they rub against the injection bumps. “Hence I’m wearing something flowy”, she laughs. Precious Mafanga, a sex worker and sex worker advocate, describes lenacapavir as “very helpful and easy to take” – unlike oral PrEP “which makes you hungry”. She and many others working in organisations serving “key populations” – those most at risk of HIV – have had a rough time since the US stopped funding these groups after Donald Trump came to power in January 2025. Mafanga describes chaos in the sex worker sector, with job losses for peer educators, sex workers defaulting on antiretroviral medication and a lack of support for people who inject drugs as specialised clinics and mobile outreach came to a screeching halt. In the past few months, a new organisation, Tholwana e Molemo, has stepped up to assist sex workers. While resources are much more limited, the organisation’s nurses have been able to work with government clinics to enable sex workers to get fast access to lenacapavir. Lindiwe Mqatazana, who is pregnant, opted for lenacapavir to protect her baby. Meanwhile, Siviwe Gaika, a 24-year-old law student and church-goer who uses PrEP to protect herself, said she tried to get lenacapavir three times before her local clinic, a designated site, was ready to administer it. She also describes bumps on her abdomen at the injection sites: “I think next time I will get it on the buttocks.” It was the buttocks for Lindiwe Mqatazana, who had a positive pregnancy test and lenacapavir all in the same day. “It was a bit scary, but the nurses explained that this is the best way to protect my baby and that it won’t hurt the baby,” said Mqatazana. Million-person rollout Dr Lise Jamieson from the Health Economics and Epidemiology Research Office (HE2RO) at Wits University is one of the health economists advising the health department. Using Thembisa, a mathematical model of the South African HIV epidemic, researchers have made various forecasts, said Jamieson. Their key message is that lenacapavir will be far more effective than oral PrEP – if it is rolled out at scale. The impact of lenacapavir in comparison to oral PrEP (TDF/ FTC) After modelling various scenarios, they calculate that lenacapvir can reduce HIV by 19-31% over 20 years in comparison to 4% by oral PrEP. It will also end AIDS seven to 10 years earlier than oral PrEP. But this impact requires serious volumes: between 1.7 million and 2.3 million people need to start lenacapavir every year for at least the next five years. The rollout needs to be more targeted at those who need it most, with the most optimal breakdown to be 45% for adolescent girls and young women (AGYW); 30% for men who have sex with men (MSM); 15% for female sex workers; and 10% for pregnant and breastfeeding women. The health department’s targets are weighted more heavily towards teenage girls, young women, and pregnant and breastfeeding women. However, currently it is hard to tell which groups most of the 47,000+ people who have opted for lenacapavir come from, as over 70% describe themselves as the “general population”. Targeting certain key populations – female sex workers (FSW), men who have sex with men (MSM), and adolescent girls and young women (AGYW) – will have more impact than an over-emphasis on pregnant and breastfeeding women (PBFW), according to experts. Meanwhile, the financial investment is substantial, with up to $106 million needed for five years – but, says Jamieson, this is still four times more cost-effective than oral PrEP. More choices “The excitement about lenacapavir is huge, but what is the follow-up going to be like?” asks Dr Pippa McDonald, from the Desmond Tutu Health Foundation. The foundation was one of the partners that ran the clinical trial of lenacapavir, and is currently monitoring people’s responses and uptake to the medication. So far, over 80% of people surveyed want the six-monthly injections rather than oral PrEP, said MacDonald. “Choice is really important,” says MacDonald, who believes that offering different PrEP options and points of delivery are important ingredients for success. A monthly PrEP pill, alimatravir, is currently undergoing clinical trials – and may prove even more popular than the six-monthly injections. At the International AIDS Society (IAS) conference in Brazil in July, the company developing the pill, Merck/ MSD, announced that it has already granted voluntary licenses to seven generic companies – three in sub-Saharan Africa and four in India – to produce the medicine for 129 low- and middle-income countries. This is even before the medicine has been proven effective. There are many possibilities in the mix, including the government distributing PrEP in partnership with private pharmacies and people self-injecting follow-up lenacapavir doses. But there are still many unknowns too, particularly how fast generic lenacapavir can be produced, whether there will be enough money for the scale-up that is needed, and how many people will come back after six months. Interviews for this article are from a media workshop on South Africa’s lenacapavir rollout organised by Bhekisisa. India’s Flagship Air Pollution Programme Is Failing 28/08/2026 Chetan Bhattacharji Dr Piyush Bharadwaj, CSTEP, presenting research on the air quality and climate co-benefits possible in India at the India Clean Air Summit. BENGALURU – India’s flagship air pollution action plan, the National Clean Air Programme (NCAP), has mostly failed to deliver, according to research presented at the eighth India Clean Air Summit. Officials, scientists, and other experts highlighted the 2019 program’s severe shortcomings and red-flagged critical gaps. An “NCAP 2.0′ has been widely expected, but the central government has yet to announce a launch timeline. Data shared by the summit organiser, the Center for Study of Science, Technology and Policy (CSTEP), showed that fewer than 7% of the 131 targeted cities met NCAP’s goal to reduce pollution by 40% by 2025-26, and 35% of cities showed an increase in coarse particulate matter (PM10). This failure comes despite the government releasing over INR 16,423 crore (approximately $1.5 billion) to support the program. Speakers at the conference emphasized that future iterations of the programme must bridge air pollution control measures with climate action policies. Crucially, at least two government experts warned of emerging, interconnected feedback loops between climate change and air quality. Structural flaws in programme According to CSTEP, NCAP’s limited impact stems from several core design flaws. These include that it targets cities; focuses on PM 10 and dust mitigation measures not the finer, deadlier PM2.5 particulate matter pollutant; has no systemic assessment of interventions; and it covers short-term measures rather than long-term planning considering growth. There is also limited technical understanding of urban local bodies (ULBs). About 95% of India’s PM2.5 pollution, a universally tracked pollutant, is emitted from cities and rural areas that are excluded from NCAP’s focus, which tracks 131 cities. Seventy percent of PM2.5 is from “non-urban areas” according to PAVITRA, an air quality management tool developed by IIT Bombay, CSTEP and two American universities. Data shows how much of India’s air pollution sources lie outside cities and outside the National Clean Air Programme’s focus centres. Source: Air Pollution Management And Intervention Tool For India (PAVITRA), by IIT Bombay, CSTEP, University of Washington, Berkeley University of California. Another limitation is the lack of funding for places where pollution is rising, such as the coastal state of Kerala. “What I really want to request is that when NCAP 2.0 is happening, there should be some funds available to the cities which are not non-attainment, but are trying to prevent becoming a non-attainment city,” says Ratish Menon, a senior official of Kerala’s Pollution Control Board. Non-attainment means cities that have consistently failed to attain air quality that meets the national ambient air quality standard of 40 micrograms/cubic metre of PM2.5. Indo-Gangetic plain: India’s pollution hotspot That plain stretches about 2,000 kilometres across northern India, south of the Himalayan foothills and east to Bangladesh. However, the most severe challenge remains concentrated in northern plains of India, described as an “emission hotspot” by SD Attri, a senior official and scientist of the Commission for Air Quality Management (CAQM). The CAQM is in-charge of reducing pollution in and around Delhi, which is situated in the plains. “The Indo-Gangetic Plain (IGP) covers only 15% of India’s land but accommodates around 37% of its population and emits 35% of India’s total emissions, making it an emission hotspot,” Attri explained, which is why Delhi and other places here often make it to the list of the top, most polluted places in the world. Residents across the northern plains are exposed to persistently high pollution levels year-round. On an annual basis, average concentrations of PM2.5 or smaller particulate matter reach 84 µg/m³ (micrograms/cubic metre), which is more than twice the permissible standard of 40 micrograms under India’s National Ambient Air Quality Standard and almost 17 times the WHO’s safety guideline of 5 µg/m³ . Target mitigation: Black carbon in UP and Bihar A sharper focus on just two states, Uttar Pradesh and Bihar, and one pollutant, black carbon or soot, has been recommended by a CSTEP report launched at the summit. The largest source of black carbon is from homes burning biomass and other dirty fuels for cooking and heating. And more than 60% of this pollution is from the IGP states. Uttar Pradesh and Bihar is where domestic emissions have the greatest regional spillover. These two states dominate India’s northern plains, with a combined area about the same as Finland but with a combined population larger than the US. Reducing black carbon emissions can save lives, and the largest benefits are to be achieved through a multisectoral airshed approach. Reducing black carbon emissions from all major sources in the IGP results in a 37% reduction in black carbon concentration and prevents 2,290 PM2.5-attributable premature deaths. This number is conservative, as the authors explain there is limited research on the health effects of black carbon, unlike that of PM2.5, which is linked to about a million deaths in the country. “The mortality burden estimated in this study is conservative because the exposure–response function used is derived for ambient PM 2.5 mass concentration rather than for individual PM 2.5 components (Black carbon, organic carbon, sulphates, nitrates, etc). “Consequently, the potential toxicity of black carbon is not explicitly captured in the mortality estimation,” Piyush Bharadwaj, head of the air quality observations and modelling group at CSTEP, told Health Policy Watch. Climate change – air pollution link The CSTEP report also highlights significant co-benefits between clean air initiatives and carbon mitigation. In a best-case scenario, aggressive black carbon reduction in northern India would yield climate co-benefits equivalent to 639.3 MT CO2, roughly similar to Germany or South Korea’s annual emissions. Dr Ratish Menon, senior official, Kerala State Pollution Control Board, India There were other warnings about the link between global warming and air pollution. Menon attributed part of the rise in Kerala’s air pollution levels to pollution from neighbouring states, but also to global warming. Last winter’s peak in “all (air quality monitoring) stations” was more because there was lesser wind transport between the land and ocean, he says, “because the ocean temperatures are increasing and that exchange is getting affected. That causes a regional buildup.” A separate climate link was flagged by a senior scientist at IIT Kanpur, SN Tripathi, whose team has overseen the deployment of almost 1,400 low-cost sensors in Uttar Pradesh and Bihar. Based on this data, Tripathi said they have been able to create an index where “we have combined temperature and relative humidity to provide some kind of a universal climate index, and we are basically trying to give that how it looks during summer times when the temperatures are very high and the overall comfort level for human beings becomes very unmanageable.” They are seeing that a good part of these two states have a “very high amount of this compound index.” When asked by Health Policy Watch, how this ‘universal climate index’ is to be used, Tripathi said it was work in progress and premature to comment. Call to change air quality action plans India’s peak pollution season begins in October and ahead of that, Attri, the most senior official from the government of India at the summit, listed several measures taken to reduce air pollution. The latest include increasing the number of top grade air quality monitoring stations from about 90 currently to 157 in the next month as well a “new GRAP” system which he says will be open for the public’s comments and suggestions; GRAP is the Delhi region’s Graded Response Action Plan, a series of tighter curbs – on transport, construction, diesel generators, cooking fuels and even schools – as pollution levels rise However, the larger messaging from ICAS 2026 is that urgent changes in air quality management are required. Pointing to a series of policy actions since the Air (Prevention and Control of Pollution) Act was cleared by Parliament 45 years ago, and the INR 16,423 crore in funding released by the government, Abinaya Sekar of Health Effects Institute underscored the need to assess the effectiveness of air pollution interventions, offering a framework on how to do this. CSTEP researchers urged the government to integrate air quality targets into both NCAP 2.0 and India’s international commitments under the UN Nationally Determined Contributions (NDCs), that is, self-identified pledges for climate action by every country. Aligning these policies would allow air quality improvement to be recognised as a critical element of near-term climate mitigation, particularly by targeting short-lived climate pollutants like black carbon. In eight years of the India Clean Air Summit and similar gatherings, the one constant has been the demand for better implementation. The other constant has been Delhi’s annual average PM2.5 pollution level stubbornly hovering around 100 micrograms, in the last eight years. Image Credits: Source: Press Information Bureau, Indian Government. Historic Meta Settlement Mandates Safer Social Media for Youth 27/08/2026 Editorial team Meta agreed to silence notifications for teens from midnight to 6:00 AM, but this excludes direct messaging and can be disabled by parents. Following a landmark agreement in the United States on Wednesday, social media giant Meta agreed to pay up to $18 billion to US states. This historic settlement obliges the company to make Instagram and Facebook safer for children. Scientific research – including a landmark report by an expert panel commissioned by the European Commission – shows that excessive social media use damages early childhood brain development and fuels mental health crises among young people. Meta emphasises that the settlement is not proof of harmful health effects caused by its platforms. However, the unprecedented sum is likely to increase global pressure on platform operators to take action. The company said it had agreed to distribute the payments in annual instalments over a 10-year period to fund youth online safety initiatives across the participating states. Meta limits social media access for youth The agreement stipulates that Meta must limit daily usage time to two hours, disable extreme beauty filters, pause nighttime notifications and hide ‘like’ counts on posts by teenagers. In addition, the company will implement an age verification system under which no more than 3% of 13- to 15-year-olds and 10% cent of older teenagers may be incorrectly classified as adults. “The framework we’ve negotiated will empower parents to easily manage how their children access our platforms,” said CJ Mahoney, chief legal officer at Meta in a statement on Wednesday. Meta is required to phase in these modifications, with a strict compliance deadline set for six months after the court has now approved the settlement. To prevent an exodus of young users, Meta is urging its competitors, YouTube and TikTok, to adopt these standards. Doubts about effectiveness of settlement However, experts question whether the agreed time limits will effectively curb deep-rooted addiction risks. Parents can easily disable these daily usage caps, and the overnight notification pause does not cover direct messaging. Biometric facial scans for age verification remain controversial because processing sensitive video data violates data protection principles. Furthermore, teenagers easily bypass basic digital blocks using virtual private networks (VPNs), while privacy-friendly age verification methods remain unavailable on a large scale. A signal to regulators worldwide Nevertheless, the US settlement establishes a benchmark for youth social media bans passed in Australia and proposed in New Zealand. The European Commission plans to introduce a draft regulation this autumn to enforce a harmonised European age limit and strict safety-by-design standards. This proposed framework aims to end the current patchwork of legislation across Europe, as national restrictions often clash with the strict rules of the EU’s Digital Services Act (DSA). Related Story: Warning labels, Time restrictions? Experts Mull How to Curb Social Media Harms Editorial note: The piece has been updated on 28 August to reflect that the court has now approved the settlement. Image Credits: cottonbro studio via Pexels. The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
United States to Cut Health Funding to 18 Countries 59% by 2030 31/08/2026 Kerry Cullinan Kenya’s President William Ruto applauds Kenyan Cabinet Secretary Musalia Mudavadi and US Secretary of State Marco Rubio after they signed an MOU for health funding. The United States plans to cut its health funding to 18 countries by 59% of pre-2025 levels by 2030, according to a Public Citizen and Partners In Health analysis of the bilateral agreements the US has signed with these countries. The bilateral Memorandums of Understanding (MOUs) were signed as part of the ‘America First Global Health Strategy’ adopted by the Trump administration in 2025, and are intended to rapidly wean countries off US aid by 2030. The reduction amounts to a cut of some $2 billion to US aid dispensed before 2025, according to Public Citizen, which analysed the MOUs – some of which it initially obtained via a Freedom of Information Act (FOIA) lawsuit against the Trump administration. Countries facing the steepest cuts are Rwanda (97% reduction), Liberia (84%), Burundi (78%), Madagascar (77%), and Sierra Leone (71%). All MOUs require countries to make substantial co-financing commitments. These are for activities identified as priorities by the US, and do not necessarily align with the countries’ priorities. For example, the US wants all countries to improve their ability to identify disease outbreaks, so it requires substantial investment in epidemiologists and data capturers. But many recipient countries may prefer to prioritise employing health workers. In 11 out of the 18 countries, the co-financing commitments fail to cover the US cuts over five years compared to pre-2025 government funding. “Countries may also struggle to meet these funding expectations,” says the analysis. “For example, Malawi would have to mobilize new funding equal to 56% of the country’s total health expenditure to meet its annualized co-financing commitment.” Co-financing ‘punishment’ The US government also reserves the right to reduce or cease funding if countries don’t meet their co-financing commitments. In addition, the MOUs stipulate that the co-investments “may not include funding from other donors or multilateral organizations, but must be funds ‘raised directly’ by the country”, says Public Citizen and Partners In Health. “There is no transparent logic guiding the application of penalties across countries,” their analysis notes. If Ethiopia, Kenya, Mozambique, Cameroon, and Malawi fail to meet co-financing commitments, the US will reduce its funding by $1 for every $1 shortfall. Uganda and Côte d’Ivoire face a 2:1 reduction. However, no penalties are specified in the MOUs with Rwanda, Liberia, Lesotho, Eswatini, Sierra Leone, Madagascar, Burundi, Botswana, and South Sudan. Many of the MOUs also include “performance incentives” for meeting process and outbreak response metrics, but quantifying them is vague. Seven African countries will have fewer health workers by 2030, thanks to reduced US and partner government commitments. These are Burundi, Cameroon, Eswatini, Kenya, Lesotho, Madagascar and Malawi. “This is a major concern since the African region currently has only 46% of the health workers it needs, and by 2030 it is projected to face a health workforce shortage of 5.85 million workers,” the analysis notes. Burundi will lose all US-funded community health workers (CHW). Malawi will lose 3,436 CHWs (72% of its total), and Madagascar, 8,200 (39%). Cameroon faces a 20% reduction in CHW and nurses despite already facing “a severe shortage” of both. The one piece of good news is that the MOUs reduce the duration of controversial data-sharing and pathogen specimen-sharing agreements, which were initially for up to 25 years – despite the MOUs only lasting up to five years. But “these agreements stand apart from the MOU itself, and most are not available in wider circulation, making a full assessment of final terms impossible in most cases”. Some countries have baulked at the data-sharing requirements, with Zimbabwe deciding not to pursue an MOU with the US. Several countries point out that these data-sharing agreements, usually appendices to the MOUs, directly undermine the pathogen access and benefit-sharing (PABS) system currently being negotiated at the World Health Organization (WHO). “These documents suggest that the Trump administration is on course to underspend on global health by billions of dollars compared to what Congress has ordered, risking lives and allowing diseases to spread,” said Peter Maybarduk, Access to Medicines director for Public Citizen. “The administration must answer how and when it intends to invest the missing billions for health.” Clashing Convictions of Taliban and the West is Costing Afghan Lives 31/08/2026 Mukesh Kapila Afghan women have been almost erased from public life. Two sets of dogmas contend in Afghanistan: those of the Taliban and the West. Neither side pays the real price for their beliefs. Ordinary Afghans do with their lives. Some aid agencies labour quietly to bring help and hope through a dozen practical ways that bypass competing doctrines. They deserve support. In March last year, 23-year-old Khatera (pseudonym) went into prolonged labour. Her village clinic in western Afghanistan was long shuttered, and the nearest help was Herat city across a swollen river. Her husband carried her across the raging waters, both submerged to the shoulders. It took them 12 hours to reach the hospital. Khatera’s vital signs – and those of her baby – stopped registering hours after reaching the hospital. Why were they not saved? Perhaps no medical equipment or supplies? Perhaps few trained staff? Or perhaps sheer exhaustion? This everyday tragedy is commonplace for Afghans. Their misfortune is to be squeezed between the beliefs of their Taliban rulers and those of the international community that fled the country. This clash of convictions is fought over the easiest of targets: the defenceless bodies of millions like Khatera. The outcome is a generation of losers, not just Afghans but those who would save them. As with all lose-lose “games”, the focus quickly shifts to ascribing blame, as in the acres of commentary around the fifth anniversary of the Taliban’s re-accession to power. Vital symptoms and signs Extensive research has established that the fundamental drivers of health outcomes are social determinants. Unsurprisingly, the Taliban’s draconian restrictions that pervert the noble Islamic faith have dealt a crippling blow. Women have been almost erased from public spaces (except when they are flogged), with restrictions on their movement, education, and employment. Women’s access to health care has shrunk, and very young girls are being forced into marriages to settle debts or relieve poverty. Let us begin with basic health battlefield statistics. Afghans die young, with a life expectancy of 66.3 years, and under-five child mortality exceeding 50 deaths per 1,000 births – some 40% above the global average. Mothers suffer one of the world’s highest mortality ratios at 638 deaths per 100,000 livebirths. All these numbers were improving but have reversed under the Taliban. Fourteen million Afghans – a third of the population – face crisis-level hunger and there is record-breaking malnutrition with around 4.9 million children and pregnant and breastfeeding women affected. This equates to a tenth of children acutely malnourished and 45% chronically stunted. Other conditions – communicable, non-communicable, physical and mental trauma – flourish. Suicide rates, especially among females, are mounting. Six million coerced refugee returns from Pakistan and Iran, and climate disasters add to the strain. Malnutrition amongst children and the wider public has reached record levels in Afghanistan. When levers crumble All this is familiar. But it is also well known that regimes that claim divine inspiration are not amenable to earthly leverage by traditional aid, trade, diplomatic and military tools, as I discovered in my role as a past special adviser to the United Nations Assistance Mission in Afghanistan (UNAMA). Meanwhile, the Taliban are amenable to receiving assistance but on their own terms. That poses a dilemma for those who wish to relieve the suffering of Afghans without supporting their autocratic and misogynistic rulers. So the real question in a country that has always been aid-dependent becomes: how to help, also knowing that Taliban regulations complicate aid delivery and utilisation, especially as it is not possible to employ women to reach vulnerable families. This creates a difficult picture for foreign policymakers, who have many complex problems elsewhere to deal with. With the second coming of the Taliban in 2021, they found it much easier to walk away, whatever the morality of leaving Afghanistan to its own devices in light of the historic responsibilities of external powers in creating the turmoil. The walkout, in numbers The principal consequence of the walkout has been felt in the aid sector. UN-coordinated funding dropped 69% from $3.27 billion in 2022 to $1.01 billion last year. Afghanistan’s 2026 humanitarian appeal seeks $1.71 billion. With three-quarters of the year gone, it has received just 30% or $513 million (30 August). The health cluster has around $73 million, or 38% of what it wants; nutrition has $51 million (17%), and water, sanitation and hygiene received $19.5 million (12%). As a consequence, some 445 health facilities closed or suspended operations during 2025 and another 295 in the first half of this year. This includes 203 mobile health and nutrition teams. This means that at least four million people had lifesaving services switched off, including Khatera’s village. Prevention and public health services also dwindle. The epicentre of wild poliovirus has shifted to Afghanistan with 19 cases this year compared to Pakistan’s three, as house-to-house vaccination stopped in October 2024 and women vaccinators became rare. Meanwhile, and with no trace of irony, Afghanistan’s de facto Ministry of Public Health has just launched a surreal document with the vision of health as “a fundamental right” and a “goal of care for all Afghans”. This is its National Health Strategy 2026-2030 prepared with WHO support. One of its “seven pillars” concerns human resource development. It is not clear how this will be squared with the Taliban bar on women studying medicine, midwifery, nursing, and allied sciences, closing the pipeline for producing the clinicians Afghan women need. Does cutting aid kill? The political economy of aid requires deeper scrutiny. Do aid cuts lead to deaths? The US Secretary of State has asserted that it does not, as the US drastically cut foreign assistance. It is difficult to attribute specific mortality to general loss of aid, especially in Africa where American aid cuts have, in part, been made up by host budgets and other donors. But the causal association is stronger in Afghanistan, where neither the Taliban authorities nor other donors have stepped in to replace sharply dwindled US assistance, which had peaked above 40% of the country’s humanitarian spend. The US gave $728.6 million in 2024, $243.2 million in 2025, and nothing so far in 2026. An interesting study provides frontline evidence of impacts, such as neonatal deaths in Kunar and Farah rising 156% and 167% respectively between 2024 and 2025. Two sides of the humanitarian red line But there is a paradoxical aid economy at work. Even with pre-Taliban funding, most aid bypassed the government budget – except for some health basics. Since 2021, that has also gone, with UN agencies contracting providers that pay nurses and midwives directly into their personal bank accounts. So cutting such assistance does not defund the Taliban administration but individual health workers. Thus, the ‘no Taliban support’ dogma costs nothing to their officials standing on one side of the humanitarian red line and everything to the beneficiaries on the other side. No Taliban enforcer misses a meal when yet another aid-funded nutrition site shuts. Meanwhile, some $4.2 billion of Afghan central bank money sits in a Fund for the Afghan People at a Geneva non-profit foundation that has not disbursed a single dollar since its creation in 2022. There is a further $3.5 billion frozen in the US and snarled up in post 9/11 litigation. And so, Afghanistan’s own money sits idle in Western banks while an ideological contest fires off competing virtue signals over the emaciated and expired bodies of its most vulnerable citizens who were never consulted on any of it. The wider aid chill In parallel, aid implementers relying on Western governments remain wary of counter-terrorism law. On paper, there are humanitarian carve-outs including American general licences. But, amidst the friable present mood, who is so rash as to trust a piece of paper? Apart from cumbersome procedures and added administrative costs around getting waivers, imagine what happens if an agency makes a small payment for rendered services to a doctor who happens to have a Taliban relative, or a local Taliban official demands a small tax on the cash transfer. The agency could inadvertently face the nightmare of legal penalties and criminal prosecution. Meanwhile, the general donor trend of conditioning humanitarian aid accelerates. Thus, $2 billion US global humanitarian funding via OCHA specifically excludes Afghanistan. Perhaps partly because the Taliban will not agree to a US return to control the strategic Bagram airbase? Although the European Commission – now Afghanistan’s biggest donor – has maintained funding levels (around €162 million this year), it also invited the Taliban to Brussels to discuss repatriating failed Afghan asylum seekers. With some 500,000 Afghans applying for asylum since the Taliban came, and the increased political toxicity associated with the migration issue, there is a trend towards attaching conditions to European aid. As Western-espoused humanitarian values sink under their own hypocrisy and the world order splits into ‘the West’ and ‘the Rest’, Afghanistan is finding new friends. China is courting the Taliban with infrastructure investments in return for accessing Afghanistan’s massive mineral resources. Russia is giving some aid alongside military co-operation to bring Afghanistan into its sphere of influence. Central Asian and Gulf nations, as well as India and Iran, get closer to the Taliban through aid, trade, and diplomacy. This further entrenches the Taliban regime and brings little succour for people. Creative ways to bypass Taliban Afghan women and children are paying the highest price for plunging aid. That makes it even more vital to maximise the good effects of available limited humanitarian funding. This translates into aid givers finding creative ways to bypass the Taliban without getting thrown out themselves. That high-wire act to stay in the game to do good is the real story from the past five years. It is a tale of the extraordinary resilience of the Afghan people and their own traditional community and social institutions. And a tale of redemption for the very same aid agencies – UN and NGO – that are so heavily criticised for their shortcomings in other corners of the world. Here are a dozen key strategies learnt from their trial, error and courageous risk-taking that are saving lives here and there in Afghanistan. These deserve scaling up while implementers stay under the Taliban radar as much as possible. The first is about realising that aid delivery in Afghanistan is a retail affair, not a wholesale business. It requires negotiating for access locally and quietly, knowing that fierce-sounding national decrees are enforced unevenly. Province-by-province technical exemptions, brokered by Afghan staff and elders rather than announced from Geneva or Kabul, have, for example, kept some female vaccinators and midwives working. Second, more of the dwindling numbers of Afghan professionals could be pressed into service to sustain healthcare frontlines. It means expanding direct-to-worker electronic payments, which would also inject cash into local economies without going through Taliban coffers. Electronic transactions are also easily tracked and audited to encourage small agencies fearing Western anti-terror legislation to expand their services. Third, pay the mahram, the authorised male required under Taliban restrictions to accompany a female patient or the female health worker going to work. If this offends our Western sensibilities, think of the mahram as staff akin to the clinic watchman or ambulance driver. We are already compromising on mahram in practice while refusing to fund them in principle, which buys us the moral posture and the dead mother alike. Some communities show incredible creativity with the mahram requirement. For example, groups of women going together to a health centre have negotiated to be escorted by a village elder as their ‘collective mahram’ – thereby allowing their wage-earning husbands, brothers, and sons not to take time off work. Fourth, where patients cannot travel to clinics, bring them to her. Mobile health and nutrition units are well-known worldwide. Restoring and expanding Afghanistan’s mobile teams whose funding was indiscriminately cut would be a cost-effective boost for healthcare provision. A mother and her child in a WHO-supported maternal care facility in Bajnab, Afghanistan. Fifth, co-locate necessary institutional facilities such as operating rooms, laboratory and diagnostic capacities with existing national, provincial, and district hospitals, and re-equip and re-supply them. This makes it politically difficult for the Taliban to close them. Installing or repairing an ultrasound machine and refurbishing hospital electricity and water saves lives and does not mean condoning the Taliban administration. Sixth, direct-to-clinic logistics that move vital medicines, therapeutic foods and other supplies from cargo planes to pharmacies under trusted supervision help to minimise diversion and reduce manipulated distribution. Seventh, investing in autonomous, solar-powered clinic microgrids, including battery storage, has many benefits, not just for preventing the ruin of temperature-sensitive vaccines but also to allow anaesthesia and surgery for common trauma, obstetric, and other emergencies. Eighth, revive grassroots public health surveillance for marker diseases, hunger and malnutrition, and vital statistics collection around births and deaths. That means paying local community enumerators as done in past smallpox and polio campaigns. It is when operational circumstances are most complex, that programmes cannot afford to go blind from lacking local trend data. Ninth, take more measured risks. As international humanitarianism retreats while the “duty of care” movement gathers momentum, risk-aversion and institutional self-protection also grow. Understandable, of course, but is this not getting over the top? This is one of the most expressed frustrations by motivated and seasoned aid workers. Risk assessment systems – including utilising AI – have advanced but many agencies are stuck in centralised modes that mistrust well-informed local judgements. That triggers another thought. With the growing shortage of female Afghan health professionals, could more foreign females volunteer to fill the gap? That raises the associated challenge of their accompanying mahram. There are pragmatic solutions here, including negotiating ad hoc exemptions or facilitating couples to serve together. Tenth, keep the health and training pipeline rumbling along. Afghanistan’s education sector provides remarkable inspiration through clandestine home and digital schooling initiatives for girls. Can these approaches be applied in the health sector, both for refreshing basic health worker knowledge and for general public education around essential skills such as first aid, nutrition, and preventing and treating common conditions, including psychosocial support and suicide risk handling? Further, by investing in enhanced digital connectivity in selected (especially secondary) hospitals via low-cost technologies like Starlink that are available worldwide, expert Afghan medical diaspora with relevant linguistic skills could provide online consultations. Eleventh, sustaining a health delivery system that works for people is a crucial concern as there is no possibility of political change in the foreseeable future. Meanwhile, high-profile international aid brands and large corporate logos draw intense, negative Taliban scrutiny. They could, instead, sponsor low-profile hyper-local community networks via pre-existing local volunteer bodies and underground civic networks to distribute medical micro-assistance, including medicines, hygiene kits, consultation referrals, and even skills training. Twelfth, and most crucially, health aid givers should agree on common operating rules pragmatically applied in local circumstances. That means less policy rhetoric on confrontational red lines and more about working solutions that focus on patients. Facility-by-facility, the Taliban morality inspectors are conceding that medical spaces be demilitarised. Also female and male colleagues may work alongside each other during lifesaving procedures. Such bargains can be built upon. Consistency and patience are missing The Taliban rank-and-file know that their loved ones also need healthcare, often under desperate circumstances. Their rigid mindsets are curiously mirrored in their respect for others who also stubbornly hold onto their own principles. Hence, a package of negotiated measures that bring predictable cooperation over health is quite feasible, as shown by pioneering agencies such as Médecins Sans Frontières. In short, much more can be done to safeguard the health of Afghans despite numerous obstacles. There is nothing novel in the proposed approaches that have already shown good results in Afghanistan and other complex resource-poor contexts. So what is missing? Beyond insufficient resources, it is a sense of coherent mission that believes in the feasibility of improving the health chances of Afghans. This will not come from the current defeatist attitudes among humanitarian, global health, and multilateral aid communities with low expectations and marked risk aversion. Neither will it come from composing national health strategies that are little more than fantasies. We need pragmatic but consistent labouring from the bottom-up organised around whatever Afghans find feasible. Above all is the requirement for patience that the international community is not known for. Mukesh Kapila is professor emeritus of global health and humanitarian affairs at the University of Manchester, and a board member of Health Policy Watch. Vital Signs in Global Health is a regular column, and the opinions expressed are solely those of the author. Image Credits: Charlotte Cans/ UNOCHA, Karimi/ UNICEF Afghanistan, WHO EMRO, WHO. South Africa Grapples With The Promise and Price of Injectable Lenacapavir to Prevent HIV 30/08/2026 Kerry Cullinan Sex worker advocate Precious Mafanga describes lenacapavir as very easy to take for her sector. The antiretroviral medicine lenacapavir, delivered via injection every six months, is almost completely effective in preventing HIV. But it is expensive at present, and millions will need to be initiated on it every year to make a dent on HIV transmission in South Africa. CAPE TOWN – South Africa has the biggest population of people living with HIV in the world – over eight million people, around 18% of those aged 15 to 49. So its Health Ministry and researchers are laser-focused on HIV prevention tools, particularly how to optimise pre-exposure prophylaxis (PrEP), which involves using antiretroviral medication to prevent HIV. The newest PrEP offering is lenacapavir, Gilead’s “miracle” twice-yearly injection that has prevented almost 100% of HIV transmission in clinical trials, some of which took place in South Africa. The country started to roll out lenacapavir in June, and it is now available at 360 health facilities to anyone who feels at risk of HIV. South Africa’s President Cyril Ramaphosa described the introduction of lenacapavir as “a major turning point in South Africa’s national story. It is the triumph of science over despair and the power of innovation to save lives”. But fewer than 47,000 people have been initiated so far – mainly because the health department cannot afford a huge rollout. Yet health economists advising the government have worked out that the country needs to get at least 1.7 million people on lenacapavir every year for the next five years if it wants to break the transmission of HIV. Drug price and procurement Hasina Subedar, senior technical advisor to the South Africa Department of Health. The Global Fund, which has an agreement with Gilead, is procuring the drug for South Africa, and has asked the health department to ring-fence $29.2 million of its three-year Global Fund grant for lenacapavir. “The Global Fund asked us to budget for $60 per person per annum, and it is topping this up, but the price they are paying [to Gilead] is confidential,” says Hasina Subedar, senior technical advisor at the South African Department of Health. This budget translates into doses for around 420,000 people. While the United States government is assisting other countries to buy lenacapavir, it decided not to support South Africa over political disagreements. However, the Children’s Investment Fund Foundation (CIFF) has stepped in to assist the country. “We will really only be able to have roll-out at scale when we have the generics,” says Subedar, noting that lenacapavir has been included on the country’s essential medicines list, subject to the availability of generics at $40 per annual dose. In October 2024, Gilead announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir for 120 “high-incidence, resource-limited countries”. It has prioritised 18 of these countries, including South Africa. The six are Dr Reddy’s Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero and Mylan – none South African. So far, only Hetero has submitted its dossier for regulatory approval to the South African Health Products Regulatory Authority (SAHPRA). Generics are expected by mid-2027, but it is unclear yet when they will reach South Africa. Lumps and bumps: administering lenacapavir South African health facilities have offered oral PrEP since 2016, although the small supplies initially available were first directed to groups most at risk: sex workers, then men who have sex with men and then teenage girls and young women. Since its introduction, some 2.3 million people have started oral PrEP, but have stopped taking the pills. Supply has been affected by the 2025 US budget cuts. But some people also get tired of daily pill-taking. Others, particularly vulnerable young women, are reluctant for their partners to know that they are taking precautions against potential HIV infection. This makes the six-monthly injectable option so attractive. But it’s not a simple process, as Subedar explains. Lenacapavir initiation happens over two days. On day one, people get two 1.5ml injections in separate areas, administered subcutaneously (in the fatty layer of skin). This is usually in the person’s abdomen or buttocks. At the same time, they get two 300mg pills. People are sent home with two 300 mg pills, which they need to take the following day. By day three, they are protected against HIV for the next 26 weeks until their next injections. They have a two-week grace period either side of their 26-week date to get their next injections. No pills are needed on subsequent visits unless they miss the two-week window. Patients’ experiences: ‘Next time, the buttocks’ Trans activist Dimpho Tsotetsi says oral PrEP made me nauseous. Dimpho Tsotetsi, who has used oral PrEP since 2017, switched to lenacapavir in a Soweto clinic on 4 July. “I used to work in a [USAID] donor-funded clinic, so I knew it was coming,” said Tsotetsi, an extroverted 32-year-old trans woman who describes herself as a health advocate for her community. “I had nausea every day with oral PrEP,” she added, and despite about two weeks of discomfort after her injections, Tsotetsi describes the experience as “pleasant”. “I got two shots on my stomach, one on the left, one on the right. Until today I still have the bumps. I can feel them,” said Tsotetsi, who adds that this has made wearing clothes with tight waistbands harder as they rub against the injection bumps. “Hence I’m wearing something flowy”, she laughs. Precious Mafanga, a sex worker and sex worker advocate, describes lenacapavir as “very helpful and easy to take” – unlike oral PrEP “which makes you hungry”. She and many others working in organisations serving “key populations” – those most at risk of HIV – have had a rough time since the US stopped funding these groups after Donald Trump came to power in January 2025. Mafanga describes chaos in the sex worker sector, with job losses for peer educators, sex workers defaulting on antiretroviral medication and a lack of support for people who inject drugs as specialised clinics and mobile outreach came to a screeching halt. In the past few months, a new organisation, Tholwana e Molemo, has stepped up to assist sex workers. While resources are much more limited, the organisation’s nurses have been able to work with government clinics to enable sex workers to get fast access to lenacapavir. Lindiwe Mqatazana, who is pregnant, opted for lenacapavir to protect her baby. Meanwhile, Siviwe Gaika, a 24-year-old law student and church-goer who uses PrEP to protect herself, said she tried to get lenacapavir three times before her local clinic, a designated site, was ready to administer it. She also describes bumps on her abdomen at the injection sites: “I think next time I will get it on the buttocks.” It was the buttocks for Lindiwe Mqatazana, who had a positive pregnancy test and lenacapavir all in the same day. “It was a bit scary, but the nurses explained that this is the best way to protect my baby and that it won’t hurt the baby,” said Mqatazana. Million-person rollout Dr Lise Jamieson from the Health Economics and Epidemiology Research Office (HE2RO) at Wits University is one of the health economists advising the health department. Using Thembisa, a mathematical model of the South African HIV epidemic, researchers have made various forecasts, said Jamieson. Their key message is that lenacapavir will be far more effective than oral PrEP – if it is rolled out at scale. The impact of lenacapavir in comparison to oral PrEP (TDF/ FTC) After modelling various scenarios, they calculate that lenacapvir can reduce HIV by 19-31% over 20 years in comparison to 4% by oral PrEP. It will also end AIDS seven to 10 years earlier than oral PrEP. But this impact requires serious volumes: between 1.7 million and 2.3 million people need to start lenacapavir every year for at least the next five years. The rollout needs to be more targeted at those who need it most, with the most optimal breakdown to be 45% for adolescent girls and young women (AGYW); 30% for men who have sex with men (MSM); 15% for female sex workers; and 10% for pregnant and breastfeeding women. The health department’s targets are weighted more heavily towards teenage girls, young women, and pregnant and breastfeeding women. However, currently it is hard to tell which groups most of the 47,000+ people who have opted for lenacapavir come from, as over 70% describe themselves as the “general population”. Targeting certain key populations – female sex workers (FSW), men who have sex with men (MSM), and adolescent girls and young women (AGYW) – will have more impact than an over-emphasis on pregnant and breastfeeding women (PBFW), according to experts. Meanwhile, the financial investment is substantial, with up to $106 million needed for five years – but, says Jamieson, this is still four times more cost-effective than oral PrEP. More choices “The excitement about lenacapavir is huge, but what is the follow-up going to be like?” asks Dr Pippa McDonald, from the Desmond Tutu Health Foundation. The foundation was one of the partners that ran the clinical trial of lenacapavir, and is currently monitoring people’s responses and uptake to the medication. So far, over 80% of people surveyed want the six-monthly injections rather than oral PrEP, said MacDonald. “Choice is really important,” says MacDonald, who believes that offering different PrEP options and points of delivery are important ingredients for success. A monthly PrEP pill, alimatravir, is currently undergoing clinical trials – and may prove even more popular than the six-monthly injections. At the International AIDS Society (IAS) conference in Brazil in July, the company developing the pill, Merck/ MSD, announced that it has already granted voluntary licenses to seven generic companies – three in sub-Saharan Africa and four in India – to produce the medicine for 129 low- and middle-income countries. This is even before the medicine has been proven effective. There are many possibilities in the mix, including the government distributing PrEP in partnership with private pharmacies and people self-injecting follow-up lenacapavir doses. But there are still many unknowns too, particularly how fast generic lenacapavir can be produced, whether there will be enough money for the scale-up that is needed, and how many people will come back after six months. Interviews for this article are from a media workshop on South Africa’s lenacapavir rollout organised by Bhekisisa. India’s Flagship Air Pollution Programme Is Failing 28/08/2026 Chetan Bhattacharji Dr Piyush Bharadwaj, CSTEP, presenting research on the air quality and climate co-benefits possible in India at the India Clean Air Summit. BENGALURU – India’s flagship air pollution action plan, the National Clean Air Programme (NCAP), has mostly failed to deliver, according to research presented at the eighth India Clean Air Summit. Officials, scientists, and other experts highlighted the 2019 program’s severe shortcomings and red-flagged critical gaps. An “NCAP 2.0′ has been widely expected, but the central government has yet to announce a launch timeline. Data shared by the summit organiser, the Center for Study of Science, Technology and Policy (CSTEP), showed that fewer than 7% of the 131 targeted cities met NCAP’s goal to reduce pollution by 40% by 2025-26, and 35% of cities showed an increase in coarse particulate matter (PM10). This failure comes despite the government releasing over INR 16,423 crore (approximately $1.5 billion) to support the program. Speakers at the conference emphasized that future iterations of the programme must bridge air pollution control measures with climate action policies. Crucially, at least two government experts warned of emerging, interconnected feedback loops between climate change and air quality. Structural flaws in programme According to CSTEP, NCAP’s limited impact stems from several core design flaws. These include that it targets cities; focuses on PM 10 and dust mitigation measures not the finer, deadlier PM2.5 particulate matter pollutant; has no systemic assessment of interventions; and it covers short-term measures rather than long-term planning considering growth. There is also limited technical understanding of urban local bodies (ULBs). About 95% of India’s PM2.5 pollution, a universally tracked pollutant, is emitted from cities and rural areas that are excluded from NCAP’s focus, which tracks 131 cities. Seventy percent of PM2.5 is from “non-urban areas” according to PAVITRA, an air quality management tool developed by IIT Bombay, CSTEP and two American universities. Data shows how much of India’s air pollution sources lie outside cities and outside the National Clean Air Programme’s focus centres. Source: Air Pollution Management And Intervention Tool For India (PAVITRA), by IIT Bombay, CSTEP, University of Washington, Berkeley University of California. Another limitation is the lack of funding for places where pollution is rising, such as the coastal state of Kerala. “What I really want to request is that when NCAP 2.0 is happening, there should be some funds available to the cities which are not non-attainment, but are trying to prevent becoming a non-attainment city,” says Ratish Menon, a senior official of Kerala’s Pollution Control Board. Non-attainment means cities that have consistently failed to attain air quality that meets the national ambient air quality standard of 40 micrograms/cubic metre of PM2.5. Indo-Gangetic plain: India’s pollution hotspot That plain stretches about 2,000 kilometres across northern India, south of the Himalayan foothills and east to Bangladesh. However, the most severe challenge remains concentrated in northern plains of India, described as an “emission hotspot” by SD Attri, a senior official and scientist of the Commission for Air Quality Management (CAQM). The CAQM is in-charge of reducing pollution in and around Delhi, which is situated in the plains. “The Indo-Gangetic Plain (IGP) covers only 15% of India’s land but accommodates around 37% of its population and emits 35% of India’s total emissions, making it an emission hotspot,” Attri explained, which is why Delhi and other places here often make it to the list of the top, most polluted places in the world. Residents across the northern plains are exposed to persistently high pollution levels year-round. On an annual basis, average concentrations of PM2.5 or smaller particulate matter reach 84 µg/m³ (micrograms/cubic metre), which is more than twice the permissible standard of 40 micrograms under India’s National Ambient Air Quality Standard and almost 17 times the WHO’s safety guideline of 5 µg/m³ . Target mitigation: Black carbon in UP and Bihar A sharper focus on just two states, Uttar Pradesh and Bihar, and one pollutant, black carbon or soot, has been recommended by a CSTEP report launched at the summit. The largest source of black carbon is from homes burning biomass and other dirty fuels for cooking and heating. And more than 60% of this pollution is from the IGP states. Uttar Pradesh and Bihar is where domestic emissions have the greatest regional spillover. These two states dominate India’s northern plains, with a combined area about the same as Finland but with a combined population larger than the US. Reducing black carbon emissions can save lives, and the largest benefits are to be achieved through a multisectoral airshed approach. Reducing black carbon emissions from all major sources in the IGP results in a 37% reduction in black carbon concentration and prevents 2,290 PM2.5-attributable premature deaths. This number is conservative, as the authors explain there is limited research on the health effects of black carbon, unlike that of PM2.5, which is linked to about a million deaths in the country. “The mortality burden estimated in this study is conservative because the exposure–response function used is derived for ambient PM 2.5 mass concentration rather than for individual PM 2.5 components (Black carbon, organic carbon, sulphates, nitrates, etc). “Consequently, the potential toxicity of black carbon is not explicitly captured in the mortality estimation,” Piyush Bharadwaj, head of the air quality observations and modelling group at CSTEP, told Health Policy Watch. Climate change – air pollution link The CSTEP report also highlights significant co-benefits between clean air initiatives and carbon mitigation. In a best-case scenario, aggressive black carbon reduction in northern India would yield climate co-benefits equivalent to 639.3 MT CO2, roughly similar to Germany or South Korea’s annual emissions. Dr Ratish Menon, senior official, Kerala State Pollution Control Board, India There were other warnings about the link between global warming and air pollution. Menon attributed part of the rise in Kerala’s air pollution levels to pollution from neighbouring states, but also to global warming. Last winter’s peak in “all (air quality monitoring) stations” was more because there was lesser wind transport between the land and ocean, he says, “because the ocean temperatures are increasing and that exchange is getting affected. That causes a regional buildup.” A separate climate link was flagged by a senior scientist at IIT Kanpur, SN Tripathi, whose team has overseen the deployment of almost 1,400 low-cost sensors in Uttar Pradesh and Bihar. Based on this data, Tripathi said they have been able to create an index where “we have combined temperature and relative humidity to provide some kind of a universal climate index, and we are basically trying to give that how it looks during summer times when the temperatures are very high and the overall comfort level for human beings becomes very unmanageable.” They are seeing that a good part of these two states have a “very high amount of this compound index.” When asked by Health Policy Watch, how this ‘universal climate index’ is to be used, Tripathi said it was work in progress and premature to comment. Call to change air quality action plans India’s peak pollution season begins in October and ahead of that, Attri, the most senior official from the government of India at the summit, listed several measures taken to reduce air pollution. The latest include increasing the number of top grade air quality monitoring stations from about 90 currently to 157 in the next month as well a “new GRAP” system which he says will be open for the public’s comments and suggestions; GRAP is the Delhi region’s Graded Response Action Plan, a series of tighter curbs – on transport, construction, diesel generators, cooking fuels and even schools – as pollution levels rise However, the larger messaging from ICAS 2026 is that urgent changes in air quality management are required. Pointing to a series of policy actions since the Air (Prevention and Control of Pollution) Act was cleared by Parliament 45 years ago, and the INR 16,423 crore in funding released by the government, Abinaya Sekar of Health Effects Institute underscored the need to assess the effectiveness of air pollution interventions, offering a framework on how to do this. CSTEP researchers urged the government to integrate air quality targets into both NCAP 2.0 and India’s international commitments under the UN Nationally Determined Contributions (NDCs), that is, self-identified pledges for climate action by every country. Aligning these policies would allow air quality improvement to be recognised as a critical element of near-term climate mitigation, particularly by targeting short-lived climate pollutants like black carbon. In eight years of the India Clean Air Summit and similar gatherings, the one constant has been the demand for better implementation. The other constant has been Delhi’s annual average PM2.5 pollution level stubbornly hovering around 100 micrograms, in the last eight years. Image Credits: Source: Press Information Bureau, Indian Government. Historic Meta Settlement Mandates Safer Social Media for Youth 27/08/2026 Editorial team Meta agreed to silence notifications for teens from midnight to 6:00 AM, but this excludes direct messaging and can be disabled by parents. Following a landmark agreement in the United States on Wednesday, social media giant Meta agreed to pay up to $18 billion to US states. This historic settlement obliges the company to make Instagram and Facebook safer for children. Scientific research – including a landmark report by an expert panel commissioned by the European Commission – shows that excessive social media use damages early childhood brain development and fuels mental health crises among young people. Meta emphasises that the settlement is not proof of harmful health effects caused by its platforms. However, the unprecedented sum is likely to increase global pressure on platform operators to take action. The company said it had agreed to distribute the payments in annual instalments over a 10-year period to fund youth online safety initiatives across the participating states. Meta limits social media access for youth The agreement stipulates that Meta must limit daily usage time to two hours, disable extreme beauty filters, pause nighttime notifications and hide ‘like’ counts on posts by teenagers. In addition, the company will implement an age verification system under which no more than 3% of 13- to 15-year-olds and 10% cent of older teenagers may be incorrectly classified as adults. “The framework we’ve negotiated will empower parents to easily manage how their children access our platforms,” said CJ Mahoney, chief legal officer at Meta in a statement on Wednesday. Meta is required to phase in these modifications, with a strict compliance deadline set for six months after the court has now approved the settlement. To prevent an exodus of young users, Meta is urging its competitors, YouTube and TikTok, to adopt these standards. Doubts about effectiveness of settlement However, experts question whether the agreed time limits will effectively curb deep-rooted addiction risks. Parents can easily disable these daily usage caps, and the overnight notification pause does not cover direct messaging. Biometric facial scans for age verification remain controversial because processing sensitive video data violates data protection principles. Furthermore, teenagers easily bypass basic digital blocks using virtual private networks (VPNs), while privacy-friendly age verification methods remain unavailable on a large scale. A signal to regulators worldwide Nevertheless, the US settlement establishes a benchmark for youth social media bans passed in Australia and proposed in New Zealand. The European Commission plans to introduce a draft regulation this autumn to enforce a harmonised European age limit and strict safety-by-design standards. This proposed framework aims to end the current patchwork of legislation across Europe, as national restrictions often clash with the strict rules of the EU’s Digital Services Act (DSA). Related Story: Warning labels, Time restrictions? Experts Mull How to Curb Social Media Harms Editorial note: The piece has been updated on 28 August to reflect that the court has now approved the settlement. Image Credits: cottonbro studio via Pexels. The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
Clashing Convictions of Taliban and the West is Costing Afghan Lives 31/08/2026 Mukesh Kapila Afghan women have been almost erased from public life. Two sets of dogmas contend in Afghanistan: those of the Taliban and the West. Neither side pays the real price for their beliefs. Ordinary Afghans do with their lives. Some aid agencies labour quietly to bring help and hope through a dozen practical ways that bypass competing doctrines. They deserve support. In March last year, 23-year-old Khatera (pseudonym) went into prolonged labour. Her village clinic in western Afghanistan was long shuttered, and the nearest help was Herat city across a swollen river. Her husband carried her across the raging waters, both submerged to the shoulders. It took them 12 hours to reach the hospital. Khatera’s vital signs – and those of her baby – stopped registering hours after reaching the hospital. Why were they not saved? Perhaps no medical equipment or supplies? Perhaps few trained staff? Or perhaps sheer exhaustion? This everyday tragedy is commonplace for Afghans. Their misfortune is to be squeezed between the beliefs of their Taliban rulers and those of the international community that fled the country. This clash of convictions is fought over the easiest of targets: the defenceless bodies of millions like Khatera. The outcome is a generation of losers, not just Afghans but those who would save them. As with all lose-lose “games”, the focus quickly shifts to ascribing blame, as in the acres of commentary around the fifth anniversary of the Taliban’s re-accession to power. Vital symptoms and signs Extensive research has established that the fundamental drivers of health outcomes are social determinants. Unsurprisingly, the Taliban’s draconian restrictions that pervert the noble Islamic faith have dealt a crippling blow. Women have been almost erased from public spaces (except when they are flogged), with restrictions on their movement, education, and employment. Women’s access to health care has shrunk, and very young girls are being forced into marriages to settle debts or relieve poverty. Let us begin with basic health battlefield statistics. Afghans die young, with a life expectancy of 66.3 years, and under-five child mortality exceeding 50 deaths per 1,000 births – some 40% above the global average. Mothers suffer one of the world’s highest mortality ratios at 638 deaths per 100,000 livebirths. All these numbers were improving but have reversed under the Taliban. Fourteen million Afghans – a third of the population – face crisis-level hunger and there is record-breaking malnutrition with around 4.9 million children and pregnant and breastfeeding women affected. This equates to a tenth of children acutely malnourished and 45% chronically stunted. Other conditions – communicable, non-communicable, physical and mental trauma – flourish. Suicide rates, especially among females, are mounting. Six million coerced refugee returns from Pakistan and Iran, and climate disasters add to the strain. Malnutrition amongst children and the wider public has reached record levels in Afghanistan. When levers crumble All this is familiar. But it is also well known that regimes that claim divine inspiration are not amenable to earthly leverage by traditional aid, trade, diplomatic and military tools, as I discovered in my role as a past special adviser to the United Nations Assistance Mission in Afghanistan (UNAMA). Meanwhile, the Taliban are amenable to receiving assistance but on their own terms. That poses a dilemma for those who wish to relieve the suffering of Afghans without supporting their autocratic and misogynistic rulers. So the real question in a country that has always been aid-dependent becomes: how to help, also knowing that Taliban regulations complicate aid delivery and utilisation, especially as it is not possible to employ women to reach vulnerable families. This creates a difficult picture for foreign policymakers, who have many complex problems elsewhere to deal with. With the second coming of the Taliban in 2021, they found it much easier to walk away, whatever the morality of leaving Afghanistan to its own devices in light of the historic responsibilities of external powers in creating the turmoil. The walkout, in numbers The principal consequence of the walkout has been felt in the aid sector. UN-coordinated funding dropped 69% from $3.27 billion in 2022 to $1.01 billion last year. Afghanistan’s 2026 humanitarian appeal seeks $1.71 billion. With three-quarters of the year gone, it has received just 30% or $513 million (30 August). The health cluster has around $73 million, or 38% of what it wants; nutrition has $51 million (17%), and water, sanitation and hygiene received $19.5 million (12%). As a consequence, some 445 health facilities closed or suspended operations during 2025 and another 295 in the first half of this year. This includes 203 mobile health and nutrition teams. This means that at least four million people had lifesaving services switched off, including Khatera’s village. Prevention and public health services also dwindle. The epicentre of wild poliovirus has shifted to Afghanistan with 19 cases this year compared to Pakistan’s three, as house-to-house vaccination stopped in October 2024 and women vaccinators became rare. Meanwhile, and with no trace of irony, Afghanistan’s de facto Ministry of Public Health has just launched a surreal document with the vision of health as “a fundamental right” and a “goal of care for all Afghans”. This is its National Health Strategy 2026-2030 prepared with WHO support. One of its “seven pillars” concerns human resource development. It is not clear how this will be squared with the Taliban bar on women studying medicine, midwifery, nursing, and allied sciences, closing the pipeline for producing the clinicians Afghan women need. Does cutting aid kill? The political economy of aid requires deeper scrutiny. Do aid cuts lead to deaths? The US Secretary of State has asserted that it does not, as the US drastically cut foreign assistance. It is difficult to attribute specific mortality to general loss of aid, especially in Africa where American aid cuts have, in part, been made up by host budgets and other donors. But the causal association is stronger in Afghanistan, where neither the Taliban authorities nor other donors have stepped in to replace sharply dwindled US assistance, which had peaked above 40% of the country’s humanitarian spend. The US gave $728.6 million in 2024, $243.2 million in 2025, and nothing so far in 2026. An interesting study provides frontline evidence of impacts, such as neonatal deaths in Kunar and Farah rising 156% and 167% respectively between 2024 and 2025. Two sides of the humanitarian red line But there is a paradoxical aid economy at work. Even with pre-Taliban funding, most aid bypassed the government budget – except for some health basics. Since 2021, that has also gone, with UN agencies contracting providers that pay nurses and midwives directly into their personal bank accounts. So cutting such assistance does not defund the Taliban administration but individual health workers. Thus, the ‘no Taliban support’ dogma costs nothing to their officials standing on one side of the humanitarian red line and everything to the beneficiaries on the other side. No Taliban enforcer misses a meal when yet another aid-funded nutrition site shuts. Meanwhile, some $4.2 billion of Afghan central bank money sits in a Fund for the Afghan People at a Geneva non-profit foundation that has not disbursed a single dollar since its creation in 2022. There is a further $3.5 billion frozen in the US and snarled up in post 9/11 litigation. And so, Afghanistan’s own money sits idle in Western banks while an ideological contest fires off competing virtue signals over the emaciated and expired bodies of its most vulnerable citizens who were never consulted on any of it. The wider aid chill In parallel, aid implementers relying on Western governments remain wary of counter-terrorism law. On paper, there are humanitarian carve-outs including American general licences. But, amidst the friable present mood, who is so rash as to trust a piece of paper? Apart from cumbersome procedures and added administrative costs around getting waivers, imagine what happens if an agency makes a small payment for rendered services to a doctor who happens to have a Taliban relative, or a local Taliban official demands a small tax on the cash transfer. The agency could inadvertently face the nightmare of legal penalties and criminal prosecution. Meanwhile, the general donor trend of conditioning humanitarian aid accelerates. Thus, $2 billion US global humanitarian funding via OCHA specifically excludes Afghanistan. Perhaps partly because the Taliban will not agree to a US return to control the strategic Bagram airbase? Although the European Commission – now Afghanistan’s biggest donor – has maintained funding levels (around €162 million this year), it also invited the Taliban to Brussels to discuss repatriating failed Afghan asylum seekers. With some 500,000 Afghans applying for asylum since the Taliban came, and the increased political toxicity associated with the migration issue, there is a trend towards attaching conditions to European aid. As Western-espoused humanitarian values sink under their own hypocrisy and the world order splits into ‘the West’ and ‘the Rest’, Afghanistan is finding new friends. China is courting the Taliban with infrastructure investments in return for accessing Afghanistan’s massive mineral resources. Russia is giving some aid alongside military co-operation to bring Afghanistan into its sphere of influence. Central Asian and Gulf nations, as well as India and Iran, get closer to the Taliban through aid, trade, and diplomacy. This further entrenches the Taliban regime and brings little succour for people. Creative ways to bypass Taliban Afghan women and children are paying the highest price for plunging aid. That makes it even more vital to maximise the good effects of available limited humanitarian funding. This translates into aid givers finding creative ways to bypass the Taliban without getting thrown out themselves. That high-wire act to stay in the game to do good is the real story from the past five years. It is a tale of the extraordinary resilience of the Afghan people and their own traditional community and social institutions. And a tale of redemption for the very same aid agencies – UN and NGO – that are so heavily criticised for their shortcomings in other corners of the world. Here are a dozen key strategies learnt from their trial, error and courageous risk-taking that are saving lives here and there in Afghanistan. These deserve scaling up while implementers stay under the Taliban radar as much as possible. The first is about realising that aid delivery in Afghanistan is a retail affair, not a wholesale business. It requires negotiating for access locally and quietly, knowing that fierce-sounding national decrees are enforced unevenly. Province-by-province technical exemptions, brokered by Afghan staff and elders rather than announced from Geneva or Kabul, have, for example, kept some female vaccinators and midwives working. Second, more of the dwindling numbers of Afghan professionals could be pressed into service to sustain healthcare frontlines. It means expanding direct-to-worker electronic payments, which would also inject cash into local economies without going through Taliban coffers. Electronic transactions are also easily tracked and audited to encourage small agencies fearing Western anti-terror legislation to expand their services. Third, pay the mahram, the authorised male required under Taliban restrictions to accompany a female patient or the female health worker going to work. If this offends our Western sensibilities, think of the mahram as staff akin to the clinic watchman or ambulance driver. We are already compromising on mahram in practice while refusing to fund them in principle, which buys us the moral posture and the dead mother alike. Some communities show incredible creativity with the mahram requirement. For example, groups of women going together to a health centre have negotiated to be escorted by a village elder as their ‘collective mahram’ – thereby allowing their wage-earning husbands, brothers, and sons not to take time off work. Fourth, where patients cannot travel to clinics, bring them to her. Mobile health and nutrition units are well-known worldwide. Restoring and expanding Afghanistan’s mobile teams whose funding was indiscriminately cut would be a cost-effective boost for healthcare provision. A mother and her child in a WHO-supported maternal care facility in Bajnab, Afghanistan. Fifth, co-locate necessary institutional facilities such as operating rooms, laboratory and diagnostic capacities with existing national, provincial, and district hospitals, and re-equip and re-supply them. This makes it politically difficult for the Taliban to close them. Installing or repairing an ultrasound machine and refurbishing hospital electricity and water saves lives and does not mean condoning the Taliban administration. Sixth, direct-to-clinic logistics that move vital medicines, therapeutic foods and other supplies from cargo planes to pharmacies under trusted supervision help to minimise diversion and reduce manipulated distribution. Seventh, investing in autonomous, solar-powered clinic microgrids, including battery storage, has many benefits, not just for preventing the ruin of temperature-sensitive vaccines but also to allow anaesthesia and surgery for common trauma, obstetric, and other emergencies. Eighth, revive grassroots public health surveillance for marker diseases, hunger and malnutrition, and vital statistics collection around births and deaths. That means paying local community enumerators as done in past smallpox and polio campaigns. It is when operational circumstances are most complex, that programmes cannot afford to go blind from lacking local trend data. Ninth, take more measured risks. As international humanitarianism retreats while the “duty of care” movement gathers momentum, risk-aversion and institutional self-protection also grow. Understandable, of course, but is this not getting over the top? This is one of the most expressed frustrations by motivated and seasoned aid workers. Risk assessment systems – including utilising AI – have advanced but many agencies are stuck in centralised modes that mistrust well-informed local judgements. That triggers another thought. With the growing shortage of female Afghan health professionals, could more foreign females volunteer to fill the gap? That raises the associated challenge of their accompanying mahram. There are pragmatic solutions here, including negotiating ad hoc exemptions or facilitating couples to serve together. Tenth, keep the health and training pipeline rumbling along. Afghanistan’s education sector provides remarkable inspiration through clandestine home and digital schooling initiatives for girls. Can these approaches be applied in the health sector, both for refreshing basic health worker knowledge and for general public education around essential skills such as first aid, nutrition, and preventing and treating common conditions, including psychosocial support and suicide risk handling? Further, by investing in enhanced digital connectivity in selected (especially secondary) hospitals via low-cost technologies like Starlink that are available worldwide, expert Afghan medical diaspora with relevant linguistic skills could provide online consultations. Eleventh, sustaining a health delivery system that works for people is a crucial concern as there is no possibility of political change in the foreseeable future. Meanwhile, high-profile international aid brands and large corporate logos draw intense, negative Taliban scrutiny. They could, instead, sponsor low-profile hyper-local community networks via pre-existing local volunteer bodies and underground civic networks to distribute medical micro-assistance, including medicines, hygiene kits, consultation referrals, and even skills training. Twelfth, and most crucially, health aid givers should agree on common operating rules pragmatically applied in local circumstances. That means less policy rhetoric on confrontational red lines and more about working solutions that focus on patients. Facility-by-facility, the Taliban morality inspectors are conceding that medical spaces be demilitarised. Also female and male colleagues may work alongside each other during lifesaving procedures. Such bargains can be built upon. Consistency and patience are missing The Taliban rank-and-file know that their loved ones also need healthcare, often under desperate circumstances. Their rigid mindsets are curiously mirrored in their respect for others who also stubbornly hold onto their own principles. Hence, a package of negotiated measures that bring predictable cooperation over health is quite feasible, as shown by pioneering agencies such as Médecins Sans Frontières. In short, much more can be done to safeguard the health of Afghans despite numerous obstacles. There is nothing novel in the proposed approaches that have already shown good results in Afghanistan and other complex resource-poor contexts. So what is missing? Beyond insufficient resources, it is a sense of coherent mission that believes in the feasibility of improving the health chances of Afghans. This will not come from the current defeatist attitudes among humanitarian, global health, and multilateral aid communities with low expectations and marked risk aversion. Neither will it come from composing national health strategies that are little more than fantasies. We need pragmatic but consistent labouring from the bottom-up organised around whatever Afghans find feasible. Above all is the requirement for patience that the international community is not known for. Mukesh Kapila is professor emeritus of global health and humanitarian affairs at the University of Manchester, and a board member of Health Policy Watch. Vital Signs in Global Health is a regular column, and the opinions expressed are solely those of the author. Image Credits: Charlotte Cans/ UNOCHA, Karimi/ UNICEF Afghanistan, WHO EMRO, WHO. South Africa Grapples With The Promise and Price of Injectable Lenacapavir to Prevent HIV 30/08/2026 Kerry Cullinan Sex worker advocate Precious Mafanga describes lenacapavir as very easy to take for her sector. The antiretroviral medicine lenacapavir, delivered via injection every six months, is almost completely effective in preventing HIV. But it is expensive at present, and millions will need to be initiated on it every year to make a dent on HIV transmission in South Africa. CAPE TOWN – South Africa has the biggest population of people living with HIV in the world – over eight million people, around 18% of those aged 15 to 49. So its Health Ministry and researchers are laser-focused on HIV prevention tools, particularly how to optimise pre-exposure prophylaxis (PrEP), which involves using antiretroviral medication to prevent HIV. The newest PrEP offering is lenacapavir, Gilead’s “miracle” twice-yearly injection that has prevented almost 100% of HIV transmission in clinical trials, some of which took place in South Africa. The country started to roll out lenacapavir in June, and it is now available at 360 health facilities to anyone who feels at risk of HIV. South Africa’s President Cyril Ramaphosa described the introduction of lenacapavir as “a major turning point in South Africa’s national story. It is the triumph of science over despair and the power of innovation to save lives”. But fewer than 47,000 people have been initiated so far – mainly because the health department cannot afford a huge rollout. Yet health economists advising the government have worked out that the country needs to get at least 1.7 million people on lenacapavir every year for the next five years if it wants to break the transmission of HIV. Drug price and procurement Hasina Subedar, senior technical advisor to the South Africa Department of Health. The Global Fund, which has an agreement with Gilead, is procuring the drug for South Africa, and has asked the health department to ring-fence $29.2 million of its three-year Global Fund grant for lenacapavir. “The Global Fund asked us to budget for $60 per person per annum, and it is topping this up, but the price they are paying [to Gilead] is confidential,” says Hasina Subedar, senior technical advisor at the South African Department of Health. This budget translates into doses for around 420,000 people. While the United States government is assisting other countries to buy lenacapavir, it decided not to support South Africa over political disagreements. However, the Children’s Investment Fund Foundation (CIFF) has stepped in to assist the country. “We will really only be able to have roll-out at scale when we have the generics,” says Subedar, noting that lenacapavir has been included on the country’s essential medicines list, subject to the availability of generics at $40 per annual dose. In October 2024, Gilead announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir for 120 “high-incidence, resource-limited countries”. It has prioritised 18 of these countries, including South Africa. The six are Dr Reddy’s Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero and Mylan – none South African. So far, only Hetero has submitted its dossier for regulatory approval to the South African Health Products Regulatory Authority (SAHPRA). Generics are expected by mid-2027, but it is unclear yet when they will reach South Africa. Lumps and bumps: administering lenacapavir South African health facilities have offered oral PrEP since 2016, although the small supplies initially available were first directed to groups most at risk: sex workers, then men who have sex with men and then teenage girls and young women. Since its introduction, some 2.3 million people have started oral PrEP, but have stopped taking the pills. Supply has been affected by the 2025 US budget cuts. But some people also get tired of daily pill-taking. Others, particularly vulnerable young women, are reluctant for their partners to know that they are taking precautions against potential HIV infection. This makes the six-monthly injectable option so attractive. But it’s not a simple process, as Subedar explains. Lenacapavir initiation happens over two days. On day one, people get two 1.5ml injections in separate areas, administered subcutaneously (in the fatty layer of skin). This is usually in the person’s abdomen or buttocks. At the same time, they get two 300mg pills. People are sent home with two 300 mg pills, which they need to take the following day. By day three, they are protected against HIV for the next 26 weeks until their next injections. They have a two-week grace period either side of their 26-week date to get their next injections. No pills are needed on subsequent visits unless they miss the two-week window. Patients’ experiences: ‘Next time, the buttocks’ Trans activist Dimpho Tsotetsi says oral PrEP made me nauseous. Dimpho Tsotetsi, who has used oral PrEP since 2017, switched to lenacapavir in a Soweto clinic on 4 July. “I used to work in a [USAID] donor-funded clinic, so I knew it was coming,” said Tsotetsi, an extroverted 32-year-old trans woman who describes herself as a health advocate for her community. “I had nausea every day with oral PrEP,” she added, and despite about two weeks of discomfort after her injections, Tsotetsi describes the experience as “pleasant”. “I got two shots on my stomach, one on the left, one on the right. Until today I still have the bumps. I can feel them,” said Tsotetsi, who adds that this has made wearing clothes with tight waistbands harder as they rub against the injection bumps. “Hence I’m wearing something flowy”, she laughs. Precious Mafanga, a sex worker and sex worker advocate, describes lenacapavir as “very helpful and easy to take” – unlike oral PrEP “which makes you hungry”. She and many others working in organisations serving “key populations” – those most at risk of HIV – have had a rough time since the US stopped funding these groups after Donald Trump came to power in January 2025. Mafanga describes chaos in the sex worker sector, with job losses for peer educators, sex workers defaulting on antiretroviral medication and a lack of support for people who inject drugs as specialised clinics and mobile outreach came to a screeching halt. In the past few months, a new organisation, Tholwana e Molemo, has stepped up to assist sex workers. While resources are much more limited, the organisation’s nurses have been able to work with government clinics to enable sex workers to get fast access to lenacapavir. Lindiwe Mqatazana, who is pregnant, opted for lenacapavir to protect her baby. Meanwhile, Siviwe Gaika, a 24-year-old law student and church-goer who uses PrEP to protect herself, said she tried to get lenacapavir three times before her local clinic, a designated site, was ready to administer it. She also describes bumps on her abdomen at the injection sites: “I think next time I will get it on the buttocks.” It was the buttocks for Lindiwe Mqatazana, who had a positive pregnancy test and lenacapavir all in the same day. “It was a bit scary, but the nurses explained that this is the best way to protect my baby and that it won’t hurt the baby,” said Mqatazana. Million-person rollout Dr Lise Jamieson from the Health Economics and Epidemiology Research Office (HE2RO) at Wits University is one of the health economists advising the health department. Using Thembisa, a mathematical model of the South African HIV epidemic, researchers have made various forecasts, said Jamieson. Their key message is that lenacapavir will be far more effective than oral PrEP – if it is rolled out at scale. The impact of lenacapavir in comparison to oral PrEP (TDF/ FTC) After modelling various scenarios, they calculate that lenacapvir can reduce HIV by 19-31% over 20 years in comparison to 4% by oral PrEP. It will also end AIDS seven to 10 years earlier than oral PrEP. But this impact requires serious volumes: between 1.7 million and 2.3 million people need to start lenacapavir every year for at least the next five years. The rollout needs to be more targeted at those who need it most, with the most optimal breakdown to be 45% for adolescent girls and young women (AGYW); 30% for men who have sex with men (MSM); 15% for female sex workers; and 10% for pregnant and breastfeeding women. The health department’s targets are weighted more heavily towards teenage girls, young women, and pregnant and breastfeeding women. However, currently it is hard to tell which groups most of the 47,000+ people who have opted for lenacapavir come from, as over 70% describe themselves as the “general population”. Targeting certain key populations – female sex workers (FSW), men who have sex with men (MSM), and adolescent girls and young women (AGYW) – will have more impact than an over-emphasis on pregnant and breastfeeding women (PBFW), according to experts. Meanwhile, the financial investment is substantial, with up to $106 million needed for five years – but, says Jamieson, this is still four times more cost-effective than oral PrEP. More choices “The excitement about lenacapavir is huge, but what is the follow-up going to be like?” asks Dr Pippa McDonald, from the Desmond Tutu Health Foundation. The foundation was one of the partners that ran the clinical trial of lenacapavir, and is currently monitoring people’s responses and uptake to the medication. So far, over 80% of people surveyed want the six-monthly injections rather than oral PrEP, said MacDonald. “Choice is really important,” says MacDonald, who believes that offering different PrEP options and points of delivery are important ingredients for success. A monthly PrEP pill, alimatravir, is currently undergoing clinical trials – and may prove even more popular than the six-monthly injections. At the International AIDS Society (IAS) conference in Brazil in July, the company developing the pill, Merck/ MSD, announced that it has already granted voluntary licenses to seven generic companies – three in sub-Saharan Africa and four in India – to produce the medicine for 129 low- and middle-income countries. This is even before the medicine has been proven effective. There are many possibilities in the mix, including the government distributing PrEP in partnership with private pharmacies and people self-injecting follow-up lenacapavir doses. But there are still many unknowns too, particularly how fast generic lenacapavir can be produced, whether there will be enough money for the scale-up that is needed, and how many people will come back after six months. Interviews for this article are from a media workshop on South Africa’s lenacapavir rollout organised by Bhekisisa. India’s Flagship Air Pollution Programme Is Failing 28/08/2026 Chetan Bhattacharji Dr Piyush Bharadwaj, CSTEP, presenting research on the air quality and climate co-benefits possible in India at the India Clean Air Summit. BENGALURU – India’s flagship air pollution action plan, the National Clean Air Programme (NCAP), has mostly failed to deliver, according to research presented at the eighth India Clean Air Summit. Officials, scientists, and other experts highlighted the 2019 program’s severe shortcomings and red-flagged critical gaps. An “NCAP 2.0′ has been widely expected, but the central government has yet to announce a launch timeline. Data shared by the summit organiser, the Center for Study of Science, Technology and Policy (CSTEP), showed that fewer than 7% of the 131 targeted cities met NCAP’s goal to reduce pollution by 40% by 2025-26, and 35% of cities showed an increase in coarse particulate matter (PM10). This failure comes despite the government releasing over INR 16,423 crore (approximately $1.5 billion) to support the program. Speakers at the conference emphasized that future iterations of the programme must bridge air pollution control measures with climate action policies. Crucially, at least two government experts warned of emerging, interconnected feedback loops between climate change and air quality. Structural flaws in programme According to CSTEP, NCAP’s limited impact stems from several core design flaws. These include that it targets cities; focuses on PM 10 and dust mitigation measures not the finer, deadlier PM2.5 particulate matter pollutant; has no systemic assessment of interventions; and it covers short-term measures rather than long-term planning considering growth. There is also limited technical understanding of urban local bodies (ULBs). About 95% of India’s PM2.5 pollution, a universally tracked pollutant, is emitted from cities and rural areas that are excluded from NCAP’s focus, which tracks 131 cities. Seventy percent of PM2.5 is from “non-urban areas” according to PAVITRA, an air quality management tool developed by IIT Bombay, CSTEP and two American universities. Data shows how much of India’s air pollution sources lie outside cities and outside the National Clean Air Programme’s focus centres. Source: Air Pollution Management And Intervention Tool For India (PAVITRA), by IIT Bombay, CSTEP, University of Washington, Berkeley University of California. Another limitation is the lack of funding for places where pollution is rising, such as the coastal state of Kerala. “What I really want to request is that when NCAP 2.0 is happening, there should be some funds available to the cities which are not non-attainment, but are trying to prevent becoming a non-attainment city,” says Ratish Menon, a senior official of Kerala’s Pollution Control Board. Non-attainment means cities that have consistently failed to attain air quality that meets the national ambient air quality standard of 40 micrograms/cubic metre of PM2.5. Indo-Gangetic plain: India’s pollution hotspot That plain stretches about 2,000 kilometres across northern India, south of the Himalayan foothills and east to Bangladesh. However, the most severe challenge remains concentrated in northern plains of India, described as an “emission hotspot” by SD Attri, a senior official and scientist of the Commission for Air Quality Management (CAQM). The CAQM is in-charge of reducing pollution in and around Delhi, which is situated in the plains. “The Indo-Gangetic Plain (IGP) covers only 15% of India’s land but accommodates around 37% of its population and emits 35% of India’s total emissions, making it an emission hotspot,” Attri explained, which is why Delhi and other places here often make it to the list of the top, most polluted places in the world. Residents across the northern plains are exposed to persistently high pollution levels year-round. On an annual basis, average concentrations of PM2.5 or smaller particulate matter reach 84 µg/m³ (micrograms/cubic metre), which is more than twice the permissible standard of 40 micrograms under India’s National Ambient Air Quality Standard and almost 17 times the WHO’s safety guideline of 5 µg/m³ . Target mitigation: Black carbon in UP and Bihar A sharper focus on just two states, Uttar Pradesh and Bihar, and one pollutant, black carbon or soot, has been recommended by a CSTEP report launched at the summit. The largest source of black carbon is from homes burning biomass and other dirty fuels for cooking and heating. And more than 60% of this pollution is from the IGP states. Uttar Pradesh and Bihar is where domestic emissions have the greatest regional spillover. These two states dominate India’s northern plains, with a combined area about the same as Finland but with a combined population larger than the US. Reducing black carbon emissions can save lives, and the largest benefits are to be achieved through a multisectoral airshed approach. Reducing black carbon emissions from all major sources in the IGP results in a 37% reduction in black carbon concentration and prevents 2,290 PM2.5-attributable premature deaths. This number is conservative, as the authors explain there is limited research on the health effects of black carbon, unlike that of PM2.5, which is linked to about a million deaths in the country. “The mortality burden estimated in this study is conservative because the exposure–response function used is derived for ambient PM 2.5 mass concentration rather than for individual PM 2.5 components (Black carbon, organic carbon, sulphates, nitrates, etc). “Consequently, the potential toxicity of black carbon is not explicitly captured in the mortality estimation,” Piyush Bharadwaj, head of the air quality observations and modelling group at CSTEP, told Health Policy Watch. Climate change – air pollution link The CSTEP report also highlights significant co-benefits between clean air initiatives and carbon mitigation. In a best-case scenario, aggressive black carbon reduction in northern India would yield climate co-benefits equivalent to 639.3 MT CO2, roughly similar to Germany or South Korea’s annual emissions. Dr Ratish Menon, senior official, Kerala State Pollution Control Board, India There were other warnings about the link between global warming and air pollution. Menon attributed part of the rise in Kerala’s air pollution levels to pollution from neighbouring states, but also to global warming. Last winter’s peak in “all (air quality monitoring) stations” was more because there was lesser wind transport between the land and ocean, he says, “because the ocean temperatures are increasing and that exchange is getting affected. That causes a regional buildup.” A separate climate link was flagged by a senior scientist at IIT Kanpur, SN Tripathi, whose team has overseen the deployment of almost 1,400 low-cost sensors in Uttar Pradesh and Bihar. Based on this data, Tripathi said they have been able to create an index where “we have combined temperature and relative humidity to provide some kind of a universal climate index, and we are basically trying to give that how it looks during summer times when the temperatures are very high and the overall comfort level for human beings becomes very unmanageable.” They are seeing that a good part of these two states have a “very high amount of this compound index.” When asked by Health Policy Watch, how this ‘universal climate index’ is to be used, Tripathi said it was work in progress and premature to comment. Call to change air quality action plans India’s peak pollution season begins in October and ahead of that, Attri, the most senior official from the government of India at the summit, listed several measures taken to reduce air pollution. The latest include increasing the number of top grade air quality monitoring stations from about 90 currently to 157 in the next month as well a “new GRAP” system which he says will be open for the public’s comments and suggestions; GRAP is the Delhi region’s Graded Response Action Plan, a series of tighter curbs – on transport, construction, diesel generators, cooking fuels and even schools – as pollution levels rise However, the larger messaging from ICAS 2026 is that urgent changes in air quality management are required. Pointing to a series of policy actions since the Air (Prevention and Control of Pollution) Act was cleared by Parliament 45 years ago, and the INR 16,423 crore in funding released by the government, Abinaya Sekar of Health Effects Institute underscored the need to assess the effectiveness of air pollution interventions, offering a framework on how to do this. CSTEP researchers urged the government to integrate air quality targets into both NCAP 2.0 and India’s international commitments under the UN Nationally Determined Contributions (NDCs), that is, self-identified pledges for climate action by every country. Aligning these policies would allow air quality improvement to be recognised as a critical element of near-term climate mitigation, particularly by targeting short-lived climate pollutants like black carbon. In eight years of the India Clean Air Summit and similar gatherings, the one constant has been the demand for better implementation. The other constant has been Delhi’s annual average PM2.5 pollution level stubbornly hovering around 100 micrograms, in the last eight years. Image Credits: Source: Press Information Bureau, Indian Government. Historic Meta Settlement Mandates Safer Social Media for Youth 27/08/2026 Editorial team Meta agreed to silence notifications for teens from midnight to 6:00 AM, but this excludes direct messaging and can be disabled by parents. Following a landmark agreement in the United States on Wednesday, social media giant Meta agreed to pay up to $18 billion to US states. This historic settlement obliges the company to make Instagram and Facebook safer for children. Scientific research – including a landmark report by an expert panel commissioned by the European Commission – shows that excessive social media use damages early childhood brain development and fuels mental health crises among young people. Meta emphasises that the settlement is not proof of harmful health effects caused by its platforms. However, the unprecedented sum is likely to increase global pressure on platform operators to take action. The company said it had agreed to distribute the payments in annual instalments over a 10-year period to fund youth online safety initiatives across the participating states. Meta limits social media access for youth The agreement stipulates that Meta must limit daily usage time to two hours, disable extreme beauty filters, pause nighttime notifications and hide ‘like’ counts on posts by teenagers. In addition, the company will implement an age verification system under which no more than 3% of 13- to 15-year-olds and 10% cent of older teenagers may be incorrectly classified as adults. “The framework we’ve negotiated will empower parents to easily manage how their children access our platforms,” said CJ Mahoney, chief legal officer at Meta in a statement on Wednesday. Meta is required to phase in these modifications, with a strict compliance deadline set for six months after the court has now approved the settlement. To prevent an exodus of young users, Meta is urging its competitors, YouTube and TikTok, to adopt these standards. Doubts about effectiveness of settlement However, experts question whether the agreed time limits will effectively curb deep-rooted addiction risks. Parents can easily disable these daily usage caps, and the overnight notification pause does not cover direct messaging. Biometric facial scans for age verification remain controversial because processing sensitive video data violates data protection principles. Furthermore, teenagers easily bypass basic digital blocks using virtual private networks (VPNs), while privacy-friendly age verification methods remain unavailable on a large scale. A signal to regulators worldwide Nevertheless, the US settlement establishes a benchmark for youth social media bans passed in Australia and proposed in New Zealand. The European Commission plans to introduce a draft regulation this autumn to enforce a harmonised European age limit and strict safety-by-design standards. This proposed framework aims to end the current patchwork of legislation across Europe, as national restrictions often clash with the strict rules of the EU’s Digital Services Act (DSA). Related Story: Warning labels, Time restrictions? Experts Mull How to Curb Social Media Harms Editorial note: The piece has been updated on 28 August to reflect that the court has now approved the settlement. Image Credits: cottonbro studio via Pexels. The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
South Africa Grapples With The Promise and Price of Injectable Lenacapavir to Prevent HIV 30/08/2026 Kerry Cullinan Sex worker advocate Precious Mafanga describes lenacapavir as very easy to take for her sector. The antiretroviral medicine lenacapavir, delivered via injection every six months, is almost completely effective in preventing HIV. But it is expensive at present, and millions will need to be initiated on it every year to make a dent on HIV transmission in South Africa. CAPE TOWN – South Africa has the biggest population of people living with HIV in the world – over eight million people, around 18% of those aged 15 to 49. So its Health Ministry and researchers are laser-focused on HIV prevention tools, particularly how to optimise pre-exposure prophylaxis (PrEP), which involves using antiretroviral medication to prevent HIV. The newest PrEP offering is lenacapavir, Gilead’s “miracle” twice-yearly injection that has prevented almost 100% of HIV transmission in clinical trials, some of which took place in South Africa. The country started to roll out lenacapavir in June, and it is now available at 360 health facilities to anyone who feels at risk of HIV. South Africa’s President Cyril Ramaphosa described the introduction of lenacapavir as “a major turning point in South Africa’s national story. It is the triumph of science over despair and the power of innovation to save lives”. But fewer than 47,000 people have been initiated so far – mainly because the health department cannot afford a huge rollout. Yet health economists advising the government have worked out that the country needs to get at least 1.7 million people on lenacapavir every year for the next five years if it wants to break the transmission of HIV. Drug price and procurement Hasina Subedar, senior technical advisor to the South Africa Department of Health. The Global Fund, which has an agreement with Gilead, is procuring the drug for South Africa, and has asked the health department to ring-fence $29.2 million of its three-year Global Fund grant for lenacapavir. “The Global Fund asked us to budget for $60 per person per annum, and it is topping this up, but the price they are paying [to Gilead] is confidential,” says Hasina Subedar, senior technical advisor at the South African Department of Health. This budget translates into doses for around 420,000 people. While the United States government is assisting other countries to buy lenacapavir, it decided not to support South Africa over political disagreements. However, the Children’s Investment Fund Foundation (CIFF) has stepped in to assist the country. “We will really only be able to have roll-out at scale when we have the generics,” says Subedar, noting that lenacapavir has been included on the country’s essential medicines list, subject to the availability of generics at $40 per annual dose. In October 2024, Gilead announced that it has signed non-exclusive, royalty-free voluntary licensing agreements with six pharmaceutical manufacturers to make and sell generic lenacapavir for 120 “high-incidence, resource-limited countries”. It has prioritised 18 of these countries, including South Africa. The six are Dr Reddy’s Laboratories, Emcure, Eva Pharma, Ferozsons Laboratories Limited, Hetero and Mylan – none South African. So far, only Hetero has submitted its dossier for regulatory approval to the South African Health Products Regulatory Authority (SAHPRA). Generics are expected by mid-2027, but it is unclear yet when they will reach South Africa. Lumps and bumps: administering lenacapavir South African health facilities have offered oral PrEP since 2016, although the small supplies initially available were first directed to groups most at risk: sex workers, then men who have sex with men and then teenage girls and young women. Since its introduction, some 2.3 million people have started oral PrEP, but have stopped taking the pills. Supply has been affected by the 2025 US budget cuts. But some people also get tired of daily pill-taking. Others, particularly vulnerable young women, are reluctant for their partners to know that they are taking precautions against potential HIV infection. This makes the six-monthly injectable option so attractive. But it’s not a simple process, as Subedar explains. Lenacapavir initiation happens over two days. On day one, people get two 1.5ml injections in separate areas, administered subcutaneously (in the fatty layer of skin). This is usually in the person’s abdomen or buttocks. At the same time, they get two 300mg pills. People are sent home with two 300 mg pills, which they need to take the following day. By day three, they are protected against HIV for the next 26 weeks until their next injections. They have a two-week grace period either side of their 26-week date to get their next injections. No pills are needed on subsequent visits unless they miss the two-week window. Patients’ experiences: ‘Next time, the buttocks’ Trans activist Dimpho Tsotetsi says oral PrEP made me nauseous. Dimpho Tsotetsi, who has used oral PrEP since 2017, switched to lenacapavir in a Soweto clinic on 4 July. “I used to work in a [USAID] donor-funded clinic, so I knew it was coming,” said Tsotetsi, an extroverted 32-year-old trans woman who describes herself as a health advocate for her community. “I had nausea every day with oral PrEP,” she added, and despite about two weeks of discomfort after her injections, Tsotetsi describes the experience as “pleasant”. “I got two shots on my stomach, one on the left, one on the right. Until today I still have the bumps. I can feel them,” said Tsotetsi, who adds that this has made wearing clothes with tight waistbands harder as they rub against the injection bumps. “Hence I’m wearing something flowy”, she laughs. Precious Mafanga, a sex worker and sex worker advocate, describes lenacapavir as “very helpful and easy to take” – unlike oral PrEP “which makes you hungry”. She and many others working in organisations serving “key populations” – those most at risk of HIV – have had a rough time since the US stopped funding these groups after Donald Trump came to power in January 2025. Mafanga describes chaos in the sex worker sector, with job losses for peer educators, sex workers defaulting on antiretroviral medication and a lack of support for people who inject drugs as specialised clinics and mobile outreach came to a screeching halt. In the past few months, a new organisation, Tholwana e Molemo, has stepped up to assist sex workers. While resources are much more limited, the organisation’s nurses have been able to work with government clinics to enable sex workers to get fast access to lenacapavir. Lindiwe Mqatazana, who is pregnant, opted for lenacapavir to protect her baby. Meanwhile, Siviwe Gaika, a 24-year-old law student and church-goer who uses PrEP to protect herself, said she tried to get lenacapavir three times before her local clinic, a designated site, was ready to administer it. She also describes bumps on her abdomen at the injection sites: “I think next time I will get it on the buttocks.” It was the buttocks for Lindiwe Mqatazana, who had a positive pregnancy test and lenacapavir all in the same day. “It was a bit scary, but the nurses explained that this is the best way to protect my baby and that it won’t hurt the baby,” said Mqatazana. Million-person rollout Dr Lise Jamieson from the Health Economics and Epidemiology Research Office (HE2RO) at Wits University is one of the health economists advising the health department. Using Thembisa, a mathematical model of the South African HIV epidemic, researchers have made various forecasts, said Jamieson. Their key message is that lenacapavir will be far more effective than oral PrEP – if it is rolled out at scale. The impact of lenacapavir in comparison to oral PrEP (TDF/ FTC) After modelling various scenarios, they calculate that lenacapvir can reduce HIV by 19-31% over 20 years in comparison to 4% by oral PrEP. It will also end AIDS seven to 10 years earlier than oral PrEP. But this impact requires serious volumes: between 1.7 million and 2.3 million people need to start lenacapavir every year for at least the next five years. The rollout needs to be more targeted at those who need it most, with the most optimal breakdown to be 45% for adolescent girls and young women (AGYW); 30% for men who have sex with men (MSM); 15% for female sex workers; and 10% for pregnant and breastfeeding women. The health department’s targets are weighted more heavily towards teenage girls, young women, and pregnant and breastfeeding women. However, currently it is hard to tell which groups most of the 47,000+ people who have opted for lenacapavir come from, as over 70% describe themselves as the “general population”. Targeting certain key populations – female sex workers (FSW), men who have sex with men (MSM), and adolescent girls and young women (AGYW) – will have more impact than an over-emphasis on pregnant and breastfeeding women (PBFW), according to experts. Meanwhile, the financial investment is substantial, with up to $106 million needed for five years – but, says Jamieson, this is still four times more cost-effective than oral PrEP. More choices “The excitement about lenacapavir is huge, but what is the follow-up going to be like?” asks Dr Pippa McDonald, from the Desmond Tutu Health Foundation. The foundation was one of the partners that ran the clinical trial of lenacapavir, and is currently monitoring people’s responses and uptake to the medication. So far, over 80% of people surveyed want the six-monthly injections rather than oral PrEP, said MacDonald. “Choice is really important,” says MacDonald, who believes that offering different PrEP options and points of delivery are important ingredients for success. A monthly PrEP pill, alimatravir, is currently undergoing clinical trials – and may prove even more popular than the six-monthly injections. At the International AIDS Society (IAS) conference in Brazil in July, the company developing the pill, Merck/ MSD, announced that it has already granted voluntary licenses to seven generic companies – three in sub-Saharan Africa and four in India – to produce the medicine for 129 low- and middle-income countries. This is even before the medicine has been proven effective. There are many possibilities in the mix, including the government distributing PrEP in partnership with private pharmacies and people self-injecting follow-up lenacapavir doses. But there are still many unknowns too, particularly how fast generic lenacapavir can be produced, whether there will be enough money for the scale-up that is needed, and how many people will come back after six months. Interviews for this article are from a media workshop on South Africa’s lenacapavir rollout organised by Bhekisisa. India’s Flagship Air Pollution Programme Is Failing 28/08/2026 Chetan Bhattacharji Dr Piyush Bharadwaj, CSTEP, presenting research on the air quality and climate co-benefits possible in India at the India Clean Air Summit. BENGALURU – India’s flagship air pollution action plan, the National Clean Air Programme (NCAP), has mostly failed to deliver, according to research presented at the eighth India Clean Air Summit. Officials, scientists, and other experts highlighted the 2019 program’s severe shortcomings and red-flagged critical gaps. An “NCAP 2.0′ has been widely expected, but the central government has yet to announce a launch timeline. Data shared by the summit organiser, the Center for Study of Science, Technology and Policy (CSTEP), showed that fewer than 7% of the 131 targeted cities met NCAP’s goal to reduce pollution by 40% by 2025-26, and 35% of cities showed an increase in coarse particulate matter (PM10). This failure comes despite the government releasing over INR 16,423 crore (approximately $1.5 billion) to support the program. Speakers at the conference emphasized that future iterations of the programme must bridge air pollution control measures with climate action policies. Crucially, at least two government experts warned of emerging, interconnected feedback loops between climate change and air quality. Structural flaws in programme According to CSTEP, NCAP’s limited impact stems from several core design flaws. These include that it targets cities; focuses on PM 10 and dust mitigation measures not the finer, deadlier PM2.5 particulate matter pollutant; has no systemic assessment of interventions; and it covers short-term measures rather than long-term planning considering growth. There is also limited technical understanding of urban local bodies (ULBs). About 95% of India’s PM2.5 pollution, a universally tracked pollutant, is emitted from cities and rural areas that are excluded from NCAP’s focus, which tracks 131 cities. Seventy percent of PM2.5 is from “non-urban areas” according to PAVITRA, an air quality management tool developed by IIT Bombay, CSTEP and two American universities. Data shows how much of India’s air pollution sources lie outside cities and outside the National Clean Air Programme’s focus centres. Source: Air Pollution Management And Intervention Tool For India (PAVITRA), by IIT Bombay, CSTEP, University of Washington, Berkeley University of California. Another limitation is the lack of funding for places where pollution is rising, such as the coastal state of Kerala. “What I really want to request is that when NCAP 2.0 is happening, there should be some funds available to the cities which are not non-attainment, but are trying to prevent becoming a non-attainment city,” says Ratish Menon, a senior official of Kerala’s Pollution Control Board. Non-attainment means cities that have consistently failed to attain air quality that meets the national ambient air quality standard of 40 micrograms/cubic metre of PM2.5. Indo-Gangetic plain: India’s pollution hotspot That plain stretches about 2,000 kilometres across northern India, south of the Himalayan foothills and east to Bangladesh. However, the most severe challenge remains concentrated in northern plains of India, described as an “emission hotspot” by SD Attri, a senior official and scientist of the Commission for Air Quality Management (CAQM). The CAQM is in-charge of reducing pollution in and around Delhi, which is situated in the plains. “The Indo-Gangetic Plain (IGP) covers only 15% of India’s land but accommodates around 37% of its population and emits 35% of India’s total emissions, making it an emission hotspot,” Attri explained, which is why Delhi and other places here often make it to the list of the top, most polluted places in the world. Residents across the northern plains are exposed to persistently high pollution levels year-round. On an annual basis, average concentrations of PM2.5 or smaller particulate matter reach 84 µg/m³ (micrograms/cubic metre), which is more than twice the permissible standard of 40 micrograms under India’s National Ambient Air Quality Standard and almost 17 times the WHO’s safety guideline of 5 µg/m³ . Target mitigation: Black carbon in UP and Bihar A sharper focus on just two states, Uttar Pradesh and Bihar, and one pollutant, black carbon or soot, has been recommended by a CSTEP report launched at the summit. The largest source of black carbon is from homes burning biomass and other dirty fuels for cooking and heating. And more than 60% of this pollution is from the IGP states. Uttar Pradesh and Bihar is where domestic emissions have the greatest regional spillover. These two states dominate India’s northern plains, with a combined area about the same as Finland but with a combined population larger than the US. Reducing black carbon emissions can save lives, and the largest benefits are to be achieved through a multisectoral airshed approach. Reducing black carbon emissions from all major sources in the IGP results in a 37% reduction in black carbon concentration and prevents 2,290 PM2.5-attributable premature deaths. This number is conservative, as the authors explain there is limited research on the health effects of black carbon, unlike that of PM2.5, which is linked to about a million deaths in the country. “The mortality burden estimated in this study is conservative because the exposure–response function used is derived for ambient PM 2.5 mass concentration rather than for individual PM 2.5 components (Black carbon, organic carbon, sulphates, nitrates, etc). “Consequently, the potential toxicity of black carbon is not explicitly captured in the mortality estimation,” Piyush Bharadwaj, head of the air quality observations and modelling group at CSTEP, told Health Policy Watch. Climate change – air pollution link The CSTEP report also highlights significant co-benefits between clean air initiatives and carbon mitigation. In a best-case scenario, aggressive black carbon reduction in northern India would yield climate co-benefits equivalent to 639.3 MT CO2, roughly similar to Germany or South Korea’s annual emissions. Dr Ratish Menon, senior official, Kerala State Pollution Control Board, India There were other warnings about the link between global warming and air pollution. Menon attributed part of the rise in Kerala’s air pollution levels to pollution from neighbouring states, but also to global warming. Last winter’s peak in “all (air quality monitoring) stations” was more because there was lesser wind transport between the land and ocean, he says, “because the ocean temperatures are increasing and that exchange is getting affected. That causes a regional buildup.” A separate climate link was flagged by a senior scientist at IIT Kanpur, SN Tripathi, whose team has overseen the deployment of almost 1,400 low-cost sensors in Uttar Pradesh and Bihar. Based on this data, Tripathi said they have been able to create an index where “we have combined temperature and relative humidity to provide some kind of a universal climate index, and we are basically trying to give that how it looks during summer times when the temperatures are very high and the overall comfort level for human beings becomes very unmanageable.” They are seeing that a good part of these two states have a “very high amount of this compound index.” When asked by Health Policy Watch, how this ‘universal climate index’ is to be used, Tripathi said it was work in progress and premature to comment. Call to change air quality action plans India’s peak pollution season begins in October and ahead of that, Attri, the most senior official from the government of India at the summit, listed several measures taken to reduce air pollution. The latest include increasing the number of top grade air quality monitoring stations from about 90 currently to 157 in the next month as well a “new GRAP” system which he says will be open for the public’s comments and suggestions; GRAP is the Delhi region’s Graded Response Action Plan, a series of tighter curbs – on transport, construction, diesel generators, cooking fuels and even schools – as pollution levels rise However, the larger messaging from ICAS 2026 is that urgent changes in air quality management are required. Pointing to a series of policy actions since the Air (Prevention and Control of Pollution) Act was cleared by Parliament 45 years ago, and the INR 16,423 crore in funding released by the government, Abinaya Sekar of Health Effects Institute underscored the need to assess the effectiveness of air pollution interventions, offering a framework on how to do this. CSTEP researchers urged the government to integrate air quality targets into both NCAP 2.0 and India’s international commitments under the UN Nationally Determined Contributions (NDCs), that is, self-identified pledges for climate action by every country. Aligning these policies would allow air quality improvement to be recognised as a critical element of near-term climate mitigation, particularly by targeting short-lived climate pollutants like black carbon. In eight years of the India Clean Air Summit and similar gatherings, the one constant has been the demand for better implementation. The other constant has been Delhi’s annual average PM2.5 pollution level stubbornly hovering around 100 micrograms, in the last eight years. Image Credits: Source: Press Information Bureau, Indian Government. Historic Meta Settlement Mandates Safer Social Media for Youth 27/08/2026 Editorial team Meta agreed to silence notifications for teens from midnight to 6:00 AM, but this excludes direct messaging and can be disabled by parents. Following a landmark agreement in the United States on Wednesday, social media giant Meta agreed to pay up to $18 billion to US states. This historic settlement obliges the company to make Instagram and Facebook safer for children. Scientific research – including a landmark report by an expert panel commissioned by the European Commission – shows that excessive social media use damages early childhood brain development and fuels mental health crises among young people. Meta emphasises that the settlement is not proof of harmful health effects caused by its platforms. However, the unprecedented sum is likely to increase global pressure on platform operators to take action. The company said it had agreed to distribute the payments in annual instalments over a 10-year period to fund youth online safety initiatives across the participating states. Meta limits social media access for youth The agreement stipulates that Meta must limit daily usage time to two hours, disable extreme beauty filters, pause nighttime notifications and hide ‘like’ counts on posts by teenagers. In addition, the company will implement an age verification system under which no more than 3% of 13- to 15-year-olds and 10% cent of older teenagers may be incorrectly classified as adults. “The framework we’ve negotiated will empower parents to easily manage how their children access our platforms,” said CJ Mahoney, chief legal officer at Meta in a statement on Wednesday. Meta is required to phase in these modifications, with a strict compliance deadline set for six months after the court has now approved the settlement. To prevent an exodus of young users, Meta is urging its competitors, YouTube and TikTok, to adopt these standards. Doubts about effectiveness of settlement However, experts question whether the agreed time limits will effectively curb deep-rooted addiction risks. Parents can easily disable these daily usage caps, and the overnight notification pause does not cover direct messaging. Biometric facial scans for age verification remain controversial because processing sensitive video data violates data protection principles. Furthermore, teenagers easily bypass basic digital blocks using virtual private networks (VPNs), while privacy-friendly age verification methods remain unavailable on a large scale. A signal to regulators worldwide Nevertheless, the US settlement establishes a benchmark for youth social media bans passed in Australia and proposed in New Zealand. The European Commission plans to introduce a draft regulation this autumn to enforce a harmonised European age limit and strict safety-by-design standards. This proposed framework aims to end the current patchwork of legislation across Europe, as national restrictions often clash with the strict rules of the EU’s Digital Services Act (DSA). Related Story: Warning labels, Time restrictions? Experts Mull How to Curb Social Media Harms Editorial note: The piece has been updated on 28 August to reflect that the court has now approved the settlement. Image Credits: cottonbro studio via Pexels. The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
India’s Flagship Air Pollution Programme Is Failing 28/08/2026 Chetan Bhattacharji Dr Piyush Bharadwaj, CSTEP, presenting research on the air quality and climate co-benefits possible in India at the India Clean Air Summit. BENGALURU – India’s flagship air pollution action plan, the National Clean Air Programme (NCAP), has mostly failed to deliver, according to research presented at the eighth India Clean Air Summit. Officials, scientists, and other experts highlighted the 2019 program’s severe shortcomings and red-flagged critical gaps. An “NCAP 2.0′ has been widely expected, but the central government has yet to announce a launch timeline. Data shared by the summit organiser, the Center for Study of Science, Technology and Policy (CSTEP), showed that fewer than 7% of the 131 targeted cities met NCAP’s goal to reduce pollution by 40% by 2025-26, and 35% of cities showed an increase in coarse particulate matter (PM10). This failure comes despite the government releasing over INR 16,423 crore (approximately $1.5 billion) to support the program. Speakers at the conference emphasized that future iterations of the programme must bridge air pollution control measures with climate action policies. Crucially, at least two government experts warned of emerging, interconnected feedback loops between climate change and air quality. Structural flaws in programme According to CSTEP, NCAP’s limited impact stems from several core design flaws. These include that it targets cities; focuses on PM 10 and dust mitigation measures not the finer, deadlier PM2.5 particulate matter pollutant; has no systemic assessment of interventions; and it covers short-term measures rather than long-term planning considering growth. There is also limited technical understanding of urban local bodies (ULBs). About 95% of India’s PM2.5 pollution, a universally tracked pollutant, is emitted from cities and rural areas that are excluded from NCAP’s focus, which tracks 131 cities. Seventy percent of PM2.5 is from “non-urban areas” according to PAVITRA, an air quality management tool developed by IIT Bombay, CSTEP and two American universities. Data shows how much of India’s air pollution sources lie outside cities and outside the National Clean Air Programme’s focus centres. Source: Air Pollution Management And Intervention Tool For India (PAVITRA), by IIT Bombay, CSTEP, University of Washington, Berkeley University of California. Another limitation is the lack of funding for places where pollution is rising, such as the coastal state of Kerala. “What I really want to request is that when NCAP 2.0 is happening, there should be some funds available to the cities which are not non-attainment, but are trying to prevent becoming a non-attainment city,” says Ratish Menon, a senior official of Kerala’s Pollution Control Board. Non-attainment means cities that have consistently failed to attain air quality that meets the national ambient air quality standard of 40 micrograms/cubic metre of PM2.5. Indo-Gangetic plain: India’s pollution hotspot That plain stretches about 2,000 kilometres across northern India, south of the Himalayan foothills and east to Bangladesh. However, the most severe challenge remains concentrated in northern plains of India, described as an “emission hotspot” by SD Attri, a senior official and scientist of the Commission for Air Quality Management (CAQM). The CAQM is in-charge of reducing pollution in and around Delhi, which is situated in the plains. “The Indo-Gangetic Plain (IGP) covers only 15% of India’s land but accommodates around 37% of its population and emits 35% of India’s total emissions, making it an emission hotspot,” Attri explained, which is why Delhi and other places here often make it to the list of the top, most polluted places in the world. Residents across the northern plains are exposed to persistently high pollution levels year-round. On an annual basis, average concentrations of PM2.5 or smaller particulate matter reach 84 µg/m³ (micrograms/cubic metre), which is more than twice the permissible standard of 40 micrograms under India’s National Ambient Air Quality Standard and almost 17 times the WHO’s safety guideline of 5 µg/m³ . Target mitigation: Black carbon in UP and Bihar A sharper focus on just two states, Uttar Pradesh and Bihar, and one pollutant, black carbon or soot, has been recommended by a CSTEP report launched at the summit. The largest source of black carbon is from homes burning biomass and other dirty fuels for cooking and heating. And more than 60% of this pollution is from the IGP states. Uttar Pradesh and Bihar is where domestic emissions have the greatest regional spillover. These two states dominate India’s northern plains, with a combined area about the same as Finland but with a combined population larger than the US. Reducing black carbon emissions can save lives, and the largest benefits are to be achieved through a multisectoral airshed approach. Reducing black carbon emissions from all major sources in the IGP results in a 37% reduction in black carbon concentration and prevents 2,290 PM2.5-attributable premature deaths. This number is conservative, as the authors explain there is limited research on the health effects of black carbon, unlike that of PM2.5, which is linked to about a million deaths in the country. “The mortality burden estimated in this study is conservative because the exposure–response function used is derived for ambient PM 2.5 mass concentration rather than for individual PM 2.5 components (Black carbon, organic carbon, sulphates, nitrates, etc). “Consequently, the potential toxicity of black carbon is not explicitly captured in the mortality estimation,” Piyush Bharadwaj, head of the air quality observations and modelling group at CSTEP, told Health Policy Watch. Climate change – air pollution link The CSTEP report also highlights significant co-benefits between clean air initiatives and carbon mitigation. In a best-case scenario, aggressive black carbon reduction in northern India would yield climate co-benefits equivalent to 639.3 MT CO2, roughly similar to Germany or South Korea’s annual emissions. Dr Ratish Menon, senior official, Kerala State Pollution Control Board, India There were other warnings about the link between global warming and air pollution. Menon attributed part of the rise in Kerala’s air pollution levels to pollution from neighbouring states, but also to global warming. Last winter’s peak in “all (air quality monitoring) stations” was more because there was lesser wind transport between the land and ocean, he says, “because the ocean temperatures are increasing and that exchange is getting affected. That causes a regional buildup.” A separate climate link was flagged by a senior scientist at IIT Kanpur, SN Tripathi, whose team has overseen the deployment of almost 1,400 low-cost sensors in Uttar Pradesh and Bihar. Based on this data, Tripathi said they have been able to create an index where “we have combined temperature and relative humidity to provide some kind of a universal climate index, and we are basically trying to give that how it looks during summer times when the temperatures are very high and the overall comfort level for human beings becomes very unmanageable.” They are seeing that a good part of these two states have a “very high amount of this compound index.” When asked by Health Policy Watch, how this ‘universal climate index’ is to be used, Tripathi said it was work in progress and premature to comment. Call to change air quality action plans India’s peak pollution season begins in October and ahead of that, Attri, the most senior official from the government of India at the summit, listed several measures taken to reduce air pollution. The latest include increasing the number of top grade air quality monitoring stations from about 90 currently to 157 in the next month as well a “new GRAP” system which he says will be open for the public’s comments and suggestions; GRAP is the Delhi region’s Graded Response Action Plan, a series of tighter curbs – on transport, construction, diesel generators, cooking fuels and even schools – as pollution levels rise However, the larger messaging from ICAS 2026 is that urgent changes in air quality management are required. Pointing to a series of policy actions since the Air (Prevention and Control of Pollution) Act was cleared by Parliament 45 years ago, and the INR 16,423 crore in funding released by the government, Abinaya Sekar of Health Effects Institute underscored the need to assess the effectiveness of air pollution interventions, offering a framework on how to do this. CSTEP researchers urged the government to integrate air quality targets into both NCAP 2.0 and India’s international commitments under the UN Nationally Determined Contributions (NDCs), that is, self-identified pledges for climate action by every country. Aligning these policies would allow air quality improvement to be recognised as a critical element of near-term climate mitigation, particularly by targeting short-lived climate pollutants like black carbon. In eight years of the India Clean Air Summit and similar gatherings, the one constant has been the demand for better implementation. The other constant has been Delhi’s annual average PM2.5 pollution level stubbornly hovering around 100 micrograms, in the last eight years. Image Credits: Source: Press Information Bureau, Indian Government. Historic Meta Settlement Mandates Safer Social Media for Youth 27/08/2026 Editorial team Meta agreed to silence notifications for teens from midnight to 6:00 AM, but this excludes direct messaging and can be disabled by parents. Following a landmark agreement in the United States on Wednesday, social media giant Meta agreed to pay up to $18 billion to US states. This historic settlement obliges the company to make Instagram and Facebook safer for children. Scientific research – including a landmark report by an expert panel commissioned by the European Commission – shows that excessive social media use damages early childhood brain development and fuels mental health crises among young people. Meta emphasises that the settlement is not proof of harmful health effects caused by its platforms. However, the unprecedented sum is likely to increase global pressure on platform operators to take action. The company said it had agreed to distribute the payments in annual instalments over a 10-year period to fund youth online safety initiatives across the participating states. Meta limits social media access for youth The agreement stipulates that Meta must limit daily usage time to two hours, disable extreme beauty filters, pause nighttime notifications and hide ‘like’ counts on posts by teenagers. In addition, the company will implement an age verification system under which no more than 3% of 13- to 15-year-olds and 10% cent of older teenagers may be incorrectly classified as adults. “The framework we’ve negotiated will empower parents to easily manage how their children access our platforms,” said CJ Mahoney, chief legal officer at Meta in a statement on Wednesday. Meta is required to phase in these modifications, with a strict compliance deadline set for six months after the court has now approved the settlement. To prevent an exodus of young users, Meta is urging its competitors, YouTube and TikTok, to adopt these standards. Doubts about effectiveness of settlement However, experts question whether the agreed time limits will effectively curb deep-rooted addiction risks. Parents can easily disable these daily usage caps, and the overnight notification pause does not cover direct messaging. Biometric facial scans for age verification remain controversial because processing sensitive video data violates data protection principles. Furthermore, teenagers easily bypass basic digital blocks using virtual private networks (VPNs), while privacy-friendly age verification methods remain unavailable on a large scale. A signal to regulators worldwide Nevertheless, the US settlement establishes a benchmark for youth social media bans passed in Australia and proposed in New Zealand. The European Commission plans to introduce a draft regulation this autumn to enforce a harmonised European age limit and strict safety-by-design standards. This proposed framework aims to end the current patchwork of legislation across Europe, as national restrictions often clash with the strict rules of the EU’s Digital Services Act (DSA). Related Story: Warning labels, Time restrictions? Experts Mull How to Curb Social Media Harms Editorial note: The piece has been updated on 28 August to reflect that the court has now approved the settlement. Image Credits: cottonbro studio via Pexels. The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
Historic Meta Settlement Mandates Safer Social Media for Youth 27/08/2026 Editorial team Meta agreed to silence notifications for teens from midnight to 6:00 AM, but this excludes direct messaging and can be disabled by parents. Following a landmark agreement in the United States on Wednesday, social media giant Meta agreed to pay up to $18 billion to US states. This historic settlement obliges the company to make Instagram and Facebook safer for children. Scientific research – including a landmark report by an expert panel commissioned by the European Commission – shows that excessive social media use damages early childhood brain development and fuels mental health crises among young people. Meta emphasises that the settlement is not proof of harmful health effects caused by its platforms. However, the unprecedented sum is likely to increase global pressure on platform operators to take action. The company said it had agreed to distribute the payments in annual instalments over a 10-year period to fund youth online safety initiatives across the participating states. Meta limits social media access for youth The agreement stipulates that Meta must limit daily usage time to two hours, disable extreme beauty filters, pause nighttime notifications and hide ‘like’ counts on posts by teenagers. In addition, the company will implement an age verification system under which no more than 3% of 13- to 15-year-olds and 10% cent of older teenagers may be incorrectly classified as adults. “The framework we’ve negotiated will empower parents to easily manage how their children access our platforms,” said CJ Mahoney, chief legal officer at Meta in a statement on Wednesday. Meta is required to phase in these modifications, with a strict compliance deadline set for six months after the court has now approved the settlement. To prevent an exodus of young users, Meta is urging its competitors, YouTube and TikTok, to adopt these standards. Doubts about effectiveness of settlement However, experts question whether the agreed time limits will effectively curb deep-rooted addiction risks. Parents can easily disable these daily usage caps, and the overnight notification pause does not cover direct messaging. Biometric facial scans for age verification remain controversial because processing sensitive video data violates data protection principles. Furthermore, teenagers easily bypass basic digital blocks using virtual private networks (VPNs), while privacy-friendly age verification methods remain unavailable on a large scale. A signal to regulators worldwide Nevertheless, the US settlement establishes a benchmark for youth social media bans passed in Australia and proposed in New Zealand. The European Commission plans to introduce a draft regulation this autumn to enforce a harmonised European age limit and strict safety-by-design standards. This proposed framework aims to end the current patchwork of legislation across Europe, as national restrictions often clash with the strict rules of the EU’s Digital Services Act (DSA). Related Story: Warning labels, Time restrictions? Experts Mull How to Curb Social Media Harms Editorial note: The piece has been updated on 28 August to reflect that the court has now approved the settlement. Image Credits: cottonbro studio via Pexels. The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
The Next Global Health Architecture Must Deliver More Than Reform 27/08/2026 David Reddy A sterile, high-precision manufacturing laboratory. Global health architecture reform efforts should protect and strengthen the conditions for innovation. After months of speculation, prospective candidates in the race to become the next Director-General of the World Health Organization (WHO) are now emerging. At the same time, member states have launched a process to review the global health architecture, with the aim of clarifying roles, strengthening coordination, and aligning financing more closely with national, regional, and global priorities. The next WHO Director-General will inherit not only a changing organization, but a broader debate about how the international health system should be organized, financed, and governed. These discussions come at a time when governments are trying to do more with less. Health systems are managing growing burdens from chronic disease, public finances are under pressure, and geopolitical tensions are reshaping international cooperation. But science is not standing still. As governments consider the future of the global health architecture, three principles should guide reform. Foster an environment where innovation can thrive Research and development for Pfizer’s COVID-19 vaccine candidate. Investment in the research and development (R&D) of innovative medicines and vaccines has helped drive remarkable progress in health, economic growth, and societal well-being. New medicines are estimated to account for around 70% of gains in life expectancy in high-income countries. Global immunization efforts have saved an estimated 154 million lives over the past 50 years, while emerging evidence suggests that adult immunization programs can generate 19 times the return to society. This progress is continuing. Today, more than 9,600 potential medicines for noncommunicable diseases (NCDs) are currently in development, while hundreds of new medicines are expected to launch globally in the coming years. At the same time, artificial intelligence and data-driven research are opening new pathways for discovery and development. Yet innovation is accelerating at exactly the moment when support for the innovation ecosystem is becoming less certain. Today’s R&D pipeline reflects decades of investment in science, research infrastructure, regulatory capacity, and intellectual property frameworks. These conditions cannot be assumed to persist. The world needs more innovation, not less, as it confronts rising rates of NCDs, antimicrobial resistance, and future pandemic threats. That is why reform efforts should protect and strengthen the conditions for innovation. Predictable regulatory frameworks, strong intellectual property protections, resilient supply chains, open trade, and respect for science are not abstract policy concepts. They are the foundations upon which future medical breakthroughs depend. Strengthen health systems so innovations reach those who need them Countries need to address the barriers that prevent citizens from accessing the vaccines, medicines and diagnostics they need. Scientific progress alone does not improve health outcomes. Medicines, vaccines, and diagnostics only deliver impact when health systems can effectively finance, regulate, procure, and ensure access to the people who need them. Many barriers to better health outcomes are well understood. Regulatory processes can be slow or duplicative. Health systems often face workforce shortages, infrastructure constraints, financing challenges, and fragile supply chains. As misinformation, political polarization, and rapid advances in AI, genomics, and other emerging technologies reshape public discourse, strengthening trust in science and health institutions is critical. Countries may still struggle to move efficiently from policy recommendation to procurement, introduction, and uptake. The result is that innovations can take years to reach the people who need them most. However, when governments prioritize investments in prevention, earlier diagnosis, and effective treatment, millions of lives can be saved, while supporting more sustainable health systems and economies. The most successful reforms will be those that connect innovation and access and reinforce national ownership, ensuring that product development, financing, regulation, procurement, and delivery are viewed as part of a single continuum rather than separate challenges. This is not only a health imperative. It is increasingly an economic one. As populations age and the global burden of chronic disease grows, resilient and efficient health systems will become even more important to economic growth, workforce participation, and societal resilience. Forge partnerships to advance health globally Global health reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. The current global health architecture does not suffer from a lack of institutions. It suffers when institutions duplicate efforts, compete for resources, or drift beyond their comparative strengths. WHO, development banks, global health institutions, civil society, governments, and industry each bring different capabilities. Effective reform should build on those comparative strengths rather than create additional layers of duplication. Meaningful reform will require confronting difficult questions about mandates, accountability, and where organizations can contribute to better health outcomes. This principle should also apply to engagement with industry. The innovative pharmaceutical sector contributes scientific expertise, clinical research, manufacturing capacity, regulatory experience, and global supply networks that are essential to both health innovation and delivery. Reforms should create predictable and transparent opportunities for industry to contribute where that expertise can help accelerate progress. This engagement should happen early enough to identify technical, manufacturing, supply, and implementation constraints before they become barriers to access. As discussions continue about reforming the global health architecture, they should not only ask how to distribute today’s innovations, but how to sustain the ecosystem that delivers tomorrow’s breakthroughs. Done well, reform can help unlock a future of better health, stronger health systems, greater societal resilience, and economic growth. If we get it wrong, we risk slowing progress at precisely the moment when science is expanding what is possible. David Reddy is the Director-General of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA). Image Credits: Pfizer, Alamy, (Photo: Adobe Stock). Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
Four DRC Health Zones Mark 42 Days With No New Ebola Infections 27/08/2026 Kerry Cullinan Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, Four of the 58 health zones in the Democratic Republic of Congo (DRC) affected by the Ebola Bundibugyo outbreak have had no new cases in the past 42 days, while five others have been case-free for at least three weeks. “The message is that it is definitely possible in that environment to break the transmission,” said Professor Yap Boum, Africa CDC’s head of Emergency Preparedness and Response, at a media briefing on Thursday. The four zones are Kambala, Goma, Lubunga and Miti-Murhesa. Meanwhile, an additional five DRC zones have recorded no new cases in the past three weeks or more. Uganda also marked 42 Ebola-free days on Thursday, marking the end of its outbreak. The 42-day period is twice the 21-day incubation period for Ebola, the established international benchmark for determining that Ebola transmission has ended. However, on the other end of the spectrum in the DRC, Mongbwalu (also known as Mongulu), Rwampara, and Nizi, all in Ituri province, are reporting the highest Ebola incidence. Boum also revealed details of the village-based approach recently adopted by the DRC government and partners. It will be built from clusters of households to villages, health areas, health zones and finally, specialised teams to deal with a range of issues from dignified burials to vaccinations. This decentralised community approach “will improve the trust, the access, but more critically, the mobilisation”, said Boum. Essential health services disrupted The outbreak has disrupted essential health services, particularly maternal health and immunisation services. In Mangala health district, births in facilities have fallen by 25%, while in Bambu, antenatal visits have plummeted. Meanwhile, baby immunisations have dropped in eight health zones, the worst effect has been on measles vaccinations, which plummeted by 31% in Nia Nia and 25% in Bambu. New consultations have decreased across the affected health zones. Boum said that there were two main reasons for the drop. First, some health facilities at the epicentre of the outbreak had closed after health workers became infected. Second, some people avoided health facilities with Ebola treatment centres as they feared being infected. Health worker strikes Boum said that the ongoing strikes by health workers over non-payment of salaries are being addressed “health zone by health zone”. A “major challenge” has been to ensure that all the health workers working on the outbreak are registered on the government payroll, as some had been recruited by different partners. “Implementing that registration and payment has been quite tedious,” said Boum. “But I can confirm that, as we speak now, 2,800 of those health workers have been paid by the government and some by partners.” Community healthcare workers are to be paid $150 per month, which Boum described as a positive development that will “fast-track the deployment of community healthcare workers within the village-centred approach”. By Thursday, 5,656 cases and 2,715 deaths had been recorded, with 1,245 recoveries. The case fatality rate is 48%. New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts
New TB vaccines are moving closer. Is Africa ready? 27/08/2026 Stephen Mutinda Mule A baby who is part of a TB vaccine trial at the SATVI facility in Worcester, South Africa. African scientists, institutions and communities are helping advance the development of new TB vaccines. Governments must now work together to prepare national systems, secure fair pricing and ensure scientific progress leads to timely and equitable access. When I visited the University of Cape Town Lung Institute and the South African Tuberculosis Vaccine Initiative (SATVI) in May, I saw African scientific excellence at work. Researchers showed us how new screening tools, mobile technologies and advances in diagnosis are bringing TB services closer to communities. We also heard about the progress being made across the TB vaccine pipeline, including candidates that could become the first new TB vaccines in more than a century and offer protection to adolescents and adults. I left Cape Town encouraged by the science, but concerned by the gap between scientific progress and government preparation. We have seen this happen before. A new health tool becomes available, but countries are not ready to approve it, finance it, procure it or deliver it. Years are then lost between scientific success and access for the people and communities who need it most. Africa cannot afford to repeat that mistake. Developers and manufacturers are already preparing for the possibility that one or more TB vaccine candidates will succeed. Manufacturing partnerships, technology transfer and production planning are beginning before final trial results are known. This is responsible preparation. Manufacturing capacity takes time to build. Supply chains take time to establish. Regulatory processes take time to complete. Governments must apply the same logic. Africa is not standing on the sidelines of this scientific effort. African scientists, health workers, research institutions, communities and people participating in clinical trials are helping advance the development of new vaccines. Political leadership must now match that scientific leadership. SATVI Associate Professor Angelique Kany Kany Luabeya, investigator on the M72 investigational TB vaccine study, told the visting MPs that for the first time in over a century there is reason for real optimism. What African governments must do now At our meeting in Cape Town, parliamentary Health and Finance Committee leaders from 14 African countries discussed what vaccine readiness would require. We agreed that this could no longer be treated as a future conversation. Governments must begin preparing before final trial results arrive. Prepare national systems Every country should begin developing a national TB vaccine readiness plan. This does not assume that any particular candidate will succeed. It ensures that countries will not be starting from zero when the evidence becomes available. Governments must consider who should be reached first, where vaccination could take place and how new vaccines would be integrated into existing health services. Because future TB vaccines may be intended for adolescents and adults, countries cannot rely solely on systems designed for childhood immunisation. This work must bring together national TB programmes, immunisation teams, HIV programmes, primary health care services and other relevant sectors. Health workers, data systems, supply chains and delivery infrastructure will all need to be assessed. Communities must also be involved from the beginning. People affected by TB, civil society and health workers understand the barriers that may prevent people from accessing services. Their participation will help governments understand community preferences, address concerns and build trust. Public confidence cannot be created a few weeks before a vaccination programme begins. Plan and finance together Vaccine readiness cannot remain within ministries of health. In Cape Town, we deliberately brought Health and Finance Committee leaders into the same room because scientific progress cannot be translated into public health impact without financing, implementation plans and accountability. Governments need credible information about possible prices, supply timelines and the full cost of delivery. Developers and manufacturers should provide this information early enough to support realistic national planning. Finance ministries must begin considering how vaccine introduction could be funded without weakening other essential health services. Parliaments must ask whether these discussions are taking place, scrutinise budget decisions and ensure that national plans are transparent. We also need to move beyond country-by-country preparation. African governments should work together to forecast demand, share information and strengthen regulatory readiness. Cooperation can reduce unnecessary duplication and help countries avoid delays once the evidence is available. It can also give manufacturers greater confidence about future demand. Use Africa’s collective power An African TB clinic supported by the Global Fund. African countries need to work together to procure and roll out new TB vaccines. African countries should not be forced to compete against one another for access to new TB vaccines. If each country negotiates alone, those with greater resources may secure earlier access while countries with the greatest need are left waiting. That would deepen existing inequalities and weaken the continent’s influence. Governments should explore pooled procurement, coordinated demand forecasting and collective negotiations on pricing and supply. A united African approach would strengthen purchasing power, support fairer prices and reduce the risk of fragmented access. It would also support Africa’s ambition to expand vaccine manufacturing on the continent. Sustainable manufacturing requires investment, strong regulation and predictable markets. Governments can help create those conditions by planning and purchasing together. Global partners also have responsibilities. Developers, manufacturers, donors and multilateral institutions should share information early, support national and regional readiness and strengthen existing health systems rather than create parallel structures that countries cannot sustain. But they cannot replace government leadership. Policy development, regulatory approval, budget allocation, community engagement and implementation planning remain the responsibility of national governments. Parliamentarians must hold them accountable for delivering these commitments. At SATVI, I saw African scientists, institutions and communities helping to shape the future of TB prevention. Across the vaccine pipeline, researchers and manufacturers are preparing because they understand how much work must take place before a successful vaccine can reach people. African political leaders must now demonstrate the same foresight. We must work together to ensure scientific success is matched by prepared health systems, fair pricing, strong regulation and delivery plans that reach people across the continent. The question is no longer whether African governments should prepare for new TB vaccines. The question is whether we will act early enough to get it right. Stephen Mutinda Mule is a Kenyan Member of Parliament and the Vice-Chair of the Global TB Caucus. Image Credits: University of Cape Town, European Union. Posts navigation Older posts